Novel tools for molecular imaging and bioconjugation. Synthesis and characterization of new probes and tracers for the visualization of β-Cells by Bertrand, R.D.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/182823
 
 
 
Please be advised that this information was generated on 2018-04-11 and may be subject to
change.
 
  
 
 
Novel Tools for Molecular Imaging and 
Bioconjugation 
Synthesis and Characterization of New Probes and Tracers for the Visualization of β-Cells 
 
 
 
 
 
 
 
 
 
 
 
Romain Bertrand 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research leading to these results has received funding from the People Program (Marie Curie Actions) of the 
European Union’s Seventh Framework Program FP7/2007-2013/under REA Grant Agreement No. 289932. 
 
Printing of this thesis was financially supported by Radboud University Nijmegen. 
 
Cover design: Mathieu Bourlion 
Printed by: Ipskamp Printing 
ISBN: 978-94-028-0891-9 
Copyright © Romain Bertrand, 2017 
 
  
 
 
Novel tools for molecular imaging and 
bioconjugation 
Synthesis and characterization of new probes and tracers for the visualization of β-cells 
 
Doctoral Thesis 
 
to obtain the degree of doctor 
from the Radboud University Nijmegen 
on authority of the Rector Magnificus prof. dr. J.H.J.M. van Krieken, 
according to the decision of the Council of Deans 
to be defended in public on Friday, February 2, 2018 
at 16.30 hours 
 
by 
 
 
Romain Bertrand 
born on September 29, 1989 
in Neuilly sur Seine, France 
 
  
 
 
 
 
 
 
 
  
 
Supervisors 
Prof. dr. Martin Gotthardt 
Prof. dr. Oliver Plettenburg (Leibniz Universität Hannover, Germany) 
 
Co-supervisors 
Dr. Volker Derdau (Sanofi, Germany) 
Dr. Maarten Brom 
 
Doctoral thesis committee 
Prof. dr. Ir. Jan van Hest 
Prof. dr. Roland Brock 
Dr. Fijs van Leeuwen (Leiden University Medical Center) 
Paranymphen 
Romain Grosse 
Marion Alriquet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Novel tools for molecular imaging and 
bioconjugation 
Synthesis and characterization of new probes and tracers for the visualization of β-cells 
 
Proefschrift  
 
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken, 
volgens besluit van het college van decanen 
in het openbaar te verdedigen op vrijdag 2 februari 2018 
om 16.30 uur precies 
 
door 
 
 
Romain Bertrand 
geboren op 29 september 1989 
te Neuilly sur Seine, France 
 
  
 
 
 
 
 
 
 
 
  
Promotoren 
Prof. dr. Martin Gotthardt 
Prof. dr. Oliver Plettenburg (Leibniz Universität Hannover, Duitsland) 
 
Copromotoren 
Dr. Volker Derdau (Sanofi, Duitsland) 
Dr. Maarten Brom 
 
Manuscriptcommissie 
Prof. dr. ir. Jan van Hest 
Prof. dr. Roland Brock 
Dr. Fijs van Leeuwen (LUMC) 
 
Paranymphen 
Romain Grosse 
Marion Alriquet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
« Connaître, ce n'est point démontrer, ni expliquer. C'est accéder à la vision » 
Antoine de Saint Exupéry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This work is dedicated to Lise Deval 
8 
 
 
  
9 
 
Table of content 
 
 
Outline of the thesis                                                                                                                 11                                         
   
Chapter 1                                                                                                                                    15 
General introduction 
 
Chapter 2                                                                                                                                    41 
Synthesis and characterization of a novel FFAR1-GPR40 fluorescent probes  
for β-cell imaging 
 
Chapter 3                                                                                                                                 101 
Synthesis of FFAR1-GPR40 targeting 3H- and 18F-probes towards selective  
β-cell imaging 
 
Chapter 4                                                                                                                                 119 
Mild and effective mono-iodination of tyrosine on unprotected peptides  
as initial step for the synthesis of bioimaging probes 
 
Chapter 5                                                                                                                                 203        
General discussion and future perspectives 
 
Summary                                                                                                                                  217 
Samenvatting                                                                                                                          221 
List of publications                                                                                                                  227 
Acknowledgements                                                                                                                229 
About the author                                                                                                                    235 
 
 
 
10 
 
  
Outline of the thesis 
 
11 
 
Outline of the Thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outline of the thesis 
 
12 
 
Diabetes is a group of metabolic diseases characterized by a deficiency in control of glucose 
homeostasis which can have severe life-threatening consequences. To date, no cure for diabetes 
exists. The disease affects an increasing number of people and imposes a massive public health 
challenge for almost every country around the globe. Contrary to preconceived ideas, diabetes is not 
confined to western world countries, with lower socioeconomic groups being disproportionately 
affected in high-income countries, and with over three-quarters of the world’s diabetic population 
living in low- and middle-income countries. Considering the serious human, societal, and economic 
consequences, major research efforts have been undertaken in the last decades to tackle the disease 
and its complications. However, our knowledge on the pathogenesis of diabetes remains limited. In 
type 1 diabetes, autoimmune destruction of insulin-producing cells, also called β-cells, leads to an 
insulin shortage and a subsequent glycemic dysregulation. In type 2 diabetes, insulin resistance of the 
target cells combined with an impaired β-cell function are the main causes of hyperglycemia. The 
changes in β-cell mass and function in the development and progression of diabetes are not well 
identified, nor well characterized. Imaging tools to visualize and monitor β-cells non-invasively would 
improve our understanding of the disease onset and progression. Furthermore, β-cell imaging might 
help in the development of novel anti-diabetic medication, or for therapies such as islet 
transplantation by providing information on the graft’s survival. Due to β-cell sparsity, and to β-cell 
location, β-cell imaging faces numerous hurdles. Consequently, finding an ideal biological target that 
is highly and specifically expressed by the β-cells, and a suitable probe that binds tightly and exclusively 
to the β-cells, is a challenging process. As of today, despite extensive efforts from researchers 
worldwide, there is no probe or tracer that can precisely detect and quantify β-cells in vivo.  
 
In this thesis, the design, the synthesis, and the characterization of novel fluorescent probes and 
radioactive tracers as new promising tools for β-cell imaging are described. The development of new 
imaging probes relies on the field of bioconjugation chemistry. The most widespread approaches to 
functionalize peptides rely on the chemistry of lysine and cysteine side chains. However, in some cases 
these conjugation strategies present shortcomings such as high abundance of lysine residues or the 
need of preliminary reductive treatment to cleave disulfide bridges. Therefore, we report a novel 
methodology to label unprotected peptides, based on the reactivity of tyrosine.  
 
Diabetes and its consequences are presented in Chapter 1, and how non-invasive β-cell imaging could 
give a better understanding of the disease is discussed. We also reviewed potential targets and the 
most promising approaches for selective visualization of β-cells, with a particular emphasis on the free 
fatty acid receptor 1 (FFAR1/GPR40), which is predominantly expressed in human and rodent 
pancreatic β-cells. Accordingly, we report in Chapter 2 the design and development of the first 
fluorescent probes targeting the FFAR1, which was until now unexplored for imaging purposes. The 
novel probes, which are based on the scaffold of TAK875, a synthetic FFAR1 agonist with high affinity 
and selectivity for the receptor, were characterized in vitro on different kind of β-cell models. Using 
the same scaffold, we synthesized the first [18F]-radioactive analog of TAK875, as described in Chapter 
3, which could serve as a potential PET tracer for selective β-cell imaging. Incretin derivatives such as 
Exendin-4, a potent agonist of the glucagon-like peptide 1 receptor (GLP-1R), are promising peptides 
for β-cell imaging. In the search of novel bioconjugation techniques to allow synthesis of new peptidic 
imaging probes, we examined in Chapter 4 the mono-iodination of tyrosine residues on fully 
unprotected peptides. The introduced iodine can subsequently serve as a handle for further 
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functionalization such as for the introduction of fluorescent dyes. Finally, in Chapter 5 the remaining, 
yet unpublished experimental results and future perspectives are discussed. 
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Introduction 
 
Diabetes, a global burden   
Diabetes mellitus, commonly referred to as diabetes, is a chronic, metabolic disease diagnosed by 
observing raised levels of glucose in the blood. Over time, these high blood glucose levels, known as 
hyperglycemia, damage many tissues in the body, leading to the development of disabling and life-
threatening health complications.1 Symptoms of the condition range from frequent urination, 
persistent thirst, increased hunger, fatigue, weight loss or blurry vision.2 The disease is also associated 
with reduced life expectancy, significant morbidity due to specific diabetes related microvascular 
complications (retinopathy, neuropathy, nephropathy), increased risk of macrovascular complications 
(ischemic heart disease, stroke and peripheral vascular disease) and diminished quality of life.3 Three 
ways to diagnose diabetes mellitus exist, and each, in the absence of unequivocal hyperglycemia, must 
be confirmed by any one of the three methods given in Figure 1.4 
 
Symptoms of diabetes plus casual plasma glucose concentration ≥ 200 mg/dL (11.1 mmol/L)a 
or 
Fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L)b 
or 
2-h post load glucose ≥ 200 mg/dL (11.1 mmol/L) during an oral glucose tolerance testc 
Figure 1 Criteria for the diagnosis of diabetes. a) Casual is defined as any time of day without regard to time since 
last meal. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss. b) Fasting 
is defined as no caloric intake for at least 8 h. c) The test should be performed as described by the World Health 
Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. 
 
Diabetes can be classified into three main categories: type 1 diabetes (T1D), type 2 diabetes (T2D) and 
gestational diabetes (GDM). 
Type 1 diabetes (T1D), also called insulin-dependent diabetes, is an autoimmune disease5 
characterized by the expansion of pathogenic T effector cells which cause the irreversible destruction 
of insulin producing cells. As a consequence, insulin production is insufficient and thus glucose 
homeostasis uncontrolled.6 T1D is usually observed in children, teens or young adults. Management 
of T1D requires the careful maintenance of near-normalized blood glucose levels while minimizing the 
risk of hypoglycemic episodes. These latter events can lead to symptoms varying from anxiety, 
palpitations, and tremor, to neurological impairments, including behavioral changes, cognitive 
dysfunction and seizures. Severe prolonged hypoglycemia can cause permanent brain damage.7 As a 
result of insufficient insulin dosing, a person with T1D can also lapse into a life-threatening diabetic 
coma, also known as diabetic ketoacidosis.8 
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Type 2 diabetes (T2D) is the most prevalent form of the disease. In high-income countries, more than 
91% of adults with diabetes have T2D.9-12 It usually occurs in adults, but is increasingly seen in children 
and adolescents. In T2D, the body is able to produce insulin but is unable to respond to its effects: this 
is known as insulin resistance. Over time, insulin levels may also subsequently become insufficient. 
Both the insulin resistance and deficiency lead to high blood glucose levels. Although the exact causes 
for the development of T2D are still not fully identified, there are several known risk factors. The most 
important are excess body weight and obesity, sedentary lifestyle and unhealthy diet.13-17 Many people 
with T2D remain unaware of their condition for a long time because the symptoms are usually less 
marked than in T1D and may take years to be recognized. However, during this time the body is already 
being damaged by excess blood glucose. In contrast to people with T1D, most people with T2D do not 
require daily insulin treatment to survive. The cornerstone of treatment of T2D is the adoption of a 
healthy diet, increased physical activity and maintenance of a normal body weight. If followed 
carefully, these three guidelines can yield to disease remission, for cases of T2D being diagnosed early 
enough.18 In the absence of contraindications, an oral antidiabetic drug (such as metformin) is 
recommended as a first line treatment, when changes in lifestyle were inefficient in controlling 
glycemia (Figure 2). A second oral agent of another class (sulfonylureas, thiazolidinediones, dipeptidyl 
peptidase-4 inhibitors, SGLT2 inhibitors - Figure 2) may also be added for patients inadequately 
controlled with metformin monotherapy. 
 
Figure 2 Examples of structures of oral antidiabetic drugs including metformin, glibenclamide (sulfonylurea), 
pioglitazone (thiazolidinediones), sitagliptin (dipeptidyl peptidase-4 inhibitors), and canaglifozin (SGLT2 
inhibitor). 
 
Gestational diabetes mellitus (GDM) is defined as glucose intolerance of various degrees which 
appears, or is first diagnosed, during pregnancy.19 Approximately 7% of all pregnancies are affected by 
GDM20 which engenders a risk of morbidity and mortality to mother, fetus and subsequent 
newborn.21,22 Gestational diabetes normally disappears after birth. However, women with the history 
of gestational diabetes mellitus are at higher risk of being affected by gestational diabetes in 
subsequent pregnancies and of developing type 2 diabetes later in life. They have a 20 to 70% chance 
of developing T2D within the 5 to 10 years following delivery.23 They also have a significantly increased 
risk of cardiovascular disease in the years after pregnancy.24 It was also observed that offspring born 
to mothers with GDM also have a higher risk of developing T2D in their life.25 
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The two main subtypes of diabetes are summarized in Figure 3, and compared to the healthy situation. 
 
 
 
Figure 3 Schematic representation of the healthy situation compared to the main different types of diabetes. In 
normal situation, insulin acts as a key that lets the body’s cells take in glucose and use it as energy. The lack of 
insulin (for T1D patients), or insulin resistance (for T2D and GDM patients) in a person with diabetes results in 
high circulating levels of blood glucose causing damages to many tissues in the body. Retrieved with permission 
from http://www.healthstyle.net.au/article/diabetes-the-tale-of-two-types as accessed on 2016, November 11). 
 
A challenge arising in the last years is that more and more individuals are diagnosed with forms of 
diabetes that do not fit in the three above-mentioned categories. Other metabolic disorders of glucose 
include, for instance, monogenic diabetes (maturity onset diabetes of the young MODY) or latent 
autoimmune diabetes of adults (LADA) which is sometimes referred to as type 1.5 diabetes, as it is a 
form of T1D that shares some characteristics with T2D. Classification of diabetes is permanently 
evolving as efforts are undertaken to understand the pathogenesis of each form, with the purpose of 
gaining relevant information on the cause, natural history, genetics and heritability, clinical phenotype 
and, most importantly, to provide the patients with optimum treatments for the disease.26 
 
In 2015, according to the International Diabetes Federation (IDF), 415 million adults were estimated 
to have diabetes worldwide and this number is expected to reach 642 million in 2040.1 Notably, the 
IDF estimates that one in two adults with diabetes is undiagnosed. Diabetes is major causes of death 
in most countries: in 2013, the disease and its related complications engendered 5.1 million deaths,27 
which is more than HIV/AIDS (1.5 million28), tuberculosis (1.5 million29) or malaria (0.6 million30). In 
addition to the daunting human and social costs, the condition has heavy financial consequences. Not 
only does diabetes impose a large financial burden on individuals and their families due to the cost of 
healthcare, but it also has a substantial economic impact on communities and their national health 
systems.31-36 This is due to the high and globally increasing prevalence of diabetes, the demand for 
multi-modal treatment, and the serious complications associated with long disease duration. The 
American Diabetes Association estimated the total economic cost of diagnosed diabetes in the United 
States in 2012 to be $245 billion.37 Furthermore, the costs related to undiagnosed diabetes are 
considerable: they include medical (hospital inpatient, physician and emergency care, and retail 
prescriptions) and nonmedical (workdays absent or reduced performance at work). One study from 
the United States found that undiagnosed diabetes was responsible for an additional $18 billion in 
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healthcare costs in 2007.38 In Europe, the ageing population will place an increasing number of people 
at risk of diabetes and, consequently, place a greater cost burden on health systems. A majority of 
countries already spend between 5% and 20% of their total health expenditure on diabetes.1 With such 
a high cost, the disease is a major challenge for healthcare systems today and this challenge will grow 
greater in the future. 
 
The link between insulin and pancreatic β-cells 
 
Diabetes occurs when the body cannot produce enough insulin or because the body does not respond 
properly to insulin.39 The link between insulin, the pancreas and diabetes was first postulated by 
Minkowski and Mering at the end of the 19th century when they noticed that a dog developed signs of 
diabetes after a total pancreatectomy.40 A few years later, Hédon observed that grafting a small piece 
of pancreatic tissue under the skin after a total pancreatectomy relieved diabetes, but the disease 
promptly returned on removal of the tissue.41 These results led Gustave-Edouard Laguesse to 
hypothesize that the small clusters of ductless cells within the pancreas - described by Paul Langerhans 
in 1869 and named Langerhans islets as a tribute to the discoverer42 - could be the source of the 
substance involved in glucose control. In 1901, Opie finally confirmed the association between the islet 
cells and diabetes by connecting the degeneration of the islet cells to the appearance of diabetes.43  
Human insulin is a polypeptide with a molecular mass of 5.808 g/mol, comprising an A and a B chain 
connected by two disulphide bridges (Figure 4). Within mammals, the amino acid sequence of insulin 
is highly conserved. The sequence of insulin was determined by British molecular biologist Frederick 
Sanger, while British biochemist Dorothy Hodgkin resolved the spatial conformation of the molecule 
by means of X-ray diffraction studies. They were respectively awarded the Nobel Prize in Chemistry in 
1958 and 1964 for their work. 
 
 
 
 
 
Figure 4 Structures of human insulin. Schematic structure of insulin (a), the three-dimensional structures of 
insulin monomer (b), dimer (c), and hexamer (d). In (b–d): A chain (green), B chain (magenta). In (d) two axial 
zinc ions (grey; overlaid at center for clarity) are coordinated by six histidine side chains from residue B10 (not 
shown for clarity). (Adapted from Hilgenfeld).44 
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Insulin has a key role in vertebrates’ glucose homeostasis. It is primarily secreted in response to 
elevated blood concentrations of glucose, although some neural stimuli (e.g. sight and taste of food)45 
and increased blood concentrations of other molecules, including amino acids, fatty acids or incretins, 
can also increase glucose-induced insulin secretion.46 The hormone helps regulate the metabolism of 
carbohydrates, fats and proteins by promoting the absorption of blood glucose into fat, liver and 
skeletal muscle cells. In these tissues the absorbed glucose is converted into either glycogen or fats 
(triglycerides), or in the case of the liver, into both.47 When the islet cells are stimulated by glucose, 
insulin - which is stored as microcrystalline arrays of zinc insulin hexamers within secretory vescicles48 
- is released by exocytosis and diffuses into the blood after a complex signaling pathway involving 
glucose phosphorylation, closure of the ATP-gated potassium and a subsequent increase in cytosolic 
[Ca2+] levels, as shown in Figure 5. 
 
 
 
Figure 5 Mechanisms of glucose-stimulated insulin secretion. Increased blood glucose concentrations result in 
enhanced glucose uptake by β-cells through the glucose transporter GLUT2. Intracellular glucose is rapidly 
phosphorylated by glucokinase (1) and the product subsequently undergoes glycolysis to produce pyruvate 
which leads to elevated ATP production and a rise in the ATP/ADP ratio (2). Closure of ATP-gated potassium 
channels ensues (3), resulting in plasma-membrane depolarization and consequent opening of voltage-gated 
Ca2+ channels (L-type Ca2+ channels, LTCCs) (4). Finally, an influx of extracellular Ca2+ through LTCCs increases 
cytosolic Ca2+ levels, which promotes insulin secretion by activating the exocytotic machinery involved in fusion 
of insulin granules with the β-cell plasma membrane (5). Additional coupling factors emanating from glucose 
metabolism – the nature of which remains debated – amplify this main triggering pathway (6). (Adapted from 
Mancini).49 
 
Insulin is exclusively secreted by β-cells from the islets of Langerhans, located in the pancreas. In 
humans, the pancreas is a yellowish organ about 12-15 cm long and 4 cm wide and around 98% of it is 
composed of exocrine tissue (pancreatic acini) and ductal systems. The islets of Langerhans constitute 
approximately 2% of the pancreatic mass: there are about one million islets distributed 
heterogeneously throughout the pancreas of a healthy human adult, each of which measures about 
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0.2 mm in diameter. The combined mass of the islets is estimated to be 1 to 1.5 grams in average.50 
The islets consist of three major cell types (α, β, and δ-cells) which produce important hormones 
(glucagon, insulin, and somatostatin respectively). In all species, the β-cells are the most abundant (55-
75%) of the three, followed by the α-cells (15-30%) and the δ-cells (5-15%)(Figure 6).51  
 
 
 
Figure 6 Schematic representations of human pancreas and islets of Langerhans. The pancreas is located in the 
upper part of the abdomen, surrounded by the stomach, the intestine and the liver. The Langerhans islets 
(magnified) are scattered throughout the pancreas and are mostly composed of β-cells (pink), α-cells (violet), δ-
cells (green) and PP cells (blue). (Figure by Bruce Blaus, Wikiversity Journal of Medicine, 2014). 
 
Why do we need β-cell imaging? Understanding the link between β-cell mass, 
function, and onset of diabetes 
 
Glucose homeostasis disorders happen when the body cannot produce enough insulin or cannot use 
insulin effectively. Shortage of insulin production can be caused by both impaired β-cell function (BCF) 
- when the amount of insulin required to restore normoglycemia is not released, and a decrease in β-
cell mass (BCM) which, though perfectly functional, do not produce enough hormone.52 The total mass 
of pancreatic β-cells in humans generally increases rapidly from birth to adulthood.53 Both T1D and 
T2D have been associated with a significant reduction of the BCM (from 0-65% for TD2 to and 70-99% 
for TD1 – Figure 7).54 For children, teens or young adults affected by TD1, the β-cell mass declines over 
many years from a young age;55 whereas for T2D patients, the functional sensitivity of β-cells to 
hyperglycemia tends to diminish with advancing age56 and the BCM may have reduced significantly 
before the first symptoms are clinically diagnosed.57-60  
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T2D situation 
 
 
 
 
 
T1D situation 
 
Figure 7 A)Postulated β-cell loss during disease progression in T2D. Impaired fasting glucose = IFG (Adapted from 
Neutzsky-Wulff).57 B) Postulated β-cell loss during disease progression in T1D (Adapted from Fakhfakh)61. 
 
Currently, BCF is evaluated by blood glucose and insulin determination, HbA1C measurements and 
intraperitoneal or oral glucose-stimulated insulin secretion (GSIS). Although the above-mentioned 
measurements may provide a surrogate assessment of the BCM, they do not afford its precise 
quantification. Insulin immunostaining for β-cells after pancreatic biopsy is the only available method 
to determine the BCM, but being invasive, unreliable and dangerous, its use as a standard to monitor 
the BCM before or during the progression of the disease is precluded. Furthermore, studies of BCM 
based on invasively extracted pancreatic tissues do not show the dynamics of the BCM over time.62,63 
Diabetes has been extensively studied for a long time, more than 100 years separates us from 
Langerhans’, Hédon’s, and Opie’s discoveries, and yet the exact role of the BCM - and its link to the 
BCF - in the development and progression of diabetes is still poorly understood. For instance, it is still 
unknown whether the disease starts preferentially in individuals with only a deficit in β-cell number, 
leading to impaired cell activity due to cellular exhaustion over time. Or, on the other hand, whether 
aggressing factors (such as high levels of lipids, sugars, cytokines or amyloid polypeptide, metabolic 
and oxidative stress, etc.) disturb BCF, and then the subsequent hyperglycemia drive β-cell apoptosis.64 
One can also hypothesize that a modulation of both BCM and BCF occurs during the development of 
A) 
B) 
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the disease to compensate for high insulin demand, this ability is called plasticity, before eventually 
declining.  
Specifically, although five stages65 in the progression of diabetes is postulated (characterized by 
different changes in BCM and BCF), we do not know the natural evolution of β-cell mass, nor do we 
have convincing evidence on potential β-cell neogenesis and on the preserved β-cell mass in patients. 
The ability to evaluate independently BCF and BCM is therefore expected to play a pivotal role in future 
diabetes research. Furthermore, with the introduction of antidiabetic treatments suggesting 
modulating, preserving or even an increasing the BCM, it becomes clear that we are in need of reliable, 
sensitive, specific, and non-invasive methods to visualize living pancreatic β-cells in order to validate 
these claims.66,67 Such imaging techniques might help to enhance our understanding of the 
pathophysiology of T2D and T1D, by getting more insights into the precise molecular mechanisms 
leading to the decrease in β-cell mass and function. 
 
Non-invasively imaging pancreatic β-cells is a challenge hindered by many obstacles.68 First, as 
described previously, β-cells comprise only 1-2% of the total pancreatic mass and are heterogeneously 
distributed in the organ. Distinguishing such a rare population of cells from the exocrine tissues in the 
pancreas is therefore extremely difficult; it was estimated that the uptake of β-cells speciﬁc probes 
must exceed the uptake of tracer in exocrine tissue cells by roughly 440-fold.69 Second, in diabetics the 
BCM is likely to decrease over time, so the ability to monitor disease progression depends on detecting 
small variations. Third, the pancreas is surrounded by the gastrointestinal system and liver, and 
consequently, probe uptake in the latter organs complicates visualization of the pancreas. 
 
Receptors or proteins that are highly expressed on β-cell membranes have been reported as potential 
targets for β-cell imaging. They include sulfonylurea receptor 1 (SUR1),70,71 membrane protein IC2,72,73 
or transmembrane protein 27 (TMEM27).74,75 However, the reported approaches focusing on SUR1, 
IC2 or TMEM27 showed limitations attributed either to the expression of the target (heterogeneous 
or non-β-cell specific expression) or to the developed tracer (low absolute uptake, or even unspecific 
accumulation of the tracer).76 Nonetheless, in the past few years, several research groups have 
developed imaging tools for the visualization of pancreatic β-cells and transplanted islets. The three 
most promising approaches that are currently being investigated through clinical trials are targeting 
either the glucagon like peptide 1 receptor (GLP-1R), the vesicular monoamine transporter 2 (VMAT2) 
or tracing the serotonin biosynthesis via dopa decarboxylase (DDC). 
 
The [11C]-radiolabeled analog of 5-hydroxytryptophan ([11C]-5-HTP) is a biogenic precursor for 
serotonin and was originally developed as a PET neuroimaging tracer to assess the rate of serotonin 
biosynthesis by DDC in the central nervous system. Since the full serotonergic metabolic pathway has 
been described in the pancreatic β-cells and has been implicated in insulin release and β-cell 
proliferation, the use of [11C]-5-HTP was investigated .77 The total pancreatic uptake of [11C]-5-HTP was 
found to be reduced by 66% in humans with T1D compared with healthy volunteers. In two of the 
individuals with T1D enrolled in the study, total uptake decreased by more than 90%.78 Inasmuch as 
the serotonin biosynthesis takes place in all pancreatic neuroendocrine tissue, and not exclusively in 
β-cells, the [11C]-5-HTP radioligand should not serve as a BCM detecting tool but rather as a good 
biomarker of total endocrine mass.77, 78 
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Vesicular monoamine transporter is a transmembrane protein that translocates monoamines from the 
cytoplasm into secretory vesicles. The type 2 protein (VMAT2) is highly expressed in pancreatic β-
cells.79 PET-imaging of VMAT2 was made possible by the development of radiolabeled 
dihydrotetrabenazine (DTBZ) analogues such as [18F]-FP-(+)-DTBZ, which specifically bind to VMAT2.80 
With this radioligand, significant differences in tracer uptake could be observed between healthy 
volunteers and people with T1D81 as displayed in Figure 8. However, doubts on the specificity of VMAT2 
ligands emerged recently, especially regarding unspecific binding to exocrine tissue in rodent models,82 
or to pancreatic PP cells.83 
 
 
 
Figure 8 [18F]-FP-(+)-DTBZ PET images of a healthy volunteer (A) and a patient with T1D (B). Pancreas uptake was 
clearly reduced in diabetic patient. PB, PH and PT = pancreas body, head, and tail. K = kidney. L = liver. M = 
myocardium. S = spleen. V = vertebrae. GI = gastrointestinal tract. (Adapted from Normandin).81  
 
Glucagon like peptide 1 receptor (GLP-1R) is abundantly expressed on native islets,84 and peptides 
targeting the GLP-1R are thus promising candidates for use in β-cell imaging. As well, GLP-1R agonists 
such as Lixisenatide, Exenatide, or Albiglutide are safe and already used clinically for the treatment of 
T2D. Exendin derivatives, which bind to the extracellular domain of GLP-1R with picomolar affinity, 
have been extensively used for visualization of β-cell using fluorescence microscopy,85 MRI,86 and 
nuclear imaging.87-89 Notably, SPECT-imaging with [111In]-Exendin-4 showed a marked reduction in 
pancreatic uptake in patients with T1D as shown in Figure 9, even if substantial inter-individual 
variability and overlap between diabetic and non-diabetic individuals was also observed.90 
 
                             
 
Figure 9 [111In]-Exendin-4 SPECT/CTPET images of the abdomen of a healthy volunteer (A) and a patient with T1D 
(B). Pancreas uptake was clearly reduced in diabetic patient. (Adapted from Brom).90 
A) B) 
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Nevertheless, one limitation with GLP-1R targeting molecules could arise: some concerns exist 
whether potential downregulation of the receptor may influence uptake of the tracer.91, 92 This 
downregulation may lead to an erroneously low quantification of β-cell number. Notably, it was shown 
that changes in Exendin-4 fluorescent probe signal intensity did not directly reflect changes in BCM in 
two T2D mouse models (Leprdb/db and Diet-Induced Obese), most likely due to receptor 
downregulation.93 However, evidence indicating that mice are not a suitable model to follow β-cell 
evolution with GLP-1R targeting probes has recently come to light.94 In contrast, in a model of T1D 
where rats were subjected to alloxan-induced beta cell depletion, a good correlation was observed 
between [111In]-Exendin uptake and BCM.90 Whether GLP-1R downregulation in the course of T1D and 
T2D also occurs in human – and if so, to which extent and under what circumstances – still has to be 
clarified. In summary, although imaging of VMAT2 or GLP-1R is promising, some shortcomings and 
challenges remain. Accordingly, the search for alternative targets and probes with ideal properties for 
accurate imaging of β-cell mass should continue. 
 
The free fatty acid receptor 1 (FFAR1-GPR40)  
 
The free fatty acid receptor 1 (FFAR1) belongs to the superfamily of the seven-transmembrane domain 
G protein-coupled receptors (GPCRs). These receptors induce biological responses via the activation 
of associated heterotrimeric G proteins (Gα, Gβ and Gγ) and/or β-arrestins. GPCR signaling is involved in 
countless physiological processes and around 40% of all clinically prescribed drugs target GPCRs.95 
FFAR1 (also called GPR40 for G protein-coupled receptor 40) was independently deorphanized by three 
different groups in 200396-98 who showed that a broad range of medium- to long-chain free fatty acids 
(C12–C22) serve as ligands for the receptor. The discovery that free fatty acids act as agonist for cell-
surface receptors created a new paradigm: free fatty acids are not only nutrients and metabolic 
substrates but also behave as extracellular signaling molecules.49 Insulin secretion in response to 
glucose occurs in two phases, and the FFAR1 activation triggers a glucose dependent insulin secretion, 
with a strong effect on the second phase as shown in Figure 10.  
 
 
Figure 10 Perifusion experiment in mouse pancreatic islets demonstrating that free fatty acids (here a C18 free 
fatty acid: oleate) primarily potentiate second-phase glucose-stimulated insulin secretion. Islets derived from 
GPR40 knock out mice exhibited a ∼50% reduction of this potentiating effect, but displayed no appreciable 
difference in first-phase glucose-induced insulin release. (Adapted from Mancini).99 
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Following FFAR1 stimulation, the α subunit of receptor-associated heterotrimeric G protein Gq/11 is 
activated upon GDP-for-GTP exchange and subsequently dissociates from the β/γ subunit. The GTP-
bound (active) α-subunit activates phospholipase C (PLC), which cleaves phosphatidylinositol-4,5-
bisphosphate (PIP2) to produce inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 triggers 
Ca2+ efflux from the endoplasmic reticulum (ER). DAG promotes the phosphorylation and activation of 
PKD1; in turn, PKD1 phosphorylates and activates targets implicated in filamentous (F)-actin 
remodeling, ultimately potentiating the 2nd phase of glucose-stimulated insulin granule exocytosis. The 
IP3 pathway also likely plays a role in the control of intracellular Ca2+ levels and insulin secretion in 
response to FFA activation of GPR40 (Figure 11). 
 
Figure 11 Free fatty acid trigger glucose-stimulated insulin secretion through FFAR1/GPR40 activation. 
(Adapted from Mancini).49 
 
An interesting target for β-cell imaging? 
 
When it was deorphanized, the corresponding mRNA receptor transcript levels were probed to 
characterize the tissue distribution of the GPR40. Although evidence of receptor expression was found 
in the human brain and in the enteroendocrine cells of the gastrointestinal tract,96, 100 the receptor was 
found to be predominantly expressed in human and rodent β-cells of the pancreas (Figure 12).96-98,101 
Remarkably the estimated mRNA copy number for the GPR40 gene in human pancreatic islets was 
comparable to those for genes encoding SUR1, GLP-1R and somatostatin receptors, all of which are 
known to be expressed abundantly in the human pancreatic islet.102 FFAR1 expression has also been 
detected in glucagon-producing α-cells within the pancreas103 using a polyclonal antibody generated 
against the C-terminal part of the receptor. However, this result remains controversial: one research 
group failed to detect expression of GPR40 mRNA in α-cells using quantitative PCR on human 
glucagonomas;104 another group who developed a monoclonal antibody directed to the extracellular 
domain of the GPR40 could not detect expression of the receptor in α-cells.105 There is an ongoing 
discussion in recent literature on the effectiveness and particularly on specificity of antibody-mediated 
detection of FFAR1.106  
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Figure 12 GPR40 mRNA is expressed abundantly in pancreatic β-cells. GPR40 mRNA in rat tissue measured by RT-
PCR. Data represent the ratios of GPR40 and other mRNAs to GAPDH mRNA. a) Distribution of GPR40 mRNA in 
rat tissues. b) Specific expression of GPR40 mRNA in rat pancreatic islets compared to pancreas as a whole.  
c) Expression of GPR40 mRNA in pancreatic β-cell lines (MIN6 mouse pancreatic β-cells; betaTC-3 mouse 
pancreatic β-cells; HIT-T15 Syrian golden hamster pancreatic β-cells; RINm5F, rat pancreatic β-cells), α-cells 
(alphaTC1 mouse pancreatic α-cells), and other cell types (NIH/3T3 mouse embryonic cells; C2C12 mouse 
myoblasts; 3T3-L1 mouse embryonic fibroblasts; MIA PaCa-2 human pancreatic carcinoma cells; PANC-1 human 
pancreatic carcinoma cells). (Adapted from Itoh).97   
 
Given that the free fatty acids only stimulate insulin release in the presence of glucose, it became 
immediately apparent that FFAR1 could be targeted to enhance insulin secretion in T2D patients while 
minimizing the risk of hypoglycemia events. Indeed, many synthetic FFAR1 agonists have been 
described in recent years, thus enabling a better understanding of the receptor signaling and 
pharmacology; many of them were or still are under development as T2D drugs.107 
 
Figure 13 Examples of structures of endogenous (γ-linolenic acid) and synthetic (TAK-875 and JTT-851) FFAR1 
agonists. 
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Typically, synthetic FFAR1 agonists mimic the free fatty acid structure with an acidic head group and a 
hydrophobic tail (Figure 13 and Table 1), based on this rationale the first small molecule FFAR1 agonist 
was reported in 2006 by Glaxo Smith Kline (GW-9508108 - Table 1). The carboxylic acid function is of 
prime importance for the activity (but can be replaced by an acidic bioisosteric group as shown by 
Astella AS-2034178109 - Table 1) and is typically attached via a two carbon atom linker to an aromatic 
ring. In more advanced compounds the β-position to the carboxylic function is substituted by small 
residues (AMG-1638/AMG-837/LY-2922470/JTT851/P-11187 - Table 1), which can be also cyclized to 
the aromatic ring (TAK-875), to reduce the potential for β-oxidation, which is the catabolic process by 
which fatty acid molecules are broken down. A second aromatic moiety, either a substituted 
monocyclic or bicyclic aryl or a biaryl residue, is linked to the first aromatic ring via a short spacer (2–
4 atoms in length). This second aromatic moiety can be used to install further substituents in order to 
manipulate the overall physicochemical properties such as polarity and solubility. 
Of the numerous FFAR1 agonists developed to date, the Takeda molecule TAK-875 (Fasiglifam) was 
the most clinically advanced by reaching the phase III. TAK-875 is an orally available and potent agonist 
of FFAR1 (EC50 in the low nanomolar range for human FFAR1) with marked selectivity for FFAR1 over 
other members of the FFA receptor family (i.e., FFAR2, FFAR3, GPR120)110. In isolated rat and human 
islets, TAK-875 stimulated insulin secretion in a glucose-dependent manner without affecting glucagon 
secretion.111, 112 In Zucker diabetic fatty rats (a commonly used genetic rodent model of T2D), TAK-875 
was found to promote glucose-stimulated insulin secretion and reduce fasting and postprandial 
hyperglycemia, as opposed to healthy normoglycemic rats where the compound did not induce 
hypoglycemia. 
These therapeutic effects observed in animal models were then translated to humans in clinical trials. 
Initial pharmacokinetic studies in healthy volunteers receiving TAK-875 revealed good safety and 
tolerability, and a pharmacokinetic profile appropriate for once-daily oral dosage.113 In two 
randomized, double-blind, placebo-controlled trials,114 T2D patients on a 12 week TAK-875 treatment 
(>50 mg/day, once daily) exhibited improved fasting plasma glucose and insulin secretion with a 1.2–
1.4% reduction in HbA1c levels. Improvements in HbA1c levels were comparable to those observed 
with the glimepiride, a sulfonylurea antidiabetic drug (sulphonylureas stimulate insulin secretion by 
selectively targeting ATP-regulated K+ channels in the plasma membrane of pancreatic β-cells. This 
mechanism is independent of plasma glucose levels which consequently increases the risk of 
hypoglycaemia);115 however, the occurrence of hypoglycemia was significantly lower in the TAK-875-
treated groups relative to the glimepiride groups. Most importantly, the beneficial effects of TAK-875 
were only observed in diabetic individuals, thus confirming that the molecule is active only when high 
levels of blood glucose are reached. Even if the clinical development of TAK-875 was terminated on 
phase III due to concerns on liver toxicity,116 the encouraging initial results reported by Takeda provide 
strong evidence in support of the clinical utility of GPR40 agonists, and unsurprisingly multiple 
pharmaceutical companies still have active GPR40 agonist programs. 
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Company Name Structure 
Endogenous ligand Gamma-linolenic acid 
 
Glaxo Smith Kline GW-9508 
 
Takeda TAK-875 
 
Amgen AM-837 
 
Amgen AM-1638 
 
Eli Lilly LY-2922470 
 
Japan Tobacco JTT-851 
 
Astella AS-2034178 
 
Piramal P-11187 
 
Hengrui SHR-0534 
 
 
Table 1 Structures of relevant FFA1 receptor agonists. 
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Currently, the molecule most advanced in clinical trials is the FFAR1 agonist JTT-851 from Japan 
Tobacco which are conducting phase II clinical trials, followed by Piramal which began phase I clinical 
trials on their FFAR1 agonist P-11187 (Piramal clinical Trial), Eli Lilly LY-2922470 (completed phase I in 
2014) and Hengrui SHR-0534 (phase I in China) (Table 1).117 
 
As already mentioned above, GPR40 was found to be expressed in enteroendocrine cells and can also 
promote ligand-stimulated secretion of incretins such as glucagon-like peptide-1 and glucose-
dependent insulinotropic polypeptide (GIP).100 These two potent metabolic hormones induce a 
decrease in blood glucose levels by both stimulating insulin release and inhibiting glucagon release. 
Consequently, in addition to their direct action on pancreatic β-cells, GPR40 agonists may also 
indirectly promote insulin secretion by stimulating incretin release through the enteroendocrine 
intestinal L cells. With the attractive hypothesis that GRP40 full agonists would lead to greater 
therapeutic efficacy, Amgen scientists discovered AM-1638 the first reported synthetic GPR40 agonist 
to stimulate both GIP and GLP-1 secretion.118 The glucose-lowering efficacy of AM-1638 was reduced 
in the presence of the GLP-1R antagonist Exendin(9–39)NH2 highlighting the importance of the GLP-1 
pathway to GPR40 full agonist pharmacology. These results provided a preclinical proof-of-mechanism 
for the therapeutic benefit and advantages of GPR40 full agonism (Figure 14). Synthetic GPR40 agonists 
developed before 2012 such as GW-9508 and TAK-875 which do not engage both the insulinogenic 
and incretinogenic axes are therefore regarded as partial agonists. 
 
 
 
Figure 14 Stimulation of the enteroendocrine and insulin axes by GPR40 full agonists (such as AM-1638) promote 
enhanced glucose control and stimulate incretins such as GLP-1/GIP and insulin secretion, whereas partial 
agonists (such as TAK-875) stimulate insulin secretion from the pancreatic β-cells but not incretin secretion from 
enteroendocrine cells. (Adapted from Luo).118 
When discovered, it was believed that GPR40 harbored one ligand-binding pocket called ‘orthosteric’ 
binding site which is used by both endogenous and synthetic ligands to induce their biological effects.49 
This binding site is defined by a cluster of hydrophilic residues in transmembrane regions 5, 6, and 7 
(Arg183, Asn244, and Arg258 shown in red in Figure 15.A) that interact with the carboxyl group present 
in most GPR40 agonists.119, 120 
 
Chapter 1 - General introduction 
 
31 
 
 
 
 
 
 
 
 
 
 
Figure 15 A) Predicted topology and functionally important residues of human GPR40. Amino acids implicated in 
ligand binding or receptor activation are shown in red (key residues in the GPR40 binding pocket, they interact 
with the carboxyl group present in various GPR40 ligands), orange (important for binding of synthetic agonist 
GW-9508 but not the endogenous ligand linoleic acid), and blue (form ionic locks with R183 and R258, 
maintaining GPR40 in an inactive conformation; ligand interaction with one or both arginine residues disrupts 
the lock and promotes receptor activation), whereas two known polymorphic residues are shown in 
green.(Adapted from Mancini).49 B) Interaction of the carboxylate of TAK-875 with the charge cluster as seen in 
a lateral view. The carboxylate moiety is highly coordinated by several key residues, notably Arg183, Arg258, and 
Asn244.(Adapted from Srivastava).121 
 
 
 
A) 
B) 
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This interaction with the three amino acids Arg183, Asn244, and Arg258 was confirmed by the high-
resolution crystal structure of the human GPR40 bound to TAK-875 at 2.3A˚ resolution121 as depicted 
in Figure 15.B. However, mutation of these key residues differentially affected the functional activity 
of different agonists,120, 122 thus suggesting the possible existence of additional, topographically distinct 
ligand-binding sites named ‘allosteric’. This hypothesis was confirmed by the work of Lin, who 
discovered three novel GPR40 allosteric agonists that bind to separate sites and display complex 
binding and functional cooperativity with one another and with the endogenous GPR40 ligands 
docosahexaenoic.123 Further research on the mode of action of TAK-875 revealed that the compound 
acts as an ago-allosteric modulator of FFAR1 that exerts its effects by acting cooperatively with 
endogenous plasma FFAs in human patients as well as diabetic animals (Figure 16).124 
 
 
 
 
Figure 16 Schematic model of insulinotropic action of TAK-875 in cooperativity with endogenous FFAs in β-cells. 
FFAR1 activation by endogenous FFAs contributes to a moderate glucose-stimulated insulin secretion (GSIS) in 
vivo (left). TAK-875 treatment potentiates FFA induced boosted insulin secretion as an allosteric modulator, 
whereas FFAs also augment the activity of TAK-875, showing reciprocal positive cooperativity (middle). TAK-875 
treatment in the absence of FFAs (nonphysiological) results in partial activation of FFAR1 and weak potentiation 
of GSIS (right) (Adapted from Yabuki).124 
 
 
Conclusion 
 
In conclusion, the evaluation of mRNA levels suggests FFAR1 is expressed highly and predominantly on 
pancreatic β-cells. Extensive work on structure-activity relationship was done by both academic and 
industrial research groups, in order to generate selective and potent ligands with optimized 
physicochemical properties. These compounds enabled research that has provided valuable insight 
into the pharmacology of the receptor, as well as precious information on ligand binding. Taken 
together, all these data paved the way for the design, synthesis and characterization of novel imaging 
probes targeting this relevant and attractive receptor, which had until now been unexplored for 
imaging based determination of β-cell mass. Additionally, as this receptor is highly conserved between 
species, it should allow good translation of binding efficacy between different animal models and 
human. 
 
Gut peptides such as GLP-1, GIP and Glucagon, stabilized analogs thereof and even combination of 
them, have already proved valuable therapeutic effects, or are currently clinically evaluated for the 
treatment of diabetes. These metabolic hormones, which can be isolated from natural sources, or their 
derivatives are an interesting basis for the design of novel bio imaging probes. The development of 
new methods to label such peptides with fluorophores or chelators is of high interest for the scientific 
community. 
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Abstract  
 
 
 
 
Diabetes affects an increasing number of patients worldwide and is responsible for a significant rise in 
healthcare expenses. Imaging of β-cells bears the potential to contribute to an improved 
understanding, diagnosis, and development of new treatment options for diabetes. Here, we describe 
the first small molecule fluorescent probe targeting the free fatty acid receptor 1 (FFAR1/GPR40). This 
receptor is highly expressed on β-cells, and was up to now unexplored for imaging purposes. We 
designed a novel probe by facile modification of the selective and potent FFAR1 agonist TAK-875. 
Effective and specific binding of the probe was demonstrated using FFAR1 overexpressing cells. We 
also successfully labeled FFAR1 on MIN6 and INS1E cells, two widely used β-cell models, by applying 
an effective amplification protocol. Finally, we showed that the probe is capable of inducing insulin 
secretion in a glucose-dependent manner, thus demonstrating that functional activity of the probe 
was maintained. These results suggest that our probe represents a first important step to successful 
β-cell imaging by targeting FFAR1. The developed probe may prove to be particularly useful for in vitro 
and ex vivo studies of diabetic cellular and animal models to gain new insights into disease 
pathogenesis. 
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Introduction 
Diabetes is a chronic metabolic disease characterized by hyperglycemia resulting either from 
deficiency in insulin secretion due to β-cell loss or dysfunction, insulin resistance, or both. According 
to the International Diabetes Federation, around 390 million* of people are affected worldwide,1 and 
treatment to date still is only symptomatic. It generates a massive and intensifying burden on 
healthcare systems by cost of direct disease management, as well as a consequence of complications 
caused by long-standing and not properly controlled diabetes, such as cardiovascular disease, diabetic 
foot ulcers, diabetic nephropathy or retinopathy. Yet, the precise molecular and cellular mechanisms 
that cause the decrease in mass of the insulin-producing cells remain to be further elucidated. 
Longitudinal studies aiming at in vivo quantification of β-cells in animal models, as well as in patients, 
would significantly improve the knowledge on the pathophysiology of the disease; it would allow 
monitoring of therapeutic efficacy and thus facilitate the discovery of new drugs for optimized diabetes 
treatment.2 However, noninvasive β-cell imaging remains a significant challenge. First, in healthy 
pancreatic tissue, endogenous β-cells account for only 2−3% of the total cells and are dispersed 
throughout the whole organ. Second, the pancreas is surrounded by the gastrointestinal system and 
liver,3, 4 and therefore, probe uptake in the latter organs obscures visualization of the pancreas.5 Several 
receptors or proteins that are selectively expressed on β-cell membranes have been described as 
potentially useful targets for β-cell imaging, including sulfonylurea receptor 1 (SUR1),6, 7 vesicular 
monoamine transporter 2 (VMAT2),8−10 membrane protein IC2,11−13 or transmembrane protein 27 
(TMEM27).14, 15 However, all these targets show limitations such as heterogeneous or non-β-cell 
specific expression, low absolute uptake, or even unspecific accumulation of the tracer.16 To date, the 
most promising probes are based on agonists of the glucagon like peptide 1 receptor (GLP-1R)17, 18 with 
proven high specificity for β-cells; however, some concerns exist whether potential downregulation of 
the receptor may influence uptake of the tracer.19, 20 This downregulation may lead to an erroneously 
low quantification of β-cell number. In summary, although imaging of the GLP-1 receptor is promising, 
the search for alternative probes with ideal properties for accurate imaging of β-cell mass should 
continue. 
The free fatty acid receptor 1 (FFAR1, also known as GPR40) belongs to the class of the seven-
transmembrane domain G-protein-coupled receptors and was deorphanized in 2003.21−23 Endogenous 
ligands of the receptor include medium to long-chain free fatty acids which enhance a glucose-
dependent insulin secretion. Although evidence of FFAR1 expression was found in human brain and 
intestine,21 the receptor is predominantly expressed in human and rodent β- cells.22−24 Since expression 
in islets is high, FFAR1 appears to be an attractive receptor to target, which had up to now been 
unexplored for imaging based determination of functional β-cell mass. It also represents an interesting 
option to follow another β-cell specific receptor population in animal models, possibly providing new 
insights in the pathogenesis of diabetes. As this receptor is highly conserved between species (see 
Supporting Information for sequence homology), it should allow good translation of binding efficacy 
between different rodent and human cells.25 As FFAR1 activation stimulates insulin release only at high 
glucose concentration, it became an attractive therapeutic target26, 27 to enhance insulin secretion in 
T2D without the risk of hypoglycemia. Numerous synthetic FFAR1 agonists have been described in the 
last years and many of them are under development as T2D drugs.28 Fasiglifam (TAK-875) is an orally 
                                                          
*When the paper was written, the last available report from the Internation Diabetes Federation dated from 
2013. At that time, 390 million people were affected by diabetes worldwide. Updated numbers can be found in 
the introduction.   
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available and potent agonist of FFAR1 with good selectivity for the receptor over other members of 
the FFA receptor family (i.e., FFAR2, FFAR3, GPR120).29 It reached clinical phase III and improved 
glucose-stimulated insulin secretion (GSIS) and blood glucose control in diabetic patients, with a low 
risk of hypoglycemia.30, 31 We therefore envisioned that the TAK-875 scaffold would serve as a good 
starting point to develop FFAR1 targeting probes. 
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Material and Methods 
Chemistry 
See the Supporting Information for a detailed description of the syntheses. 
 
Cell Culture 
Human embryonic kidney (HEK293) cells stably expressing human GPR40/FFAR1 (HEK293 cells were 
transfected with hGPR40 using a pEAK8 vector system) were grown in high glucose DMEM (41965 Life 
Technologies) containing 10% (v/v) FCS gold PAA, 1% (v/v) NEAA and puromycin (1 μg/mL), in a 
humidified 5% CO2 atmosphere at 37 °C. Human embryonic kidney (HEK293) cells were cultured under 
the same conditions except for the absence of puromycin. Transgenic C57BL/6 mouse insulinoma cell 
line (MIN6) were grown in high-glucose DMEM (Life Technologies 31966) media supplemented with 
15% FCS (Good Forte, Cat no. P40-47500), 100 units/mL penicillin and 100 μg/mL streptomycin 
antibiotics, 1× HEPES (Life Technologies) and 100 μM β-mercaptoethanol in a humidified 5% CO2 
atmosphere at 37 °C. The rat insulinoma cell line (INS1E) was grown in RPMI-1640 medium 
supplemented with 10% FBS, 2 mM glutamine, 10 mM HEPES, 50 μM β-mercaptoethanol, 1 mM 
sodium pyruvate, 100 units/mL penicillin, and 100 μg/mL streptomycin in a humidified 5% CO2 
atmosphere at 37 °C. 
 
Fluorometric Imaging Plate Reader (FLIPR) Ca2+ Assays 
HEK293 cells stably expressing human GPR40/FFAR1 were plated in a poly-D-Lys coated 96-well plate 
with 40 000 cells/well and incubated overnight in a humidified 5% CO2 atmosphere at 37 °C. Then, 
cells were incubated in Hank’s buffer salt solution supplemented with HEPES (pH = 7.5) containing 
fluorescent calcium indicator Fluo 4 AM (Molecular Devices, final concentration 2 μM) + 20% (w/v) 
pluronic acid for 60 min at 37 °C. Cells were washed with a Tecan Ultra (Tecan Group Ltd.) device before 
the addition in the wells of tested compounds at various concentrations (previously dissolved in DMSO 
at 10 mM concentration and diluted with assay buffer). Increase of the intracellular Ca2+ concentration 
after addition was monitored by FLIPR Tetra system (Molecular Devices). Experiments were performed 
in triplicates. 
 
In Vitro Live Cell Imaging 
HEK293 cells overexpressing GPR40 were plated in a 96-well plate with 50 000 cells per well and 
incubated overnight in a humidified 5% CO2 atmosphere at 37 °C. Then culture media was removed 
and replaced by PBS buffer before the addition of varying concentrations of fluorescent probe. For the 
blocking experiment, unlabeled TAK-875 (200 nM) was added 3 min before the fluorescent probe (20 
nM). After 30 min of incubation in a humidified 5% CO2 atmosphere at 37 °C, DRAQ5 was added (1/ 
1000, nucleus staining, 10 min incubation) and cells were washed twice with PBS buffer before being 
imaged with the high content imaging system Operetta from PerkinElmer with a 20× long working 
distance objective and analyzed with Harmony Imaging software. With this software, first nuclei were 
identified using DRAQ5 staining and subsequently cytoplasm was identified using the fluorescence of 
probe 16. With this information, the software calculated the mean fluorescence for each cell. 
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In Vitro Live Cell Imaging−Confocal Microscopy 
HEK293 cells overexpressing FFAR1/GPR40 were plated in a 96-well plate with 50 000 cells per well 
and incubated overnight in a humidified 5% CO2 atmosphere at 37 °C. Then, culture media was 
removed and replaced by fresh medium before the addition of probe 16 (2 μM). For the blocking 
experiment, a 10-fold excess of unlabeled TAK-875 was added 3 min before the fluorescent probe. 
After 30 min of incubation in a humidified 5% CO2 atmosphere at 37 °C, DRAQ5 was added (1/ 500, 
nucleus staining, 10 min incubation) and cells were washed once with HBSS buffer (supplemented with 
5% FCS) before being imaged with the TCS SP8 confocal microscope from Leica Microsystems with a 
40× objective. Then, cells were incubated in a humidified 5% CO2 atmosphere at 37 °C for another 2.5 
h to enhance internalization before being imaged with a 40× objective (+ numerical zoom 4). Pictures 
and quantification of fluorescence were analyzed using the Leica Application Suite X (LAS X) imaging 
software. 
 
RT-PCR mRNA Levels  
Expression levels of FFAR1 in different cell lines were analyzed using real time, quantitative PCR. To 
this end, TaqMan Gene Expression Assays were used together with TaqMan Fast Virus 1-Step Master 
Mix and the StepOnePlus Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific, Inc.). 
The PCR preparation, as well as run, was performed according to the protocol provided by the 
manufacturer. The gene expression assays used can be found in Table 1. For analysis, the house 
keeping gene GAPDH was used as control and for normalization. 2ΔCt values were calculated for fold 
change and then displayed as difference to GAPDH expression. 
Table 1. TaqMan probes for real time PCR analysis 
GENE ACCESSION NUMBER EXPRESSION ASSAY 
hFFAR1 NM_005303 Hs03045166_s1 
rFFAR1 NM_153304 Rn00824686_s1 
mFFAR1 NM_194057 Mm00809442_s1 
 
Antibody Amplification  
Cells were incubated in either PBS or PBS with 10 μM of probe 16 at RT. The incubation was carried 
out for either 15 min or 1 h. Subsequently, cells were fixed for 15 min in 3.5% formaldehyde in PBS, 
washed and blocked for 20 min in blocking buffer with 0.1% Tween (SuperBlock, Thermo Scientific). 
The antibody incubation with Anti-Alexa Fluor 488 Rabbit (Life Technologies) and with Anti-Rabbit 
Alexa Fluor 488 (Jackson Immuno Research) was done for 1 h each with a 1:100 dilution in blocking 
buffer (Figure 6). Hoechst 33342 was used to label nuclei. To evaluate the binding specificity of the 
probe, we performed a blocking experiment. Therefore, we added 1 mM of unlabeled TAK-875 (100- 
fold excess) before adding the probe 16. Immunostainings were analyzed using the Operetta System. 
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Staining of Dispersed Mouse Islets  
Adult C57BL/6 (Jackson Laboratories, ME) were euthanized by cervical dislocation. An incision around 
the upper abdomen was performed to expose liver and intestines. Thereafter, the ampulla was located 
and clipped. Pancreas was perfused through the common bile duct with 5 mL of cold collagenase (1 
mg mL−1 of collagenase P, Roche) saline solution. The pancreas was dissected and placed into a warm 
collagenase saline solution for 15 min. After enzymatic digestion of the pancreatic tissue, islets were 
picked and cultured overnight in an incubator at 37 °C. Thereafter, islets were incubated with Liberase 
(Roche) for approximately 20 min and mechanically dispersed and cultured overnight at 37 °C. Beta 
cells were placed into a physiological saline solution and incubated with the probe as indicated in the 
amplification section above. Thereafter, cells were stained for insulin. The investigation conforms to 
the Guide for the Care and Use of Laboratory Animals published by the United States National 
Institutes of Health (NIH publication no. 85-23, revised 1996). 
 
Calcium Measurements 
Cells were seeded on Ibidi culture dishes (μ-Dish, 35 mm high glass bottom) with 4 × 105 cells 
overnight. Medium was removed and the cells were loaded with Fura-2 (AM) (Invitrogen) (10 μL of a 
2.87 μM solution) in HBSS (Hanks buffered-salt solution) for 1h at RT. The cells were washed with 
tyrode buffer and the dish was mounted on the microscope (Olympus IX81). Temperature was 
regulated to 37 °C and the dishes are filled with 2 mL of tyrode buffer. Equilibration of the system was 
allowed for 5 min; then the compound of interest was added and signal was recorded for 10 min. The 
effect was determined by calculation of the ratio of fluorescence at 340 nm/380 nm using the Olympus 
Xcellence Imaging software. 
 
Glucose-Stimulated Insulin Secretion (GSIS) 
The INS1E cells were preincubated in HEPES-buffered Krebs Ringer bicarbonate buffer with 2.5 mM 
glucose and 0.1% FAF-BSA for 1.5 h at 37 °C with 5% CO2. Subsequently, the buffer was replaced with 
the same buffer supplemented with either 2.5 mM or 8.3 mM glucose, 0.1% BSA and compounds with 
indicated concentrations. This incubation was carried out for 1.5 h at 37 °C with 5% CO2. At the end of 
the incubation, the supernatant was collected and the insulin secretion was measured using the RAT 
Ultrasensitive Insulin ELISA (Alpco). 
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Results and Discussion 
Design of a New FFAR1 Targeting Optical Probe 
We started the design of a FFAR1 targeting probe with the selection of an appropriate ligand, 
demonstrating high affinity and selectivity for the target receptor. TAK-875 as a potent and selective 
agonist of the FFAR129 fulfilled these requirements. The clinical development of TAK-875 was 
terminated due to concerns on liver toxicity after meta-analysis of the pursued clinical studies,31 which 
involved extended treatment with moderate to high doses of TAK-875.30 The mechanism of the 
observed alanine aminotransferase (ALT) increase in liver is unclear, but seemingly did not result from 
an acute drug effect. We thus believe that this will not be detrimental for future diagnostic work, as 
for imaging purposes only single applications of probe are required. By inspection of the structure 
activity relationship of the TAK-875 scaffold,25 we concluded that the dihydrobenzofuran carboxylic 
acid is the key moiety for the interaction with the receptor and that modifications on the 4′-position 
of the terminal biphenyl ring were well tolerated in terms of agonistic activity and binding affinities. A 
docking model of FFAR1 supported this assumption by showing that tail substituents pointed toward 
the exit of the binding pocket.25 Accordingly, we used the 4′-position to synthesize TAK-875 derivatives 
1−8 containing various linker systems. During the course of our work, a high-resolution structure of 
the TAK-875 bound FFAR1 was published, confirming that the position we used should be suitable to 
modify the compound with minimal effects on potency.32 We envisioned incorporation of a functional 
group allowing facile conjugation with a fluorophore,33 such as an alkyne/azide for click reactions or an 
amine for peptide coupling. To evaluate the functional activity of the synthesized derivatives, we 
performed a FLIPR Ca2+ assay (Figure 1), measuring the increase in cytosolic Ca2+ concentration caused 
by stimulation of the Gαq−phospholipase C signaling pathway by FFAR1.34, 35 A short lipophilic linker 
chain seemed to be favorable since increasing number of PEG units led to a significant drop in agonistic 
potency (compounds 6−8). We decided to select the short-size amine containing linker of compound 
4, because its acylation was well tolerated as shown by 5, displaying low nanomolar potency in the 
order of the original ligand TAK-875. Furthermore, the amino group enabled convenient conjugation 
with dyes, most of them being commercially available as amine-reactive N-hydroxysuccinimide (NHS) 
esters. 
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Figure 1 In vitro activity of TAK-875 derivatives Structures and activity of TAK-875 derivatives with different 
linkers compared to the original ligand TAK-875. Activities were measured by FLIPR Ca2+ assay. All values are 
mean of triplicates. See also Supporting Information for detailed description of the syntheses. 
 
The Charge of the Fluorophore Influences the Specificity of Binding 
To evaluate the influence of the incorporated fluorophore on cellular binding, we synthesized several 
fluorescent probes in a few steps, starting from the building blocks 9 and 11 whose preparations were 
previously published25 (Figure 2). The amine function of compound 13 allowed quick attachment of a 
wide variety of dyes with different optical and physical properties. We selected small molecule 
fluorophores among representative cores used in biomolecular labeling including coumarin, 
fluorescein, BODIPY, rhodamine and cyanine.36 In the FLIPR assay described above, a drop of agonistic 
activity was observed compared to TAK-875 (EC50 = 1.72 μM (13), 2.37 μM (19)). Unfortunately, several 
other probes could not be characterized in this system due to interference with the Fluo-4AM dye used 
for detection. It was interesting to note that the near-infrared Bodipy derivative did not show agonistic 
activity up to 20 μM. However, the functional activity of a ligand may not reflect its binding properties, 
and therefore, it was difficult to assess, if attachment of the dye may reduce the agonistic properties 
of the compound, but still would allow binding. Thus, transgenic HEK293 cells overexpressing human 
FFAR1 (hFFAR1-HEK) were used to further evaluate the synthesized fluorescent probes. To assess 
specificity of the binding, regular HEK293 cells, lacking expression of FFAR1, were used as control. We 
observed that fluorophore charge strongly influenced the binding specificity of the probe. Probes with 
neutral (Bodipy 650, tetramethylrhodamine TAMRA)37 or positively charged (Cyanine Cy5.5) dyes 
exhibited medium to high unspecific membrane staining, whereas probes with negatively charged dyes 
(carboxyfluorescein CF, fluorescein isothiocyanate FITC, Alexa Fluor 488) were less prone to this 
phenomenon (Figure 3 and Supplementary Figure S1). These results are in agreement with a recent 
publication describing the strong interaction of many commonly used fluorophores with lipid bilayers. 
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The resulting unspecific signals can easily be misinterpreted as binding to targets located on the cell 
surface.38 This highlights that a careful choice of fluorophore is essential for designing a new probe, in 
particular if nonpeptidic small molecule probes are concerned. 
 
 
Figure 2 Structures of the fluorescent probes. (A) Synthetic scheme of hFFAR1-targeting fluorescent probes. CF, 
carboxyfluorescein; FITC, fluorescein isothiocyanate; TAMRA, tetramethylrhodamine; Cy, cyanine. (B) Structure 
and overall net charge of the dyes Alexa488, TAMRA, Bodipy 650, and Cy5.5 at physiological pH. Detailed 
description of the syntheses is provided in the Supporting Information. 
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Figure 3 Influence of fluorophore charge on unspecific binding. HEK293 cells overexpressing hFFAR1 show a 
distinct signal on the cell membrane when incubated with the probe 15 containing the negatively charged dye 
FITC (A and B), while HEK293 expressing no FFAR1 show no fluorescence. In contrast, probes 17 and 18 with the 
neutral fluorophores TAMRA (C and D) and Bodipy 650 (E and F) as well as probe 19 containing the positively 
charged fluorophore Cy5.5 (G and H) showed a clear signal both in hFFAR1 overexpressing and HEK293 control 
cells. Scale bar is 100 μm. (I−L) Quantification of the signal in mean fluorescence per cell versus background. 
Student’s test, *P < 0.05, **P < 0.01, ***P < 0.001; error bars indicate SD. 
 
Labeling in Live HEK293 Cells Overexpressing hFFAR1 
We thus focused on probe 16 to gain more insight into the probe binding properties, as in this case 
signal to background seemed favorable. This probe is conjugated with Alexa488 which was reported 
to be superior to other fluorescein equivalents such as fluorescein thioisocyanate and 
carboxyfluorescein.39 Live cell imaging of hFFAR1-HEK293 cells demonstrated that the receptor could 
be visualized using probe 16 (Supplementary Figure S1). As expected, membrane staining was 
concentration dependent (Supplementary Figure S2). Fluorescent signals were detectable at probe 
concentrations as low as 20 nM. To confirm whether the observed signal is specific to the receptor 
ligand interaction, a blocking experiment was performed. By co-incubation of the fluorescent probe 
with a 10-fold excess of unlabeled agonist (TAK-875), we were able to effectively prevent the binding 
of 16 to hFFAR1 (Figure 4). These results show that 16 is a specific FFAR1 targeting probe. The applied 
image analysis software (Harmony) is, in this setup, not capable of distinguishing between membrane 
and cytoplasm, thus the determined mean fluorescence graphs underestimate the levels of bound 
probe. For this reason, we performed another set of experiments to obtain confocal images, allowing 
a more detailed analysis (Supplementary Figure S3. We could determine membrane to background 
ratio to be 13.0 ± 3.7 that could be effectively blocked with only 10× excess of TAK-875 (signal-to-noise 
ratio for the blocking experiment: 1.5 ± 0.3). It is noteworthy that a concentration of 2 μM of 16 was 
used to properly assess potential nonspecific binding properties. We also investigated the tendency of 
FFAR1 to internalize upon binding of probe 16. Internalization was observed from 90 min incubation 
time. White arrows indicate strong enrichment of the probe in intracellular vesicles that were largely 
clustered in the perinuclear region (Supplementary Figure S4, 3 h incubation time). This data is in good 
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agreement with results described in two recent publications, (40,41) examining Myc and FLAG-tagged 
FFAR1/GPR40 overexpressing cells. Localization and distribution supports receptor mediated uptake 
of probe. 
 
 
Figure 4 Probe 16 specifically binds the hFFAR1. HEK293 cells incubated with probe 16 at a concentration of 20 
nM showed low fluorescence (A), while HEK293 overexpressing hFFAR1 showed strong fluorescence on cell 
membranes (B). This effect was no longer visible in cells treated with a 10-fold excess of unlabeled TAK-875 prior 
to incubation with probe 16 (C). Scale bar is 100 μm. (D) Quantification of the mean fluorescence per cell with 
Student’s test. *P < 0.05, **P < 0.01, ***P < 0.001; error bars indicate SD. 
 
Imaging of FFAR1 in Immortalized β-Cells with Endogenous Levels of FFAR1 Expression 
Having established that probe 16 can specifically detect FFAR1 in an overexpression system, we set 
out to determine whether it can be effective to label FFAR1 on cells expressing biological relevant 
levels of the targeted receptor. We chose MIN6 and INS1E as two commonly used pancreatic β-cell 
lines;(42) however, the attempt to label FFAR1 with different concentrations of probe 16 on these two 
cell lines resulted in no detectable fluorescence. We were not able to examine FFAR1 expression by 
staining with commercially available antibodies; thus, we compared the mRNA expression levels for 
FFAR1 in the used cell lines (Figure 5). The overexpressing FFAR1-HEK cells show drastically higher 
mRNA expression levels of hFFAR1 compared to MIN6 and INS1E cells, suggesting that the obtainable 
signal is too weak due to low abundance of receptors available for ligand binding on the cell surface.  
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Figure 5 Differences of FFAR1 mRNA expression levels between HEK293 overexpressing FFAR1 and β-cells lines. 
hFFAR1 mRNA expression has been determined by three independent real time PCR experiments. The control 
cell line HEK293 expressed hFFAR1 at marginal levels, while the hFFAR1 overexpressing HEK293 cell line showed 
a 230% difference in expression of hFFAR1. Both β-cell lines INS1E and MIN6 showed a significant expression of 
FFAR1. Shown data are from one representative experiment. 
 
To improve sensitivity of detection, we developed an efficient protocol for signal amplification using 
an anti-Alexa 488 antibody (Figure 6). In brief, cells were fixed after incubation with probe 16 and 
treated with Anti-Alexa Fluor 488 Rabbit and Anti-Rabbit Alexa Fluor 488 goat-antibodies, successively, 
which led to a significant increase on signal strength. With this amplification strategy, we were able to 
achieve receptor detection in the applied experimental setup. We observed that this effect increased 
with longer incubation times. Interestingly, incubation of 16 under high glucose conditions also 
resulted in an increase of fluorescence (Figure 6A−E and Supplementary Figure S5). Whether this effect 
is due to a higher abundance of receptor molecules on the cell surface or an increase in receptor 
accessibility remains to be elucidated. To rule out unspecific binding of probe 16 in MIN6 cells or of 
the Alexa488 labeled secondary antibody used in this experiment, we performed additional control 
experiments (Figure 6I−J′). Fluorescence could be efficiently blocked by coincubation with excess of 
unlabeled ligand. Incubation with secondary antibody alone also did not result in any detectable signal. 
These experiments demonstrate that we specifically label FFAR1 (Figure 6E−J′). Notably, this effect was 
also visible with INS1E cells shown in Supplementary Figure S6. Unfortunately, incubation with 16 after 
fixation was unsuccessful, likely due to alterations of the FFAR1 ligand binding site during fixation. 
Although the developed signal amplification strategy adds a layer of complexity and limits the probe 
applicability for the moment to in vitro and ex vivo work, further investigations will be carried out to 
translate these results to an in vivo environment. A possible sensitive alternative to the amplification 
protocol may be utilization of flow cytometry (FACS) for the detection of cells expressing FFAR1. With 
the help of this much more sensitive method, we were able to demonstrate that probe 16 shows 
detectable binding to FFAR1 not only to overexpressing HEK 293 cells, but also to MIN6 cells 
representing cells with endogenous expression levels of FFAR1 (Supplementary Figures S7 and S8). 
Lastly, we examined specificity of binding of probe 16 using dispersed mouse islets isolated from 
C57BL/6J mice. Beta cells were stained with anti-insulin antibodies, labeled with Alexa 594. A 
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satisfactory overlap could be observed after thorough optimization of assay conditions. It has to be 
stated that insulin content of cells may vary and may be influenced by the isolation and, moreover, by 
the dispersion and culture protocol, as well as by incubation protocol and washing conditions. Also, 
little is known on the number of FFAR-1 receptor copies presented on the surface and how this would 
be influenced by the above-mentioned factors. However, we could confirm good correlation of the 
two signals at 488 and 594 nm, underlining the binding preference of 16 to β-cells (Supplementary 
Figure S9). In recent literature, there is an ongoing discussion on the effectiveness and specificity of 
antibody-mediated detection of FFAR1.43−45 In our own hands, we have not been able to achieve 
reliable and specific staining of FFAR1 using six commercially available antibodies, as well as four 
custom-made anti-hGPR40 antibodies. Thus, FFAR1 detection in living cells is so far difficult to obtain 
with the available antibodies, while probe 16 can be effectively used to detect FFAR1 on cells. To this 
end, we propose that a further developed fluorescent FFAR1-specific probe will prove to be useful to 
study this receptor in the course of diabetes. 
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Figure 6 Probe 16 stains MIN6 cells after antibody signal amplification. MIN6 live cells incubated with probe 16 
at a 10 μM concentration showed fluorescence after signal amplification (A−D). This effect was strengthened 
with longer incubation time (C and D) or high glucose concentration (B and D). The mean intensity of Alexa488 
was measured in all MIN6 cells after 60 min incubation under high glucose condition and analyzed using 
Kruskal−Wallis test together with Dunn’s post hoc test (E). This measurement shows the increase in fluorescence 
with antibody amplification and the mean intensity of Alexa488 in the necessary controls. The blocking with 
excess of unlabeled TAK-875 shows a slight increase in fluorescence. 1, probe 16; 2, probe 16 and antibody 
amplification; 3, excess TAK-875, probe 16, and antibody amplification; 4, anti-rabbit-Alexa488 antibody control; 
*P < 0.05, **P < 0.01, ***P < 0.001; error bars indicate SEM. Schematic illustration of the antibody signal 
amplification as shown in (G− J′). Probe 16 (brown) containing the dye Alexa488 (green star) binds hFFAR1 (light 
orange). The first antibody Anti-Alexa488 Rabbit (blue) allows multiple attachment of the second antibody Anti-
Rabbit Alexa488 (purple) resulting in an amplification of the fluorescent signal. No antibody amplification in the 
presence of an excess of unlabeled TAK-875 and no unspecific binding of the secondary antibody (F). MIN6 cells 
incubated only with 10 μM of probe 16 showed no detectable fluorescence (G and G′), while after antibody 
amplification (H and H′), a high fluorescence signal was detected. Cells treated with an excess of unlabeled TAK-
875 prior to incubation with probe 16 and signal amplification showed no fluorescence (I and I′). Incubation with 
secondary antibody only showed no fluorescence (J and J′). Green: Alexa488. Blue: Hoechst 33342. Scale bar is 
100 μm. AB, antibody; α-rb-Alexa488, second antibody Anti-Rabbit Alexa488. 
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Probe 16 Is an Agonist, Stimulating Glucose-Dependent Insulin Secretion 
To gain more insight into the nature of binding of the probe to FFAR1, we checked whether 16 still 
effectively activates the receptor. Since probe 16 contains a green-range fluorophore and thus is not 
compatible with the Fluo-4AM dye used in a standard FLIPR Ca2+ assay, we performed a calcium assay 
using the dye Fura-2 which allows ratiometric detection of intracellular calcium levels. At 
concentrations of 1 μM of probe 16, we observed similar calcium response as detected when 
incubating cells with 10 nM of TAK-875 (ratio 1.45 ± 0.14 vs 1.07 ± 0.01 see Supplementary Figure S10). 
As these experiments were performed in an overexpressing cell line, we furthermore carried out a 
glucose-stimulated insulin secretion assay to confirm functional activity in a β-cell line with 
endogenous FFAR1/GPR40 levels. In agreement with previously published results, TAK-875 showed an 
insulinotropic effect in INS1E cells in a glucose-dependent manner.46 We observed similar effects with 
conjugate 16, which also enhanced insulin secretion at elevated glucose concentration (Figure 7). As 
expected, conjugation of the dye results in a certain loss of potency. Endogenous FFAR1 ligands like γ-
linolenic acid or oleic acid display functional activities in micromolar concentrations (1− 10 μM),22 
which is in the same concentration range as observed for probe 16. Accordingly, while coupling a 
fluorophore to the TAK-875 scaffold results in a drop of potency, we showed that the probe still 
behaves as a FFAR1 agonist, capable of inducing an insulin secretion upon receptor activation.  
 
Figure 7 Glucose stimulated insulin secretion of probe 16 in INS1E cells. Probe 16 induced a concentration-
dependent increase in insulin secretion only at high glucose concentrations. TAK: unlabeled ligand TAK-875. For 
each condition, N = 4, data is represented in means and error bars indicate SD, *P < 0.05, **P < 0.01, ***P < 
0.001. The whole experiment was repeated six times. 
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Conclusion 
The accurate assessment of the number and viability of remaining β-cells within the pancreas of the 
diseased animal or patient remains a veritable challenge in the development of new treatment options 
for diabetes. Imaging of β-cells is a key tool to provide insights into disease development and therapy 
status. In this study, we present the development and characterization of the first fluorescent probe 
that specifically binds the FFAR1, a G-protein coupled receptor that is specifically expressed on β- cells. 
We designed it by modification of TAK-875, a selective and potent FFAR1 agonist. Careful choice of 
linker and fluorophore proved to be essential to reduce unspecific binding. The probe is well tolerated 
at tested concentrations up to 10 μM, displaying no signs of cytotoxicity even at extended incubation 
times. Using this novel probe, we were able to successfully detect FFAR1 in INS1E and MIN6 cells, which 
could not be achieved before.45 Also, we have been able to demonstrate staining of primary β-cells 
isolated from dispersed mouse islets with probe 16. Albeit utilization of probe 16 to date is limited to 
in vitro imaging, it represents a new option to detect an important functional marker of β-cells. This 
opens up new opportunities to study β-cell fate over the course of disease and can help unravel 
underlying pathological processes, e.g., related to changes in its receptor population or β-cell 
dysfunction in different disease or nutritional conditions. We believe that this approach may in the 
future provide a valuable tool to detect and track pancreatic β-cell mass changes in the progress of 
diabetes using ex vivo models. It may thus also help to determine efficacy of newly explored treatment 
options to preserve β-cell mass or to quantify number of FFAR1 copies presented on β-cells in 
longitudinal studies. With increasing availability of highly specific small molecules for different classes 
of β-cell specific targets (e.g., FFAR1, GLP-1, ion channels, etc.), the reported approach can become an 
important addition to the growing arsenal of imaging tools for diabetes. Being able to follow another 
β-cell specific receptor type besides GLP-1, which is well established, will complement available 
information and may provide new insights in disease pathogenesis, particularly by studying animal 
models. Last but not least, providing a specific small molecule FFAR1/GPR40 probe may help to 
overcome issues arising from lack of specific antibodies and complement studies performed with 
tagged receptors, thus possibly shedding more light on binding events and receptor kinetics. However, 
more work will have to be invested to turn this into a probe suitable for in vivo examinations. 
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Supporting Information 
 
Supplementary Figure S1 related to Figure 3 Probe 14, 15 and 16 with negatively charged 
fluorophores show no unspecific binding on hFFAR1- HEK293 overexpressing cells. 
Supplementary Figure S2 related to Figure 4: Probe 16 binding to hFFAR1 is concentration 
dependent. 
Supplementary Figure S3: Cytoplasmic mean fluorescence of probe 16 (confocal microscopy). 
Supplementary Figure S4: Internalization of Probe 16 upon hFFAR1 binding 
Supplementary Figure S5 rel. to Figure 6: Cytoplasmic mean fluorescence of probe 16 in picture A-D. 
Supplementary Figure S6: Cytoplasmic mean fluorescence of INS1E cells after incubation with 16 
Supplementary Figure S7: FACS-based quantification of probe 16-fluorescence of GPR40-HEK293 and 
MIN6 cells. 
Supplementary Figure S8: Summary of GPR40-HEK293 and MIN6 cells mean fluorescence. 
Supplementary Figure S9: Staining of dispersed mouse islets 
Supplementary Figure S10: Representative calcium traces for TAK 875 and probe 16. 
Chemical synthesis: Molecules presented in Figure 1. 
Chemical synthesis: Fluorescent probes 13-19 presented in Figure 2. 
Sequence Homology of mouse, rat and human FFAR1. 
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Supplementary Figure S1 related to Figure 3 
 
 
Probe 14, 15 and 16 with negatively charged fluorophores show low unspecific binding on hFFAR1-HEK293 
overexpressing cells. hFFAR1-HEK293 overexpressing cells incubated with probe 15 (FITC), 14 (CF) and 16 (Alexa 
488) showed a clear signal on the membrane (A,C,E), while HEK293 cells expressing no FFAR1 incubated with the 
same probes show no fluorescence (B,D,F). Scale bar is 100 µm. (G-I) show the quantification of A-F in mean 
fluorescence per cell. Student’s Test, *P<0.05, **P<0.01, ***P<0.001; error bars indicate s.e.m. 
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Supplementary Figure S2 related to Figure 4 
 
 
Probe 16 binding to hFFAR1 is concentration dependent. hFFAR1-HEK293 overexpressing cells incubated with 
probe 16 at a concentration of 200 nM (B, B’) showed a more intense fluorescent signal than the same probe at 
a concentration of 20 nM (A, A’). A and A’ show the same image with different intensities to allow improved 
optical comparison, the intensity was adjusted for optimal signal intensity at 200 nM in the top lane (A and B), 
while it was adjusted to optimal signal intensity for cells treated with 20 nM in the lower lane (A’ and B’). Scale 
bar is 100 µm. 
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Supplementary Figure S3 
 
 
Probe 16 specifically binds the hFFAR. Confocal microscopy high-resolution pictures of hFFAR1-HEK29 
overexpressing cells labeled with probe 16 at a concentration of 2 µM (A) or cells treated with a tenfold excess 
of unlabeled TAK-875 (Xs) prior to incubation with probe 16 at a concentration of 2 µM (B). Fluorescence along 
an exemplary linear region of interest (ROI) shows a clear membrane labeling on cells (A’). This effect was no 
longer visible in the blocking experiment (B). Quantification of fluorescence for cells treated with probe 16 (A’’) 
or cells treated with probe 16 and a tenfold excess of unlabeled TAK-875 (B’’) (complete analysis). Green: 
Alexa488. Blue: DRAQ5 (nuclei). 
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Supplementary Figure S4 
 
Internalization of Probe 16 upon hFFAR1 binding. Confocal microscopy high-resolution pictures of hFFAR1-
HEK293 overexpressing cells labeled with probe 16 at a concentration of 2 µM show internalization of probe 16 
in vesicles clustered in the perinuclear region indicated by white arrows. (A) Green: Alexa488. (B) Merged Green: 
Alexa488 and Blue: DRAQ5 (nuclei). 
 
 
 
 
Supplementary Figure S5 rel. to Figure 6 
 
Measurements of cytoplasmic mean fluorescence of probe 16 in picture A-D of Figure 6. The mean intensity of 
Alexa488 was measured in all MIN6 cells. This analysis showed the increase in fluorescence with longer 
incubation time but only after 60 min incubation a glucose-dependent increase in fluorescence can be shown. 
Error bars indicate s.e.m. 
Chapter 2 - Synthesis and Characterization of a promising novel FFAR1-GPR40 targeting fluorescent probe for β cell imaging 
 
68 
 
Supplementary Figure S6 
 
Cytoplasmic mean fluorescence of INS1E cells after incubation with probe 16. Measurements of cytoplasmic 
mean fluorescence of probe 16 of Ins1E cells analogous to Figure 6 for MIN6. The mean intensity of Alexa488 
was measured in all INS1E cells; error bars indicate s.e.m. 
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Supplementary Figure S7 
 
FACS-based quantification of probe 16 fluorescence of GPR40-HEK293 and MIN6 cells. The cells were stained 
with probe 16 at different concentrations: A,E: no treatment, B,F: 1 µM, C,G: 3 µM, and D,H: 10 µM of probe 16. 
To distinguish non-viable cells or debris from viable cells, cells have been additionally incubated with propidium 
iodide at 1 µM and have been excluded form the analysis by appropriate gating. Mean of fluorescence increased 
upon increasing concentration of probe 16. GPR-HEK293 overexpressing cells showed stronger fluorescence 
intensity in comparison to MIN6. 
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Supplementary Figure S8 
 
Summary of GPR40-HEK293 and MIN6 cells mean fluorescence. FACS analysis of GPR40-HEK293 (A-D) and MIN6 
(E-H) cells using probe 16 at different concentrations (A,E: no treatment, B,F: 1 µM, C,G: 3 µM, and D,H: 10 µM 
of probe 16. A dose dependent increase of fluorescence has been observed for both cell lines. 
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Supplementary Figure S9 
 
 
 
Staining of dispersed mouse islets. Dispersed islets of C57 mice, stained with anti-INS (labelled with Cy5) and 
compound 16 (Alexa488). A with Hoechst control for detection of nuclei, B with glucagon staining as control 
against alpha cells), C and D confocal images with merged staining of insulin and probe 16. 
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Supplementary Figure S10 
A) Probe 16 (1 µM) (ratio 340 nm/380) = 1.07 ± 0.01) 
 
 
 
B) TAK 875 (10 nM) (ratio 340 nm/380) = 1.45 ± 0.14) 
 
Representative calcium traces for TAK 875 and probe 16. 
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Supplemental experimental procedures - chemical synthesis 
General methods 
Unless otherwise noted, all reagents were purchased from commercial suppliers (Sigma Aldrich, Fisher) 
and used without further purification. Alexa 488 and Bodipy 650 were purchased from Life 
Technologies as NHS ester, Fluorescein isothiocyanate (FITC), carboxyfluorescein (CF) NHS ester, 
carboxytetramethylrhodamine (TAMRA) NHS ester and Coumarin 343 were purchased from Sigma 
Aldrich, Cy5.5 NHS ester was purchased from InterChim. Boc-NH-PEG63-NHS ester was purchased from 
Rapp Polymer GmbH. N3-PEG4-NHS ester and N3-PEG8-NHS ester were purchased from Iris Biotech 
GmbH. All solvents used were of HPLC grade. Microwave assisted reactions were performed with a 
Biotage Initiator device. Reactions were monitored by LC-MS or by thin-layer chromatography on 
Merck 50x100 mm silica gel 60 aluminum sheets with fluorescent indicator. LC-MS data were acquired 
using the HP-Agilent 1100 MSD system with a Phenomenex Luna column Luna (C-18, 100 Å pore size, 
3 μm particle size, 10x2.0 mm) (METHOD 1: 0 min - 93%H2O (0.05%TFA) to 1.2min - 95%ACN; 95%ACN 
until 1.4min; 7%ACN 1.50min; flow: 1 1ml/min; MS: 110-1000MW. METHOD 2: 0 min 80%H2O 
(0.05%TFA) to 0.8min-95%ACN; 95%ACN until 1.4min; 20%ACN 1.45min; flow: 1.1ml/min; MS: 110-
1000MW). Final fluorescent probes were analyzed with a LC-MS Agilent Technologies 1200 Series 
system equipped with a Waters Xbridge (C-18, 130 Å pore size, 2.5 μm particle size, 50x2.1 mm) 
(METHOD 3: 0 min 85%H2O(0.05%TFA) to 6 min-95%ACN; 8.5 min 95%ACN; 10 min 15 %ACN; flow: 
0.6 ml/min; MS: 400-1500MW). Silica-gel column chromatography was carried out on a CombiFlash Rf 
- Isco Teledyne. Reverse-phase preparative HPLC was performed on the HP-Agilent 1100 with either a 
column from Agilent Zorbax Rx C-18 250x9.4mm, 5 µm (4 mL/min) or with a column from Waters 
Xbridge OBD C-18-250x19mm, 5 µm (16 mL/min) (Gradient: 0 min – 5 min 25% ACN/H2O(0.1%TFA) to 
30 min - 95%ACN; 95%ACN until 35 min). 1H and 13C NMR spectra were recorded on a Bruker DRX-400 
or 600 systems in d6-DMSO or CDCl3. Chemical shifts are given in parts per million (ppm) with 
tetramethylsilane as an internal standard. Abbreviations are used as follows: s = singlet, d = doublet, t 
= triplet, q = quartet, p = pentet, m = multiplet, dd = doublets of doublet, br = broad. Coupling constants 
(J values) are given in hertz (Hz). Absorption and Emission spectra were acquired with a Thermo 
Varioskan using the SkanIt 2.4.3 software.  
Abbreviations  
ACN = acetonitrile 
ADDP = 1,1'-(azodicarbonyl)dipiperidine 
Boc = tert-butyloxycarbonyl 
DCM = dichloromethane 
DIEA = diisopropylethyl amine  
DMF = dimethylformamide 
ESI-TOF = electrospray ionization mass spectrometry – time of flight 
EtOAc = ethylacetate  
HATU = 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
Hept = heptane 
HPLC = high performance liquid chromatography 
HRMS = high resolution mass spectrometry 
LC-MS = liquid chromatography - mass spectrometry 
MeOH = methanol 
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NMR = nuclear magnetic resonance 
TBAF = Tetra-n-butylammonium fluoride 
TFA = trifluoroacetic acid 
THF = tetrahydrofuran 
TIS = triisopropylsilane 
TLC = thin layer chromatography 
TBDMS-Cl = tert-butyldimethylsilyl chloride  
 
Supplemental experimental procedure Figure 1 – molecules measured by FLIPR Ca2+ assay 
Synthesis of compound 1 
Compound 12 methyl 2-[(3S)-6-[[3-(4-hydroxy-2,6-dimethyl-phenyl)phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetate was dissolved in 80 µL of THF and 40 µL of MeOH before 80 µL of 1N 
aqueous NaOH (800 µmol) were added. The mixture was allowed to stir at 50°C for 45 minutes. The 
mixture was then concentrated, diluted with water, acidified with 1M HCl aqueous solution and 
extracted with EtOAc. The organic layer was washed with brine and evaporated under reduced 
pressure. The crude was purified via silica gel chromatography (0-65% EtOAc/Hept) to afford desired 
product 1 2-[(3S)-6-[[3-(4-hydroxy-2,6-dimethyl-phenyl)phenyl]methoxy]-2,3-dihydrobenzofuran-3-
yl]acetic acid as a white powder (m = 44 mg, 109 µmol, yield 73%). 
1H NMR (600 MHz, CDCl3) δ: 1.94 (s, 6H), 2.61 (dd, 1H, J = 16.6, 9.0 Hz), 2.82 (dd, 1H, J = 16.6, 5.6 Hz), 
3.79 (m, 1H, 9.1, 9.0, 6.4, 5.6 Hz), 4.28 (dd, 1H, J = 9.1, 6.4 Hz), 4.74 (t, 1H, J = 9.1 Hz), 5.05 (s, 2H),  
6.45 (s, 1H), 6.48 (d, 1H, Jortho = 8.0 Hz), 6.58 (s, 2 H), 7.01 (d, 1H, Jortho = 8.0 Hz), 7.06 (d, 1H, Jortho = 7.5 
Hz), 7.15 (s, 1H), 7.38 (d, 1H, Jortho = 7.5 Hz), 7.42 (t, 1H, Jortho = 7.5 Hz). 
13C NMR (150 MHz, CDCl3) δ: 20.9, 37.5, 39.1, 70.3, 97.5, 107.4, 114.2, 121.2, 124.3, 125.5, 128.6, 
128.7, 129.3, 134.4, 137.1, 137.7, 141.0, 154.2, 160.4, 161.1, 175.9 
Retention time Rt = 0.93 min (METHOD 1) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C25H23O5: 403.1551; Found: 403.1586 
 
 
 
Synthesis of compound 2 methyl ester 
Compound 12 methyl 2-[(3S)-6-[[3-(4-hydroxy-2,6-dimethyl-phenyl)phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetate (250 mg, 597 µmol), propargyl bromide - 80% in toluene (650 µL, 
5.97 mmol), potassium carbonate (115 mg, 836 µmol) and potassium iodide (19.8 mg, 0.2 eq) were 
dissolved in 10 mL of DMF, and the mixture was allowed to stir under argon at 60°C for 24 hours. The 
volatiles were removed under reduced pressure and the crude was purified through silica gel 
chromatography (0-20% EtOAc-Hept) to afford methyl 2-[(3S)-6-[[3-(2,6-dimethyl-4-prop-2-ynoxy-
phenyl)phenyl]methoxy]-2,3-dihydrobenzofuran-3-yl]acetate as a colorless oil (m = 241 mg, 528 
µmol, yield 88%). 
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1H NMR (600 MHz, CDCl3) δ: 2.01 (s, 6H), 2.55 (t, 1H, J = 2,0 Hz), 2.57 (dd, 1H, J = 16.6,9.2 Hz), 2.74 
(dd, 1H, J = 16.6, 5.4 Hz), 3.73 (s, 3H), 3.81 (m, 1H, 9.2, 9.1, 6.2, 5.4 Hz), 4.27 (dd, 1H, J = 9.1, 6.2 Hz), 
4.71 (d, 2H, J = 2.0 Hz), 4.76 (t, 1H, J = 9.1 Hz), 5.07 (s, 2H), 6.47 (d, 1H, Jmeta = 2.0 Hz), 6.48 (dd, 1H, 
Jortho = 8.2 Hz, Jmeta = 2.2 Hz), 6.74 (s, 2 H), 7.02 (d, 1H, Jortho = 8.2 Hz), 7.08 (d, 1H, Jortho = 7.5 Hz), 7.18 
(s, 1H), 7.38 (d, 1H, Jortho = 7.5 Hz), 7.43 (t, 1H, Jortho = 7.5 Hz).   
13C NMR (150 MHz, CDCl3) δ: 21.2, 37.8, 39.5, 51.8, 55.7, 70.3, 75.4, 78.8, 97.5, 107.3, 113.5, 121.5, 
124.3, 125.6, 128.58, 128.65, 129.1, 135.1, 137.1, 137.6, 140.9, 156.3, 159.9, 161.1, 172.3  
Retention time Rt = 0.90 min (METHOD 2) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C29H27O5: 455.1864; Found: 455.1918 
 
 
Synthesis of compound 2 
Methyl 2-[(3S)-6-[[3-(2,6-dimethyl-4-prop-2-ynoxy-phenyl)phenyl]methoxy]-2,3-dihydrobenzofuran-
3-yl]acetate (220 mg, 472 µmol) synthesized previously was dissolved in 1.9 mL of THF and 950 µL of 
MeOH before 965 µL of 1N aqueous NaOH (965 µmol) were added. The mixture was allowed to stir 
at room temperature for 30 minutes. The mixture was concentrated, diluted with water, acidified 
with 1M HCl aqueous solution and extracted with EtOAc. The organic layer was washed with brine 
and evaporated under reduced pressure to afford compound 2 2-[(3S)-6-[[3-(2,6-dimethyl-4-prop-2-
ynoxy-phenyl)phenyl]methoxy]-2,3-dihydrobenzofuran-3-yl]acetic acid as a white powder (m = 201 
mg, 454 µmol, yield 96%). 
1H NMR (600 MHz, CDCl3) δ: 2.02 (s, 6H), 2.55 (t, 1H, J = 2,4 Hz), 2.63 (dd, 1H, J = 16.8, 9.2 Hz), 2.82 
(dd, 1H, J = 16.8, 5.4 Hz), 3.83 (m, 1H, 9.2, 9.1, 6.2, 5.4 Hz), 4.30 (dd, 1H, J = 9.1, 6.2 Hz), 4.72 (d, 2H, J 
= 2.4 Hz), 4.78 (t, 1H, J = 9.1 Hz), 5.08 (s, 2H), 6.48 (d, 1H, Jmeta = 2.2 Hz), 6.52 (dd, 1H, Jortho = 8.2 Hz, 
Jmeta = 2.2 Hz), 6.75 (s, 2 H), 7.06 (d, 1H, Jortho = 8.2 Hz), 7.10 (d, 1H, Jortho = 7.5 Hz), 7.19 (s, 1H), 7.39 (d, 
1H, Jortho = 7.5 Hz), 7.42 (t, 1H, Jortho = 7.5 Hz).   
13C NMR (150 MHz, CDCl3) δ: 20.6, 37.1, 38.7, 55.2, 69.9, 74.8, 78.4, 97.1, 107.0, 113.1, 120.7, 123.8, 
125.1, 128.08, 128.14, 128.7, 134.6, 136.6, 137.0, 140.5, 155.9, 159.6, 160.6, 176.1 
Retention time Rt = 0.83 min (METHOD 2) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C28H25O5: 441.1707; Found: 441.1738 
 
Synthesis of compound 3 methyl ester 
Compound 12 methyl 2-[(3S)-6-[[3-(4-hydroxy-2,6-dimethyl-phenyl)phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetate (762 mg, 1.82 mmol) and cesium carbonate (705 mg, 2.16 mmol) 
were dissolved in 9 mL of ACN under argon. Allyl bromide (740 µL, 8.42 mmol) was added to the 
solution and the mixture was allowed to stir under microwave heating (40 min, 110°C microwave 
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assisted, 30 sec. pre-stirring). Insolubles were removed by filtration and the mixture was evaporated 
under reduced pressure. The crude was then diluted in Et2O and filtered again to remove the last 
traces of cesium carbonate and evaporated to afford methyl 2-[(3S)-6-[[3-(4-allyloxy-2,6-dimethyl-
phenyl)phenyl]methoxy]-2,3-dihydrobenzofuran-3-yl]acetate as a yellowish oil (m = 765 mg, 1.67 
mmol, yield 92 %). 
1H NMR (500 MHz, CDCl3) δ: 1.99 (s, 6H), 2.55 (dd, 1H, J = 16.6, 9.0 Hz), 2.75 (dd, 1H, J = 16.6, 5.6 Hz), 
3.71 (s, 3H), 3.79 (m, 1H, 9.4, 9.0, 6.1, 5.6 Hz), 4.25 (dd, 1H, J = 9.4, 6.1 Hz), 4.54 (dd, 2H, J = 5.2 Hz), 
4.74 (t, 1H, J = 9.0 Hz), 5.05 (s, 2H), 5.28 (dd, 1H, Jcis = 10.4 Hz and Jgem = 1.4 Hz), 5.41 (dd, 1H, Jtrans = 
17.3 Hz and Jgem = 1.4 Hz), 6.07 (ddd, 1H, Jtrans = 17.3, Jcis = 10.4, J = 5.2 Hz), 6.46 (d, 1H, Jmeta = 2.2 Hz), 
6.49 (dd, 1H, Jortho = 8.2 Hz, Jmeta = 2.2 Hz), 6.67 (s, 2 H), 7.02 (d, 1H, Jortho = 8.2 Hz), 7.09 (d, 1H, Jortho = 
7.4 Hz), 7.17 (s, 1H), 7.38 (d, 1H, Jortho = 7.7 Hz), 7.41 (t, 1H, Jortho = 7.4 Hz). 
13C NMR (125 MHz, CDCl3) δ: 21.1, 37.8, 39.5, 51.8, 68.7, 70.3, 97.5, 107.3, 113.4, 117.5, 121.5, 124.3, 
125.5, 128.6, 128.7, 129.2, 133.6, 134.4, 137.1, 137.4, 141.1, 157.4, 159.4, 161.1, 172.4 
Retention time Rt = 0.99 min (METHOD 2) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C29H29O5: 457.2020; Found: 457.2056 
 
Synthesis of compound 3 
Methyl 2-[(3S)-6-[[3-(4-allyloxy-2,6-dimethyl-phenyl)phenyl]methoxy]-2,3-dihydrobenzofuran-3-
yl]acetate previously synthesized (15 mg, 32.7 µmol, 1eq) was dissolved in 250 µL of THF and 100 µL 
of MeOH before 65 µL of 1N aqueous NaOH (65 µmol) were added. The mixture was allowed to stir 
at room temperature for 45 minutes. 
The mixture was concentrated, diluted with water, acidified with 1M HCl aqueous solution down to 
pH = 2 and extracted with EtOAc three times. The organic layer was evaporated under reduced 
pressure to afford compound 3 2-[(3S)-6-[[3-(4-allyloxy-2,6-dimethyl-phenyl)phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetic acid as a white powder (m = 11.8 mg, 26.5 µmol, yield 81%). 
1H NMR (600 MHz, CDCl3) δ: 2.01 (s, 6H), 2.63 (dd, 1H, J = 16.8, 9.2 Hz), 2.82 (dd, 1H, J = 16.8, 5.3 Hz), 
3.83 (m, 1H, 9.2, 9.0, 6.2, 5.3 Hz), 4.30 (dd, 1H, J = 9.0, 6.2 Hz), 4.56 (d, 2H, J = 5.2 Hz), 4.78 (t, 1H, J = 
9.0 Hz), 5.08 (s, 2H), 5.30 (dd, 1H, Jcis = 10.4 Hz and Jgem = 1.0 Hz), 5.44 (dd, 1H, Jtrans = 17.3 Hz and Jgem 
= 1.0 Hz), 6.10 (ddd, 1H, Jtrans = 17.3, Jcis = 10.4, J = 5.2 Hz), 6.48 (s, 1H), 6.52 (dd, 1H, Jortho = 8.2 Hz), 
6.70 (s, 2 H), 7.06 (d, 1H, Jortho = 8.2 Hz), 7.10 (d, 1H, Jortho = 7.4 Hz), 7.19 (s, 1H), 7.39 (d, 1H, Jortho = 7.4 
Hz), 7.43 (t, 1H, Jortho = 7.4 Hz).     
13C NMR (150 MHz, CDCl3) δ: 20.6, 37.1, 38.6, 68.3, 69.9, 97.1, 107.0, 113.0, 116.9, 120.7, 123.8, 
125.0, 128.1, 128.2, 128.7, 133.1, 133.9, 136.6, 136.9, 140.7, 156.9, 159.6, 160.6, 175.5 
Retention time Rt = 0.87 min (METHOD 2) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C28H27O5: 443.1863; Found: 443.1935 
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Synthesis of compound 4 
See synthesis below in section “Supplemental experimental procedure Figure 2” 
 
 
Synthesis of compound 5 
Compound 4 2-[(3S)-6-[[3-[4-(3-aminopropoxy)-2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetic acid (2.9 mg, 6.28 µmol) was dissolved in 250 µL of DMF, before DIEA 
(3 µl, 17.18 µmol) and acetic anhydride (0.650 µl, 6.92 µmol) were added to the reaction mixture. 
The reaction was allowed to stir at room temperature for 15 minutes. Then 50 µL of a 1M NaOH 
aqueous solution (50 µl, 50.00 µmol) were added to the mixture. The crude was directly submitted to 
preparative HPLC (25% to 95% ACN/water) to afford, after lyophilization, compound 5 2-[(3S)-6-[[3-
[4-(3-acetamidopropoxy)-2,6-dimethyl-phenyl]phenyl] methoxy]-2,3-dihydrobenzofuran-3-yl]acetic 
acid as a lyophilized powder (m = 3.1 mg, 6.16 µmol, yield 98%). 
1H NMR (500 MHz, d6-DMSO) δ: 1.81 (s, 3H), 1.84 (p, 2H, J = 6.2 Hz), 1.92 (s, 6H), 2,47 (dd, 1H, J = 
16.8, 9.0 Hz), 2,68 (dd, 1H, J = 16.8, 5.6 Hz), 3.19 (q, 2H, J = 6.2 Hz), 3.68 (m, 1H), 3.98 (t, 2H, J = 6.2 
Hz), 4.19 (dd, 1H, J = 9.0, 6.9 Hz), 4.68 (t, 1H, J = 9.0 Hz), 5.10 (s, 2H), 6.46 (s, 1H), 6.49 (d, 1H, Jortho = 
8.1 Hz), 6.69 (s, 2 H), 7.05 (d, 1H, Jortho = 7.5 Hz), 7.09 (d, 1H, Jortho = 8.1 Hz), 7.14 (s, 1H), 7.39 (d, 1H, 
Jortho = 7.5 Hz), 7.45 (t, 1H, Jortho = 7.5 Hz), 7.92 (s, 1H), 12.32 (s, 1H)     
13C NMR (125 MHz, d6-DMSO) δ: 20.7, 22.6, 28.9, 35.5, 37.1, 64.9, 69.3, 77.1, 97.0, 107.0, 113.3, 
122.0, 124.5, 125.8, 128.6, 128.8, 128.8, 133.9, 136.5, 137.4, 140.3, 157.0, 159.1, 160.7,169.1, 173.0  
Retention time Rt = 0.88 min (METHOD 1) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C30H32NO6: 502.2235; Found: 502.2295 
                                                     
 
 
Synthesis of compound 6 
Compound 4 2-[(3S)-6-[[3-[4-(3-aminopropoxy)-2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetic acid previously synthesized (5.0 mg, 10.83 µmol) was dissolved in 400 
µL of DMF before DIEA (5.68 µl, 32.50 µmol) was added followed by N3-PEG4-NHS ester (2,5-
dioxopyrrolidin-1-yl 1-azido-3,6,9,12-tetraoxapentadecan-15-oate, 5 mg, 12.87 µmol). The reaction 
was allowed to stir at room temperature for 15 minutes. The crude was directly purified through 
preparative HPLC (25% to 95% ACN/water) to afford, after lyophilization, compound 6 2-[(3S)-6-[[3-
[4-[3-[3-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]propanoylamino]propoxy]-2,6-dimethyl-
phenyl]phenyl] methoxy]-2,3-dihydrobenzofuran-3-yl]acetic acid as a lyophilized powder (m = 3.7 
mg, 5.04 µmol, 46% yield). 
1H NMR (500 MHz, d6-DMSO) δ: 1.85 (p, 2H, J = 6.2 Hz), 1.92 (s, 6H), 2.32 (t, 2H, J = 6.4 Hz), 2.48 (dd, 
1H, J = 16.8, 9.0 Hz), 2,68 (dd, 1H, J = 16.5, 5.6 Hz), 3.21 (q, 2H, J = 6.0 Hz), 3.39 (t, 2H, J = 5.2 Hz), 
3.48-3.62 (m, 16H, PEG), 3.68 (m, 1H), 3.98 (t, 2H, J = 6.2 Hz), 4.18 (dd, 1H, J = 9.0, 6.9 Hz), 4.68 (t, 1H, 
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J = 9.0 Hz), 5.10 (s, 2H), 6.46 (s, 1H), 6.49 (d, 1H, Jortho = 8.0 Hz), 6.69 (s, 2 H), 7.05 (d, 1H, Jortho = 7.5 
Hz), 7.09 (d, 1H, Jortho = 8.0 Hz), 7.14 (s, 1H), 7.39 (d, 1H, Jortho = 7.5 Hz), 7.45 (t, 1H, Jortho = 7.5 Hz), 7.92 
(t, 1H, J = 5.4 Hz), 12.32 (s, 1H) 
13C NMR (125 MHz, d6-DMSO) δ: 20.7, 28.9, 35.5, 36.2, 37.1, 49.9, 64.9, 66.9, 69.2, 69.3, 69.5, 69.7, 
69.7, 69.8, 69.8, 77.1, 96.9, 106.9, 113.2, 121.9, 124.5, 125.8, 128.6, 128.8, 128.8, 133.7, 136.5, 
137.4, 140.3, 157.2, 159.1, 160.7, 170.0, 173.0  
Retention time Rt = 0.93 min (METHOD 1) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C39H49N4O10: 733.3454; Found: 733.3558 
 
 
Synthesis of compound 7 
Compound 4 2-[(3S)-6-[[3-[4-(3-aminopropoxy)-2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetic acid previously synthesized (4.4 mg, 9.53 µmol) was dissolved in 300 
µL of DMF before DIEA (5.0 µl, 28.63 µmol) was added followed by N3-PEG8-NHS ester (2,5-
dioxopyrrolidin-1-yl 1-azido-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oate, 5.92 mg, 10.49 µmol). 
The reaction was allowed to stir at room temperature for 15 minutes. The crude was directly purified 
through preparative HPLC (25% to 95% ACN/water) to afford, after lyophilization, compound 7 2-
[(3S)-6-[[3-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-(2- azidoethoxy) ethoxy]ethoxy]ethoxy]ethoxy]ethoxy] 
ethoxy]ethoxy] propanoylamino]propoxy]-2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetic acid as a lyophilized powder (m = 4.1 mg, 4.50 µmol, 47% yield).  
1H NMR (500 MHz, d6-DMSO) δ: 1.85 (p, 2H, J = 6.2 Hz), 1.92 (s, 6H), 2.32 (t, 2H, J = 6.4 Hz), 2.48 (dd, 
1H, J = 16.8, 9.0 Hz), 2,68 (dd, 1H, J = 16.5, 5.6 Hz), 3.21 (q, 2H, J = 6.2 Hz), 3.39 (t, 2H, J = 5.2 Hz), 
3.48-3.62 (m, 32H, PEG), 3.68 (m, 1H), 3.98 (t, 2H, J = 6.2 Hz), 4.18 (dd, 1H, J = 9.0, 6.9 Hz), 4.68 (t, 1H, 
J = 9.0 Hz), 5.09 (s, 2H), 6.46 (s, 1H), 6.49 (d, 1H, Jortho = 8.0 Hz), 6.69 (s, 2 H), 7.05 (d, 1H, Jortho = 7.5 
Hz), 7.09 (d, 1H, Jortho = 8.0 Hz), 7.14 (s, 1H), 7.39 (d, 1H, Jortho = 7.5 Hz), 7.45 (t, 1H, Jortho = 7.5 Hz), 7.92 
(t, 1H, J = 5.2 Hz), 12.32 (s, 1H) 
13C NMR (125 MHz, d6-DMSO) δ: 20.7, 28.9, 35.5, 36.2, 37.1, 49.9, 64.9, 66.9, 69.2, 69.3, 69.5, 69.7, 
69.7, 69.8, 69.8, 77.1, 96.9, 106.9, 113.2, 121.9, 124.5, 125.8, 128.6, 128.8, 128.8, 133.7, 136.5, 
137.4, 140.3, 157.2, 159.1, 160.7, 170.0, 173.0  
Retention time Rt = 0.92 min (METHOD 1) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C47H65N4O14: 909.4503; Found: 909.4621 
 
 
Synthesis of compound 8 
Compound 4 2-[(3S)-6-[[3-[4-(3-aminopropoxy)-2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetic acid previously synthesized (9.8 mg, 16.99 µmol) was dissolved in 500 
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µL of DMF before DIEA (6 µl, 34.35 µmol) was added followed by Boc-NH-PEG63-NHS ester (55,4 mg, 
15,31 µmol) (5.9 mg, 10.49 µmol). The reaction was allowed to stir at room temperature for 15 
minutes, the solvent was evaporated under reduced pressure and the crude was redissolved in 1 mL 
of DCM. Then 250 µL of TFA/TIS/water (95:2.5:2.5) were added, and the reaction ran for 45 min. The 
crude was directly purified through preparative HPLC (25% to 95% ACN/water) to afford, after 
lyophilization, compound 8 2-[(3S)-6-[[3-[4-[3-[3-(2-aminoethoxy)PEG-63-propanoylamino]propoxy] -
2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-dihydrobenzofuran-3-yl]acetic acid as a colorless oil (m = 
29.7 mg, 8.94 µmol, 53% yield). 
1H NMR (500 MHz, d6-DMSO) δ: 1.72 (p, 2H, J = 6.4 Hz), 1.85 (p, 2H, J = 6.4 Hz), 1.92 (s, 6H), 2.32 (t, 
2H, J = 7.2 Hz), 2.48 (dd, 1H, J = 16.8, 9.0 Hz), 2,68 (dd, 1H, J = 16.5, 5.6 Hz), 2.97 (t, 2H, J = 5.2 Hz), 
3.21 (q, 2H, J = 6.2 Hz), 3.36 (t, 2H, J = 6.4 Hz), 3.40-3.75 (m, PEG), 3.98 (t, 2H, J = 6.2 Hz), 4.18 (dd, 
1H, J = 9.0, 6.8 Hz), 4.68 (t, 1H, J = 9.0 Hz), 5.09 (s, 2H), 6.46 (s, 1H), 6.49 (d, 1H, Jortho = 8.0 Hz), 6.69 (s, 
2 H), 7.05 (d, 1H, Jortho = 7.5 Hz), 7.09 (d, 1H, Jortho = 8.0 Hz), 7.14 (s, 1H), 7.39 (d, 1H, Jortho = 7.5 Hz), 
7.45 (t, 1H, Jortho = 7.5 Hz), 7.86 (t, 1H, J = 5.2 Hz) 
13C NMR (125 MHz, d6-DMSO) δ: 20.7, 25.4, 28.9, 32.1, 35.5, 37.1, 38.8, 64.9, 66.9, 69.3, 69.4, 69.6, 
69.7, 69.8, 77.1, 96.9, 106.9, 113.2, 121.9, 124.5, 125.8, 128.6, 128.7, 133.7, 136.5, 137.4, 140.3, 
157.2, 159.1, 160.7, 171.7, 173.1  
Retention time Rt = 0.81 min (METHOD 1) 
HRMS (ESI-TOF) m/z: No mass 
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Supplemental experimental procedure Figure 2 – Syntheses of the fluorescent probes 13-19 
 
 
Compound 9 and 11 were synthesized as described by Negoro et al., 2012 
 
 
Synthesis of compound 10 – step (a) 
Hydroxy-dimethylbiphenyl carbaldehyde 9 (5.40 g, 23.74 mmol), TBDMS-Cl (4.30 g, 28.50 mmol) and 
imidazole (4.85 g, 71.20 mmol) were dissolved in 35 mL of DMF. The mixture was allowed to stir at 
room temperature for 1 hour. The reaction was followed by LCMS and TLC (25% EtOAc/Hept). 
After 60 minutes of reaction, the mixture was diluted with 100 mL of EtOAc and 50 mL of brine and 
the organic phase was washed with brine (3 x 50 mL) and water (1 x 50 mL), before being dried over 
MgSO4, filtered and evaporated under reduced pressure. Purification was performed via silica gel 
chromatography (0->5% EtOAc/Hept), affording the desired product 3-[4-[tert-
butyl(dimethyl)silyl]oxy-2,6-dimethyl-phenyl]benzaldehyde as an oil (m = 7.68 g, 22.55 mmol, yield 
95%). 
1H NMR (600 MHz, CDCl3) δ: 0.23 (s, 6H), 1.00 (s, 9H), 1.96 (s, 6H), 6.60 (s, 2H), 7.41 (d, 1H, Jortho= 7.6 
Hz), 7.57 (t,1H, Jortho= 7.6 Hz), 7.67 (s, 1H), 7.84 (d, 1H, Jortho= 7.6 Hz), 10.04 (s, 1H).  
13C NMR (150 MHz, CDCl3) δ: -4.28, 18.2, 20.9, 25.7, 118.9, 127.8, 129.1, 131.2, 133.5, 136.0, 136.7, 
137.1, 142.2, 154.7, 192.4 
Retention time Rt = 1.08 min (METHOD 2) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C21H27O2Si: 339.1786; Found: 339.2366 
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Synthesis of compound 10 – step (b) 
3-[4-[tert-butyl(dimethyl)silyl]oxy-2,6-dimethyl-phenyl]benzaldehyde synthesized in the previous 
step (7.68 g, 22.55 mmol) was dissolved in MeOH(15 mL)/THF(30 mL) at 0°C, and sodium 
borohydride NaBH4 (0.98 g, 25.93 mmol) was added. The mixture was allowed to stir under argon at 
0°C for 1h30. Volatiles were evaporated and the mixture was diluted with a pH=5 water solution (50 
mL) and EtOAc (100 mL). The organic phase was washed successively with brine (50 mL) and water 
(50 mL), dried over MgSO4 and concentrated to give the desired product 10 [3-[4-[tert-
butyl(dimethyl)silyl]oxy-2,6-dimethyl-phenyl]phenyl]methanol as a white powder (m = 7.69 g, 22.44 
mmol, quant.)  
1H NMR (600 MHz, CDCl3) δ: 0.26 (s, 6H), 1.03 (s, 9H), 1.99 (s, 6H), 4.75 (s, 2H), 6.60 (s, 2H), 7.08 (d, 
1H, Jortho= 7.6 Hz), 7.15 (s, 1H), 7.35 (d, 1H, Jortho= 7.6 Hz), 7.42 (t, 1H, Jortho= 7.6 Hz). 
13C NMR (150 MHz, CDCl3) δ: -4.28, 18.2, 21.0, 25.8, 65.5, 118.6, 125.1, 128.2, 128.6, 129.1, 134.8, 
137.1, 140.9, 141.5, 154.3 
Retention time Rt = 0.98 min (METHOD 2) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C21H29O2Si: 341.1942; Found: 341.2454 
 
 
 
 
Synthesis of compound 12 – step (c) 
Compound 10 [3-[4-[tert-butyl(dimethyl)silyl]oxy-2,6-dimethyl-phenyl]phenyl]methanol (3 g, 8.32 
mmol, 1eq), (S)-methyl-(6-hydroxy-2,3-dihydrobenzofuran-3-yl)acetate 11 (1.77 g, 8.32 mmol) and 
tributylphosphine P(nBu)3 (3 mL, 11.55 mmol) were dissolved in 150 mL of toluene before a solution 
of 1,1'-(azodicarbonyl)dipiperidine ADDP (3 g, 11.55 mmol, dissolved in 50 mL of toluene) was added 
dropwise during 20 minutes under argon. The mixture was then put in an ultrasound bath for 10 
minutes at room temperature. The reaction was followed by LCMS which showed appearance of the 
desired mass and TLC (25% EtOAc/Hept) which indicated total consumption of the phenol starting 
material. Then 100 mL of hexane were added and the insoluble material was removed by filtration. 
The filtrate was concentrated and the residue was purified through silica gel chromatography (0-
>15% EtOAc-Hept) to afford the desired product methyl 2-[(3S)-6-[[3-[4-[tert-butyl(dimethyl)silyl]oxy-
2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-dihydrobenzofuran-3-yl]acetate as a pale oil (m= 2.75 g, 
5.16 mmol, yield 62%) 
1H NMR (600 MHz, CDCl3) δ: 0.22 (s, 6H), 1.00 (s, 9H), 1.95 (s, 6H), 2.55 (dd, 1H, J = 16.5, 9.0 Hz), 2.75 
(dd, 1H, J = 16.5, 5.6 Hz), 3.71 (s, 3H), 3.79 (m, 1H, J = 9.1, 9.0, 6.4, 5.6 Hz), 4.25 (dd, 1H, J = 9.1, 6.4 
Hz), 4.75 (t, 1H, J = 9.1 Hz), 5.05 (s, 2H), 6.45 (d, 1H, Jmeta = 2.0 Hz), 6.49 (dd, 1H, Jortho = 8.2 Hz, Jmeta = 
2.0 Hz), 6.58 (s, 2H), 7.00 (d, 1H, Jortho = 8.2 Hz), 7.08 (d, 1H, Jortho = 7.5 Hz), 7.17 (s, 1H), 7.35 (d, 1H, 
Jortho = 7.5 Hz), 7.40 (t, 1H, Jortho = 7.5 Hz).  
13C NMR (150 MHz, CDCl3) δ: -4.28, 18.2, 21.0, 25.8, 37.8, 39.5, 51.8, 70.4, 97.5, 107.4, 118.6, 121.5, 
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124.3, 125.5, 128.6, 128.7, 129.3, 134.7, 137.1, 137.2, 141.4, 154.3, 160.0, 161.2, 172. 
Retention time Rt = 1.18 min (METHOD 2) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C32H39O5Si: 531.25722; Found: 531.2634 
 
                                                                
 
 
Synthesis of compound 12 – step (d) 
Methyl 2-[(3S)-6-[[3-[4-[tert-butyl(dimethyl)silyl]oxy-2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetate synthesized in the previous step (2.5 g, 4.55 mmol, 1eq) was 
dissolved in 20 mL of THF and the solution was cooled to 0°C before TBAF (5.5 mL, 5.5 mmol, 1M 
solution in THF) was added. The mixture was allowed to stir at 0°C for 1 hour. Solvent was removed 
by evaporation under reduced pressure. Purification was performed through silica gel 
chromatography (0-40% EtOAc-Hept) to afford desired product 12 methyl 2-[(3S)-6-[[3-(4-hydroxy-
2,6-dimethyl-phenyl)phenyl]methoxy]-2,3-dihydrobenzofuran-3-yl]acetate as a white powder (m = 
1.47g, 3.51 mmol, yield 77%) 
1H NMR (600 MHz, CDCl3) δ: 1.96 (s, 6H), 2.55 (dd, 1H, J = 16.6, 9.0 Hz), 2.75 (dd, 1H, J = 16.6, 5.6 Hz), 
3.71 (s, 3H), 3.79 (m, 1H, 9.1, 9.0, 6.4, 5.6 Hz), 4.25 (dd, 1H, J = 9.1, 6.4 Hz), 4.75 (t, 1H, J = 9.1 Hz), 
5.05 (s, 2H), 6.45 (d, 1H, Jmeta = 2.0 Hz), 6.48 (dd, 1H, Jortho = 8.2 Hz, Jmeta = 2.0 Hz), 6.58 (s, 2 H), 7.01 
(d, 1H, Jortho = 8.2 Hz), 7.06 (d, 1H, Jortho = 7.5 Hz), 7.15 (s, 1H), 7.36 (d, 1H, Jortho = 7.5 Hz), 7.41 (t, 1H, 
Jortho = 7.5 Hz).   
13C NMR (150 MHz, CDCl3) δ: 20.4, 37.3, 39.0, 51.3, 69.9, 97.0, 106.9, 113.5, 121.0, 123.8, 125.0, 
128.1, 128.2, 128.8, 133.8, 136.6, 137.2, 140.5, 153.8, 159.5, 160.6, 171.9 
Retention time Rt = 0.78 min (METHOD 2) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C26H25O5: 417.1707; Found: 417.1750 
 
Synthesis of compound 4 – step (e) 
Compound 12 (250 mg, 597.4 µmol), tert-butyl (3-bromopropyl)carbamate (223 mg, 936.5 µmol), 
potassium carbonate (99.1 mg, 716.9 µmol) and sodium iodide (17.9 mg, 119.5 µmol) were dissolved 
in 3 mL of DMF under argon. The reaction mixture was microwaved at 70°C for 8 hours. Then, 
another 1,5 equivalent of bromide and 1,1 equivalent of potassium carbonate were added to the 
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reaction mixture, and a second run of microwave heating (1 hours, 70°C) was needed to reach 
completion of reaction. The reaction was diluted with 10 mL of brine and 20 mL of EtOAc. The 
organic phase was then washed with brine (3 x 15 mL) and then with 5% NH4Cl solution (2 x 15 mL), 
dried over sodium sulfate, filtered, and evaporated under reduced pressure. 
The crude was then dissolved in 2 mL of THF and 0,6 mL of methanol before 800 µL of a 2,5M sodium 
hydroxide aqueous solution (2 mmol) were added. The mixture was allowed to stir at room 
temperature for 30 minutes. 
The mixture was concentrated under reduced pressure, diluted with 15 mL of water, acidified with 1 
HCl until pH = 2 and extracted with DCM (3 x 15 mL). The organic phase was then dried over sodium 
sulfate, filtered and evaporated under reduced pressure before being purified via silica gel 
chromatography (0-10% MeOH/DCM) to afford 2-[(3S)-6-[[3-[4-[3-(tert-
butoxycarbonylamino)propoxy]-2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-dihydrobenzofuran-3-
yl]acetic acid as a pale yellow oil (m = 241 mg, 429.1 µmol, 72% yield). 
1H NMR (600 MHz, d6-DMSO) δ: 1.37 (s, 9H), 1.81 (quint, 2H, J = 6.5 Hz), 1.90 (s, 6H), 2.46 (dd, 1H, J = 
16.6, 8.9 Hz), 2.68 (dd, 1 H, J = 16.6, 5.6 Hz), 3.08 (q, 2 H, J = 6.5 Hz), 3.66 (m, 1 H, J = 9.1, 8.9, 6.6, 5.6 
Hz ), 3. 95 (t, 2 H, J = 6.5 Hz), 4.17 (dd, 1 H, J = 9.1, 6.6 Hz), 4.66 (t, 1 H, J = 9.1 Hz), 5.08 (s, 2 H), 6.44 
(d, 1H, Jmeta = 2.1 Hz), 6.46 (dd, 1H, Jortho =8.2 Hz, Jmeta = 2.1 Hz), 6.66 (s, 2 H), 6.87 (t, 1H, J = 6.5 Hz), 
7.04 (d, 1H, Jortho = 7.5 Hz), 7.08 (d, 1H, Jortho = 8.2 Hz), 7.12 (s, 1H), 7.36 (d, 1H, Jortho = 7.5 Hz), 7.43 (t, 
1H, Jortho = 7.5 Hz). 
13C NMR (150 MHz, d6-DMSO) δ: 20.7, 28.2, 29.3, 37.0, 37.1, 65.0, 69.3, 77.1, 77.5, 96.9, 107.0, 113.2, 
121.9, 124.5, 125.8, 128.5, 128.5, 128.7, 133.6, 136.5, 137.3, 140.3, 155.6, 157.2, 159.0, 160.6, 173.0 
Retention time Rt = 0.75 min (METHOD 2) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C33H38NO7: 560.2654; Found: 560.2760   
 
 
Synthesis of 4 – step (f) 
2-[(3S)-6-[[3-[4-[3-(tert-butoxycarbonylamino)propoxy]-2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-
dihydrobenzofuran-3-yl]acetic acid synthesized in the previous step (120 mg, 213,7 µmol) was 
dissolved in 2,5 mL of dichloromethane before TFA (500 µl, 6.5 mmol) + 1% triisopropylsilane (25 µl, 
213,65 µmol) were added. The mixture was allowed to stir at room temperature for 10 minutes. The 
reaction mixture was diluted with 3 mL of water. The organic phase was washed with brine (3 x 3 
mL). During the last washing step with brine, product precipitated as a slightly brown solid. It was 
filtered, redissolved in a mixture of acetonitrile and water, and lyophilized to afford desired product 
4 2-[(3S)-6-[[3-[4-(3-aminopropoxy)-2,6-dimethyl-phenyl]phenyl]methoxy]-2,3-dihydrobenzofuran-3-
yl]acetic acid as an off-white lyophilized powder (m = 86.6 mg, 187.6 µmol, 88 % yield). 
1H NMR (400 MHz, d6-DMSO) δ: 1.91 (s, 6H), 2.04 (dd, 2H, J = 7.5, 6.2 Hz), 2.46 (dd, 1H, J = 16.4, 9.0 
Hz),  2.70 (dd, 1 H, J = 16.4, 5.6 Hz), 2.94 (t, 2 H, J = 7.5 Hz), 3.67 (m, 1 H, 9.1, 9.0, 6.8, 5.6), 4.07 (t, 2 
H, J = 6.2 Hz), 4.18 (dd, 1 H, J = 9.1, 6.8 Hz), 4.67 (t, 1H, J = 9.1 Hz), 5.09 (s, 2 H), 6.44 (d, 1H, Jmeta = 2.3 
Hz), 6.46 (dd, 1H, Jortho = 8.0, Jmeta = 2.3 Hz ), 6.71 (s, 2H), 7.04 (d, 1H, Jortho = 7.7 Hz), 7.10 (d, 1H, Jortho = 
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8.0 Hz), 7.12 (s, 1H), 7.38 (d, 1H, Jortho = 7.7 Hz), 7.44 (t, 1H, Jortho = 7.7 Hz), 8.21 (s, 3H), 12.36 (s, 1H) 
13C NMR (150 MHz, d6-DMSO) δ: 20.7, 26.9, 37.2, 37.1, 64.5, 69.4, 77.1, 97.0, 107.0, 113.3, 122.0, 
124.5, 125.8, 128.5, 128.5, 128.7, 133.9, 136.5, 137.4, 140.3, 157.0, 159.1, 160.7, 173.0 
Retention time Rt = 0.52 min (METHOD 2) 
HRMS (ESI-TOF) m/z: [M-H]-: Calcd for C28H30NO5: 460.2129; Found: 460.2131  
 
 
 
Synthesis of probe 13 (TAK-Coumarin343) 
Coumarin 343 (5.2 mg, 18.2 µmol), HATU (6.9 mg, 18.2 µmol) and DIEA (8.4 µL, 48.3 µmol) were 
dissolved in 200 µL of DMF and 200 µL of DCM in a small Eppendorf vial protected from light with 
aluminum foil, and were mixed for 5 minutes at room temperature before the addition of compound 
4 (8.1 mg, 16.3 µmol). The reaction mixture was allowed to stir for one hour. The crude was directly 
purified by preparative HPLC (25->95% ACN) to afford, after lyophilization, the desired product 13 
TAK-Coumarin343 conjugate as a yellow powder (m = 1.7 mg, 2.3 µmol, yield 14%). 
Retention time Rt = 5.172 min (METHOD 3) 
HRMS (ESI-TOF) m/z: [M-H]- : Calcd for C44H43N2O8: 727.3025; Found: 727.3092  
Max Abs/Em 438/482 nm   
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Synthesis of probe 14 (TAK-CF) 
Compound 4 (6.5 mg, 13.1 µmol) was dissolved in 500 µL of DMF in a small Eppendorf vial protected 
from light with aluminum foil, followed by DIEA (9.1 µL, 52.2 µmol) and carboxyfluorescein NHS ester 
(5.1 mg, 10.7 µmol). The reaction was allowed to stir for 30 minutes at room temperature, in the 
dark. The crude was directly purified through preparative HPLC (25->95% ACN) to afford, after 
lyophilization, the desired product 14 TAK-CF conjugate as a yellow powder (m = 4.7 mg, 5.7 µmol, 
yield 53%). 
Retention time Rt = 4.099 min (METHOD 3) 
HRMS (ESI-TOF) m/z: [M-H]- : Calcd for C49H40NO11: 818.2607; Found: 818.2663 
Max Abs/Em 496/520 nm   
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Synthesis of probe 15 (TAK-FITC) 
Compound 4 (10.7 mg, 21.53 µmol) was dissolved in 300 µL of DMF in a small Eppendorf vial 
protected from light with aluminum foil, followed by DIEA (10.3 µL, 59.13 µmol). Then was added 
fluorescein thioisocyanate (9.8 mg, 25.04 µmol) to the mixture. Reaction was allowed to run for 1 
hour in the dark. 
The crude was directly purified through preparative HPLC (25->95% ACN) to afford, after 
lyophilization, the desired product 15 TAK-FITC conjugate as a dark orange powder (m = 6.5 mg, 7.62 
µmol, 35% yield). 
Retention time Rt = 4.172 min (METHOD 3) 
HRMS (ESI-TOF) m/z: [M-H]- : Calcd for C49H41N2O10S: 849.2487; Found: 849.2480 
Max Abs/Em 496/520 nm   
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Synthesis of probe 16 (TAK-Alexa488) 
Compound 4 (2.0 mg, 4.33 µmol) was dissolved in 300 µL of water in a small Eppendorf vial protected 
from light with aluminum foil, followed by DIEA (3 µl, 17.18 µmol). Then was added Alexa-488 NHS 
ester (3.36 mg, 5.20 µmol) to the mixture and pH was adjusted to pH = 9 with DIEA. The reaction was 
allowed to run for 10 minutes in the dark. 
The crude was directly submitted to preparative HPLC (25->95% ACN) to afford, after lyophilization, 
the desired product 16 TAK-Alexa488 conjugate as a dark orange powder (m = 2.8 mg, 2.86 µmol, 
66% yield). 
Retention time Rt = 3.185 min (METHOD 3) 
HRMS (ESI-TOF) m/z: [M-H]- : Calcd for C49H43N3O15S2: 977.2136; Found: 977.2130 
1H NMR (600 MHz, d6-DMSO) δ: 1.89 (s, 3H), 1.92 (s, 3H), 1.99-1.94 (m, 1H), 2.07-2.01 (m, 1H), 2.46 
(t, 1H, J = 8.9 Hz), 2.68 (dd, 1H, J = 16.7, 5.5 Hz), 3.53-3.50 (m, 2H), 3.70-3.63 (m, 2H), 4.01 (t, 2H, J = 
6.07 Hz), 4.08 (t, 1H, J = 6.07 Hz), 4.18 (dd, 1H, J = 8.9, 6.7 Hz), 4.67 (t, 1H, J = 9.15 Hz), 5.09 (s, 2H), 
6.44 (t, 1H, J = 2.0 Hz), 6.46 (dd, 0.5H, J = 2.4, 1.4 Hz), 6.48 (dd, 0.5H, J = 2.4, 1.4 Hz), 6.67 (s, 1H), 6.72 
(s, 1H), 6.99 (s, 3H), 7.04 (dd, 1,3 Hz, J = 11.1, 7.6 Hz), 7.09 (d, 1H, J = 8.2 Hz), 7.12 (d, 1H, J = 10.4 Hz), 
7.39-7.35 (m, 1H), 7.46-7.41 (m, 1H), 7.54 (s, 0.4 H, J = 7.8 Hz), 7.85 (s, 0.5H), 8.22 (dd, 0.5H, J = 8.2, 
1.7 Hz), 8.31-8.27 (m, 1H), 8.71 (s, 0.7H), 8.76 (t, 0.7H, J = 5.6 Hz), 8.95 (t, 0.6H, J = 5.5 Hz) (mixture of 
isomers) 
Max Abs/Em 496/518 nm   
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Synthesis of probe 17 (TAK-TAMRA) 
Compound 4 (4.8 mg, 9.7 µmol) was dissolved in 400 µL of DMF in a small Eppendorf vial protected 
from light with aluminum foil, followed by DIEA (3.5 µL, 20.1 µL) and TAMRA NHS-ester (7.4 mg, 9.8 
µmol). The reaction was allowed to stir for 30 minutes at room temperature, in the dark. The crude 
was directly purified through preparative HPLC (25->95% ACN) to afford, after lyophilization, the 
desired product 17 TAK-TAMRA conjugate as a dark orange powder (m = 5.5 mg, 6.3 µmol, yield 
65%). 
Retention time Rt = 4.172 (METHOD 3) 
HRMS (ESI-TOF) m/z: [M-H]- : Calcd for C53H50N3O9: 872.3552; Found: 872.3592 
Max Abs/Em 544/574 nm   
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Synthesis of probe 18 (TAK-Bodipy 650) 
Compound 4 (2.6 mg, 3.92 µmol) was dissolved in 500 µL of DMF in a small Eppendorf vial protected 
from light with aluminum foil, followed by DIEA (2.6 µL, 14.89 µmol). Then Bodipy 650/665-X NHS 
ester (2.1 mg, 3.26 µmol) was added to the mixture. Reaction was allowed to run overnight in the 
dark.  
The crude was directly purified through preparative HPLC (25->95% ACN) to afford, after 
lyophilization, the desired product 18 TAK-Bodipy650 conjugate a dark blue powder (m = 2.0 mg, 
2.02 µmol, 62% yield). 
Retention time Rt = 4.925 min (METHOD 3) 
HRMS (ESI-TOF) m/z: [M-H]- : Calcd for C57H58BF2N5O8: 988.4383; Found: 988.4457 
Max Abs/Em 646/666 nm   
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Synthesis of probe 19 (TAK-Cy5.5) 
Compound 4 (10.2 mg, 20.52 µmol) was dissolved in 400 µL of DMF in a small Eppendorf vial 
protected from light with aluminum foil, followed by DIEA (10 µL, 57.41 µmol). Cy5.5 NHS ester (17 
mg, 23.72 µmol) was then added to the mixture. Reaction was allowed to run for 10 minutes in the 
dark. The crude was directly purified through preparative HPLC (25->95% ACN) to afford, after 
lyophilization, the desired product 19 TAK-Cy5.5 conjugate as a dark blue powder (m = 10.0 mg, 9.73 
µmol, 47% yield).  
Retention time Rt = 5.096 min (METHOD 3) 
HRMS (ESI-TOF) m/z: [M-H]- : Calcd for C68H72N3O6: 1026.5421; Found: 1026.5445 
Max Abs/Em 680/710 nm   
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Species homology of FFAR1 
 
According to database searches in http://www.expasy.org, the homology of FFAR 1 between the 
different species is as follows: 
 
Homology FFAR1 Human // FFAR1 Mouse: 83% 
Homology FFAR1 Human // FFAR1 Rat: 81.7% 
Homology FFAR1 Rat // FFAR1 Mouse: 95.7%  
 
http://www.uniprot.org/uniprot/O14842 
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Synthesis of FFAR1-GPR40 targeting 3H- and 18F probes towards 
selective β-cell imaging 
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Adapted from: Journal of Labelled Compounds and Radiopharmaceuticals, 2016, “Synthesis of GPR40 targeting 
3H- and 18F probes towards selective beta cell imaging” 
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Abstract 
Diabetes affects an increasing number of patients worldwide and is responsible for a significant rise in 
healthcare expenses. Imaging of β-cells in vivo is expected to contribute to an improved understanding 
of the underlying pathophysiology, improved diagnosis, and development of new treatment options 
for diabetes. Here, we describe the first radiosyntheses of [3H]-TAK875 and [18F]-TAK875 derivatives to 
be used as β-cell imaging probes addressing the free fatty acid receptor 1 (FFAR1/GPR40). The fluorine- 
labeled derivative showed similar agonistic activity as TAK875 in a functional assay. The radiosynthesis 
of the 18F-labelled tracer 2a was achieved with 16.7 ± 5.7% radiochemical yield in a total synthesis time 
of 60–70 min. 
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Introduction 
Diabetes is a chronic metabolic disease characterized by hyperglycemia resulting either from 
deficiency in insulin secretion, insulin resistance, or both. Around 387 million people are affected 
worldwide, and the burden on healthcare costs imposed by the disease is dramatically increasing.1 
However, the precise molecular and cellular mechanisms that cause the decrease in mass and function 
of the insulin-producing β-cells remain to be elucidated. Longitudinal studies on quantification of β-
cells in animal models as well as in patients would significantly improve the knowledge on the 
pathophysiology of the disease.2 One approach to provide new tools for efficient noninvasive β-cell 
imaging is the development of chemical probes with high selectivity to provide transferable and 
reliable information on mass of the insulin-producing β-cells.3 Positron-emission tomography (PET) 
imaging is an attractive imaging modality to determine the variation in β-cell mass because of its high 
sensitivity and the possibility to quantitatively analyze the images.4 Several positron emitting isotopes 
can be used in PET imaging.5 Because of its favorable physical and nuclear characteristics, [18F] is often 
regarded as the “radionuclide of choice”, as the 110 min half-life allows sufficient time for the synthetic 
labeling reaction and purification. Furthermore, the short positron linear range in tissue (2.3 mm) gives 
the highest resolution PET images of all the available positron emitters.6–8 Therefore, we investigated 
the development of a new [18F]-labeled PET tracer with high β-cell affinity for selective β-cell imaging. 
Because the G protein–coupled receptor 40 (GPR40 – also known as free fatty-acid receptor 1 FFAR1) 
is highly and predominantly expressed in human and rodents islets β-cells,9–11 it attracted our attention 
as a β-cell specific receptor for imaging. Moreover, many GPR40 agonists are described in the 
literature.12 TAK875 is an orally available, selective, and potent agonist of GPR40,13 which reached 
clinical phase III: administration of the compound to diabetic patients resulted in improvements in 
blood glucose control.14 We envisioned that the TAK875 1 scaffold would serve as a good starting point 
to develop a GPR40-targeting [18F]-labeled PET tracer and specifically selected compound 2a, as 
favorable pharmacokinetic and pharmacodynamics data were reported for 215 (Scheme 1).  
 
 
Scheme 1 Structure of TAK875 1 and envisioned [19F/18F] tracer 2/2a 
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Material and Methods 
 
Chemistry 
See the Supporting Information for a detailed description of the syntheses. 
 
Cell Culture 
Human embryonic kidney (HEK293) cells stably expressing human GPR40/FFAR1 (HEK293 cells were 
transfected with hGPR40 using a pEAK8 vector system) were grown in highglucose DMEM (41965 Life 
Technologies) containing 10% (v/v) FCS gold PAA, 1% (v/v) NEAA and puromycin (1 μg/mL), in a 
humidified 5% CO2 atmosphere at 37 °C. Human embryonic kidney (HEK293) cells were cultured under 
the same conditions except for the absence of puromycin. 
 
Fluorometric Imaging Plate Reader (FLIPR) Ca2+ Assays 
HEK293 cells stably expressing human GPR40/FFAR1 were plated in a poly-D-Lys coated 96-well plate 
with 40 000 cells/well and incubated overnight in a humidified 5% CO2 atmosphere at 37 °C. Then, cells 
were incubated in Hank’s buffer salt solution supplemented with HEPES (pH = 7.5) containing 
fluorescent calcium indicator Fluo 4 AM (Molecular Devices, final concentration 2 μM) + 20% (w/v) 
pluronic acid for 60 min at 37 °C. Cells were washed with a Tecan Ultra (Tecan Group Ltd.) device before 
the addition in the wells of tested compounds at various concentrations (previously dissolved in DMSO 
at 10 mM concentration and diluted with assay buffer). Increase of the intracellular Ca2+ concentration 
after addition was monitored by FLIPR Tetra system (Molecular Devices). Experiments were performed 
in triplicates. 
 
Binding experiments with [3H]-TAK875 on GPR-HEK and HEK cells 
Twenty-four hours before the experiment 400 × 105 cells/well of either GPR40-HEK cells or HEK cells 
(control) were plated on a 48 well plate (well volume 1 mL) and incubated overnight in a humidified 
5% CO2 atmosphere at 37°C. The day of the experiment, the culture media were removed from the 
cells, and they were washed once with Roswell Park Memorial Institute (RPMI) medium supplemented 
with 0.5% albumin (Gibco LifeTechnologies, ThermoFisher, Gibco, MA, USA). Then was added the 
tritiated compound to all the wells (100 μL of 2.05 × 103 Bq/ mL solution), and the cells were incubated 
in a humidified 5% CO2 atmosphere at 37°C. The same amount of hot compound (100 μL) was also 
added to wells without any cells as a standard. After 1 hour of incubation, were extracted out from the 
supernatant 75 μL and mixed with 225 μL of a scintillation cocktail before being measured on a 
TopCounter NXT (PerkinElmer, MA, USA). All the experiments were carried out as quadruplicates. P-
value was determined with a t-test performed with Excel (p = 0.0017). 
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Results and discussion 
 
We first synthesized [3H]-TAK875 1a to obtain a model compound for in vitro binding evaluation 
studies. To our knowledge, a [3H]-synthesis of TAK875 has not been reported. Briefly, 1 was mono-
brominated with one equivalent of N-bromosuccinimide (NBS). The tritiation was performed with dry 
5% Pd/C catalyst and 98 MBq/2.61 Ci tritium gas16 using a tritium manifold at room temperature to 
afford 1a in 4 h with 5.3% radiochemical yield (RCY) (Scheme 2). 
 
Scheme 2 Synthesis of [3H]-TAK875 1a 
 
In the next step, the receptor binding of 1a on HEK293-cells (Human Embryonic Kidney 293 cells) 
transfected to overexpress the GPR40 receptor (GPR40-HEK) was evaluated. In order to assess the 
specificity of the binding, wild type HEK293-cells (HEK) lacking expression of GPR40 were used as 
control 
(Figure 1). After 1 hour of incubation, we observed binding of 1a in HEK cells at levels above 
background. However, specifically bound signal was at least sevenfold higher in the GPR40-transfected 
cells preparation. These results indicate that 1a bound to the targeted receptor in vitro and therefore 
encouraged us to investigate this structure for the design and synthesis of a [18F]-labeled tracer. 
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Figure 1 [3H]-TAK875 1a binds preferably HEK-cells expressing GPR40 
 
 
The design of a new [18F]-tracer started with the selection of a suitable labeling position. It was 
reported that modifications on the 4′-position of the terminal biphenyl ring of 1 were well tolerated in 
terms of agonistic activities and binding affinities.13, 15 Consequently, we envisioned to use the phenol 
side chain to introduce a tosylate leaving group as precursor for [18F]-introduction. Starting from 
phenol 4, alkylation with a fivefold excess of allyl bromide under microwave irradiation afforded 
compound 5 in 94% yield. The sulfone function was introduced by using a thiol-ene click approach17 
with thiopropanol. This reaction was reported not only with several Michael acceptors such as 
maleimide or acrylates18 but also with non-conjugated alkenes.19 We then performed a selective 
oxidation of the sulfur with meta-chloroperbenzoic acid (mCPBA), affording compound 6 in 88% yield 
over two steps. 
Finally, alcohol 6 was tosylated to provide the fluorination precursor 7 (Scheme 3). 
 
 
Scheme 3 Synthesis of the fluorination precursor 7 
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To evaluate the impact of structural modification in the phenol side chain of TAK875 building block 4 
we measured compounds 2, 4, 5, 6 (as the active free carboxylic acid form) in a Fluorometric Imaging 
Plate Reader (FLIPR, Molecular Devices, Sunnyvale, CA, USA) Ca2+ assay (molecular functional assay of 
agonistic receptor activity). The agonistic activities of the acid compounds of 6 and 2 were 1.5 and 2.4-
fold more potent than parent ligand TAK875 1, confirming that introduction of fluorine was well 
tolerated (Table 1).  
 
 
 
Table 1 In Vitro activities of TAK875 derivatives 
 
To establish the reaction conditions for the PET radiochemistry laboratory under non-radioactive 
conditions, we decided to use KF as 19F-source, potassium carbonate, acetonitrile and Kryptofix 2.2.2 
(K2.2.2) as standard parameters in our labeling optimization approach. We studied the SN2 
substitution reaction of the tosylate 7 under various temperatures and reaction times (Table 2). At 
room temperature we observed only limited conversion (Entry 1). We increased the temperature to 
40°C, which led to a moderate conversion to the desired product (Entry 2–5). At a temperature of 
100°C or 130°C (Entry 6–10) we reached full conversion of the starting material. However, we also 
observed formation of hydrolyzed and elimination side products. This was accentuated at higher 
temperature, resulting in reduced yields (Entry 9–10). Furthermore, extended reaction times were also 
detrimental for the yields (Entry 6–8 and 9–10). Based on these results, we concluded that the 
preferred conditions to implement the [18F] radiolabeling are 2 min reaction time at 100°C (Entry 6). 
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Table 2 Screening of conditions for 19F-labeling of tosylate 7 with potassium fluoride 
 
 
[18F]-labeling of the tosylate 7 was performed using azeotropically dried n.c.a. [18F] fluoride, activated 
by the potassium carbonate/K2.2.2-system. The conditions of entry 6 from the non-radioactive 
optimization were directly transferable to the n.c.a. radiosynthesis. The radiolabeling (n = 10) showed 
very fast kinetics with 30–35% RCY within only 1 min (Scheme 4). However, the excellent yields (83-
86%) from the cold optimization could not be reached under n.c.a. condition, which is presumably due 
to the inverse stoichiometry in both situations. Already within the first minutes of the labeling reaction, 
the strong basic conditions cause partly deprotection of the intermediate labeling product to the final 
radiotracer 2a. Prolonged reaction times did not result in higher RCY, but further deprotection (Scheme 
4). The sum of both products, protected intermediate and 2a, stays constant over 15 min. A complete 
deprotection after 5 min at room temperature was achieved by adding a 1/1 solution of 
methanol/2.5M aqueous sodium hydroxide solution. During the deprotection step, product losses 
were observed, which we assume to be due to hydrolysis and elimination as shown by the cold 19F-
optimization study. Optimization studies of the deprotection step resulted either in full degradation of 
the product or incomplete deprotection. Still the deprotection step gives room for improvement.  
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Scheme 4 Radiosynthesis of 18F-radiotracer 2a. The diagram shows the course of the radiolabeling over 15 min 
for the protected intermediate (blue line) product and the final product (red line). In addition, the green graph 
represents the sum of both products. Radiochemical yield (RCY) were determined by radio-TLC. 
 
 
The final radiotracer 2a was obtained in 16.7% ± 5.7% RCY (n = 6) and with only a low specific activity 
of ≥0.6 GBq/μmol. So far, only low specific activities could be obtained, which is a crucial issue in 
imaging targets of low density such as the GPR40. The low specific activities are mainly due to low 
starting activities. We expect good to high specific activities after automation of the radiosynthesis and 
the use of high starting activities. The identity 2a was confirmed by coinjection with the cold reference 
compound 2 on analytical radio-HPLC and co-spotting on radio-TLC. For upscaling and potential 
translation, the first steps of the radiosynthesis of 2a were successfully transferred to an automated, 
cassette-based radiosynthesis module (selfdesigned, custom-made cassettes, and materials are 
available from ABX) giving identical good results in labeling and deprotection. The automated HPLC-
purification with subsequent SPE-isolation and formulation are currently under optimization. The 
tracer is currently evaluated in in-vitro and in-vivo studies, whose outcome will be reported in due 
course. 
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Conclusion 
 
We described the radiosyntheses of two potent GPR40 ligands for selective β-cell imaging. The tritiated 
[3H]-TAK875 analog 1a was successfully synthesized and evaluated on HEK293-cells transfected to 
overexpress the GPR40 receptor. Based on these positive results, we investigated the development of 
a potential new [18F]-PET tracer 2a. The fluoride labeled derivative 2 showed similar agonistic activity 
as TAK875 1 in a functional assay. The synthesis of 18F-tracer 2a was achieved in reasonable RCY and is 
already transferred to an automated, cassette-based radiosynthesis module. 
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Supporting Information 
General Methods 
1H, 19F and 13C NMR spectra were obtained on Bruker spectrometers in the indicated solvents. Silica-
gel column chromatography was carried out on a CombiFlash Rf - Isco Teledyne. Microwave assisted 
reactions were performed with a Biotage Initiator device. The purity of the products was determined 
by an LC-MS system with a Symmetry Shield RP18 column, 3.9x150 mm with a gradient program 
under the following conditions: mobile phase A: water (900 mL), acetonitrile (100 mL), TFA (1 mL); 
mobile phase B: water (100 mL), acetonitrile (900 mL), TFA (0.75 mL); flow 1.5 mL/min; detection UV 
254 nm and UV 210 nm. Commercially available chemicals and solvents were used as received. 
Analytical radio-HPLC was performed on a Varian ProStar HPLC system (pump model 240, UV/Vis 
detector model 335) equipped with a radiodetector (Berthold LB500) using a monolithic RP 18 
column, Chromolith® High Resolution RP-18e (Merck), 100 x 4.6 mm, with a solvent system and 
gradient as follows: Eluent A was 100% water; Eluent B was 100% acetonitrile. The gradient was from 
100% eluent A to 95% eluent A in 0–4 min, 0% eluent A in 4–16 min, 0% eluent A in 16-21 min, from 
0% eluent A to 100% eluent A in 21–23 min and 100% eluent A in 23-28 min. The flow was 1 mL/min. 
RadioTLC was performed on silica gel coated aluminium sheets using ethyl acetate with 0.5% acetic 
acid as mobile phase. The radioTLC were analysed on a autoradiography system (Instant Imager, 
Canberra). 
2-[5-bromo-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]2,3-
dihydrobenzofuran-3-yl]acetic acid (3) 
2-[6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]2,3-dihydro-benzofuran-
3-yl]acetic acid (1) (30 mg, 57.2 µmol) was dissolved in 3 ml DCM and N-bromsuccinimide (10.2 mg, 
57.2 µmol) was added at room temperature. The solution was stirred for 30 min and the mixture was 
evaporated to dryness to afford 39 mg of (3). The product was used in the next step without further 
purification. MS (ESI-) m/z: 601/603 [M-H]- 
 
2-[6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]5-tritio-2,3-
dihydrobenzofuran-3-yl]acetic acid (1a) 
2-[5-bromo-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]2,3-
dihydrobenzofuran-3-yl]acetic acid (3) (9 mg, 14.9 µmol), methanol (0.7 mL), Et3N (20.7 µL, 0.3 
mmol) and Pd/C (2 mg, Pd dry 5% Heraeus K02102) were placed in a 1 mL reaction vessel. The vessel 
was connected to a tritium manifold, cooled with liquid nitrogen and [3H2] (0.27 mg, 44.7 µmol, 96 
GBq, 2.6 Ci) was added. The reaction mixture was allowed to reach room temperature (pressure 
inside 220 mbar) and stirred for 4 hours. After three times removal of all the volatiles by addition and 
removal of methanol, the residue was purified by HPLC to afford [3H] compound (1a) (4.5 mg, 8.55 
µmol, 5146 MBq, 139 mCi, 57.5% chemical yield; 5.3 % RCY). 1H NMR (500 MHz, DMSO-d6) δ: 1.91 (s, 
6H), 2.14-2.25 (m, 4H), 3.05 (s, 3H), 3.62-3.71 (m, 3H), 4.21 (t, J = 6 Hz, 1H), 4.35 (t, J = 5 Hz, 2H), 4.65 
(t, J = 6 Hz, 1H), 5.12 (s, 2H), 6.45 (s, 1H), 6.7 (s, 2H), 7.05 (d, J = 7.5 Hz, 1H), 7.1 (d, J = 8.5 Hz, 1H), 
7.15 (s, 1H), 7.38 (d, J = 8 Hz, 1H), 7.45 (t, J = 7.5 Hz, 1H); 3H NMR (533 MHz, DMSO-d6) δ: 6.47 (s, 1H) 
ppm; HPLC RD purity: 99.3%; 1143 MBq/mg, 599 GBq/mmol, 16.2 Ci/mmol; MS (ESI+)(%) m/z: 465 
[M-HCO2H]+ (27); 525 [M+H]+(100); 549 [M+Na]+ (12); 565 [M+K]+(6).  
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Methyl-2-[(3S)-6-[[3-(4-allyloxy-2,6-dimethyl-phenyl)phenyl]methoxy]2,3-dihydrobenzo-furan-3-
yl]acetate(5)        
Methyl-2-[(3S)-6-[[3-(4-hydroxy-2,6-dimethyl-phenyl)phenyl]methoxy]2,3-dihydrobenzo-furan-3-
yl]acetate (4) (762 mg, 1.8 mmol) and cesium carbonate (705 mg, 2.2 mmol) were dissolved in 9 mL 
of acetonitrile under argon. Allyl bromide (740 µL, 8.4 mmol) was added to the solution and the 
mixture was allowed to stir under microwave heating (45 min, 110°C microwave assisted, 30 sec pre-
stirring). Insolubles were removed by filtration and the mixture was evaporated under reduced 
pressure. The crude product was then diluted in Et2O and filtered again to remove the last traces of 
cesium carbonate and evaporated to afford (5) methyl 2-[(3S)-6-[[3-(4-allyloxy-2,6-dimethyl-
phenyl)phenyl]methoxy]2,3-dihydrobenzo-furan-3-yl]acetate as a yellowish oil (765 mg, 1.7 mmol, 
yield 94%). 1H NMR (500 MHz, CDCl3) δ: 1.99 (s, 6H), 2.55 (dd, 1H, J = 16.6, 9.0 Hz), 2.75 (dd, 1H, J = 
16.6, 5.6 Hz), 3.71 (s, 3H), 3.79 (m, 1H, J = 9.4, 9.0, 6.1, 5.6 Hz), 4.25 (dd, 1H, J = 9.4, 6.1 Hz), 4.54 (dd, 
2H, J = 5.2 Hz), 4.74 (t, 1H, J = 9.0 Hz), 5.05 (s, 2H), 5.28 (dd, 1H, J = 10.4, 1.4 Hz), 5.41 (dd, 1H, J = 
17.3, 1.4 Hz), 6.07 (ddd, 1H, J = 17.3, 10.4, 5.2 Hz), 6.46 (d, 1H, J = 2.2 Hz), 6.49 (dd, 1H, J = 8.2, 2.2 
Hz), 6.67 (s, 2 H), 7.02 (d, 1H, J = 8.2 Hz), 7.09 (d, 1H, J = 7.4 Hz), 7.17 (s, 1H), 7.38 (d, 1H, J = 7.7 Hz), 
7.41 (t, 1H, J = 7.4 Hz); 13C NMR (125 MHz, CDCl3) δ: 21.1, 37.8, 39.5, 51.8, 68.7, 70.3, 97.5, 107.3, 
113.4, 117.5, 121.5, 124.3, 125.5, 128.6, 128.7, 129.2, 133.6, 134.4, 137.1, 137.4, 141.1, 157.4, 159.4, 
161.1, 172.4 ppm; HRMS(ESI-TOF) m/z: [M-H]: Calcd for C29H29O5: 457.2020; Found: 457.2056.   
 
 
 
2-[(3S)-6-[[3-(4-allyloxy-2,6-dimethyl-phenyl)phenyl]methoxy]2,3-dihydrobenzofuran-3-yl] acetic acid 
(free acid of 5) 
Methyl ester (5) (15 mg, 32.7 µmol) was dissolved in 250 µL of THF and 100 µL of methanol before 65 
µL of 1N aqueous NaOH (65 µmol) were added. The mixture was allowed to stir at room temperature 
for 45 minutes. The mixture was concentrated, diluted with water, acidified with 1M HCl aqueous 
solution down to pH = 2 and extracted with ethyl acetate three times. The organic layer was 
evaporated under reduced pressure to afford compound (5a) 2-[(3S)-6-[[3-(4-allyloxy-2,6-dimethyl-
phenyl)phenyl]methoxy]2,3-dihydrobenzofuran-3-yl]acetic acid as a white powder (m = 11.8 mg, 26.5 
µmol, yield 81%). 1H NMR (600 MHz, CDCl3) δ: 2.01 (s, 6H), 2.63 (dd, 1H, J = 16.8, 9.2 Hz), 2.82 (dd, 1H, 
J = 16.8, 5.3 Hz), 3.83 (m, 1H, J = 9.2, 9.0, 6.2, 5.3 Hz), 4.30 (dd, 1H, J = 9.0, 6.2 Hz), 4.56 (d, 2H, J = 5.2 
Hz), 4.78 (t, 1H, J = 9.0 Hz), 5.08 (s, 2H), 5.30 (dd, 1H, J = 10.4, 1.0 Hz), 5.44 (dd, 1H, J = 17.3, 1.0 Hz), 
6.10 (ddd, 1H, J = 17.3, 10.4, 5.2 Hz), 6.48 (s, 1H), 6.52 (dd, 1H, J = 8.2 Hz), 6.70 (s, 2 H), 7.06 (d, 1H, J = 
8.2 Hz), 7.10 (d, 1H, J = 7.4 Hz), 7.19 (s, 1H), 7.39 (d, 1H, J = 7.4 Hz), 7.43 (t, 1H, J = 7.4 Hz); 13C NMR 
(150 MHz, CDCl3) δ: 20.6, 37.1, 38.6, 68.3, 69.9, 97.1, 107.0, 113.0, 116.9, 120.7, 123.8, 125.0, 128.1, 
128.2, 128.7, 133.1, 133.9, 136.6, 136.9, 140.7, 156.9, 159.6, 160.6, 175.5 ppm; HRMS (ESI-TOF) m/z: [M-
H]: Calcd for C28H27O5: 443.1863; Found: 443.1935.  
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(S)-methyl-2-(6-((4'-(3-((3-hydroxypropyl)sulfonyl)propoxy)-2',6'-dimethyl-[1,1'-biphenyl]3-
yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetate (6) 
A mixture of thio-propanol (150 µL, d= 1.07, 1.83 mmol) and alkene 5 (158 mg, 345 µmol) were 
dissolved in dry dioxane (1 mL) under argon. The mixture was allowed to stir under argon at 75°C for 
3 hours. The mixture was evaporated and then diluted in 500 µL of acetonitrile and 4500 µL of water 
were added which resulted in precipitation of the product. The product was washed once with 250 
µL acetonitrile/4750 µL water, and finally once with 4000 µL of water, before being redissolved in 
acetonitrile and evaporated. The crude was subsequently dissolved in 2.5 mL of DCM and the 
mixture was cooled down to -10°C with an ice/NaCl bath. Then mCPBA (200 mg, 862 µmol) 
previously dissolved in 500 µL of DCM was added and the mixture was allowed to stir from -10°C to 
room temperature for 2 hours. Then, the reaction was quenched with 3 mL of a saturated NaHCO3 
solution to get rid of the excess of mCPBA and diluted with DCM and water. The organic phase was 
washed three times with water, dried over magnesium sulfate and evaporated under reduced 
pressure to afford compound 6 as yellowish oil. (S)-methyl 2-(6-((4'-(3-((3-hydroxypropyl)sulfonyl) 
propoxy)-2',6'-dimethyl-[1,1'-biphenyl]3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetate (177.6 mg, 
304.8 µmol, 88 % yield). 1H NMR (500 MHz, CDCl3) δ: 1.99 (s, 6H), 2.13 (m, 2H), 2.35 (m, 2H), 2.56 
(dd, 1H, J = 16.2, 9.2 Hz), 2.75 (dd, 1H, J = 16.2, 5.5 Hz), 3.17 (t, 2H, J = 7.5 Hz), 3.25 (t, 2H, J = 7.5 Hz), 
3.72 (s, 3H), 3.79 (m, 1H), 3.83 (t, 2H, J = 5.9 Hz), 4.12 (t, 2H, J = 5.7 Hz), 4.25 (dd, 1H, J = 9.2, 6.1 Hz), 
4.75 (t, 1H, J = 9.0 Hz), 5.05 (s, 2H), 6.44 (d, 1H, J = 2.1 Hz), 6.47 (dd, 1H, J = 8.1, 2.1 Hz), 6.64 (s, 2 H), 
7.00 (d, 1H, J = 8.1 Hz), 7.07 (d, 1H, J = 7.5 Hz), 7.15 (s, 1H), 7.36 (d, 1H, J = 7.5 Hz), 7.41 (t, 1H, J = 7.5 
Hz); 13C NMR (125 MHz, CDCl3) δ: 21.2, 22.4, 25.0, 29.7, 37.8, 39.5, 50.0, 50.1, 51.8, 60.6, 65.4, 70.3, 
77.6, 97.5, 107.3, 113.2, 121.5, 124.3, 125.6, 128.6, 128.7, 129.1, 134.8, 137.2, 137.7, 140.9, 157.1, 
159.9, 161.1, 172.4 ppm; HRMS (ESI-TOF) m/z: [M-H]: Calcd for C32H37O8S: 581.2215; Found: 
581.2241. 
 
(S)-2-(6-((4'-(3-((3-hydroxypropyl)sulfonyl)propoxy)-2',6'-dimethyl-[1,1'-biphenyl]3-yl)meth-oxy)-2,3-
dihydrobenzofuran-3-yl)acetic acid (free acid of 6) 
Methyl ester 6 (8 mg, 13.7 µmol) was dissolved in 150 µL of THF and 50 µL of methanol before the 
addition of 1M aqueous NaOH (28 µL, 28 µmol). The mixture was allowed to stir at room 
temperature for 60 minutes. Then, the reaction was neutralized with 28 µL of a 1M HCl aqueous 
solution and diluted with acetonitrile/water (1/1) before being submitted to HPLC purification to 
afford compound 6a as a white powder after lyophilization. 
(S)-2-(6-((4'-(3-((3-hydroxypropyl)sulfonyl)propoxy)-2',6'-dimethyl-[1,1'-biphenyl]3-yl) methoxy)-2,3-
dihydrobenzofuran-3-yl)acetic acid (3.4 mg, 6.0 µmol, 44 % yield). 1H NMR (600 MHz, d6-DMSO) δ: 
1.83 (m, 2H), 1.85 (s, 1H), 1.91 (s, 6H), 2.12 (m, 2H), 2.47 (dd, 1H, J = 16.4, 9.0 Hz), 2.66 (dd, 1H, J = 
16.4, 5.5 Hz), 3.15 (t, 2H, J = 7.8 Hz), 3.24 (t, 2H, J = 7.8 Hz), 3.49 (t, 2H, J = 6.0 Hz), 3.66 (m, 1H), 4.09 
(t, 2H, J = 6.2 Hz), 4.17 (dd, 1H, J = 9.2, 6.8 Hz), 4.66 (t, 1H, J = 9.0 Hz), 5.09 (s, 2H), 6.44 (s, 1H), 6.48 
(dd, 1H, J = 8.2 Hz), 6.70 (s, 2 H), 7.05 (d, 1H, J = 7.5 Hz), 7.08 (d, 1H, J = 8.2 Hz), 7.13 (s, 1H), 7.37 (d, 
1H, J = 7.5 Hz), 7.43 (t, 1H, J = 7.5 Hz); 13C NMR (150 MHz, d6-DMSO) δ: 20.7, 21.7, 24.8, 37.1, 48.7, 
49.1, 58.9, 65.4, 69.3, 77.1, 96.9, 106.9, 113.3, 121.9, 124.5, 125.8, 128.4, 128.5, 128.7, 133.9, 136.6, 
137.3, 140.2, 156.9, 159.1, 160.6, 173.0 ppm; HRMS (ESI-TOF) m/z: [M-H]: Calcd for C31H35O8S: 
567.2058; Found: 567.2136. 
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(S)-methyl-2-(6-((2',6'-dimethyl-4'-(3-((3-(tosyloxy)propyl)sulfonyl)propoxy)-[1,1'-biphenyl] 3-
yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetate (7) 
Alcohol 6 (42.4 mg, 76.7 µmol), triethylamine (15 µl, 109 µmol), and tetramethylhexane-1,6-diamine 
(1.5 µl, 7.3 µmol) were dissolved in 500 µL of toluene and 500 µL of DCM, before the addition of  a 
solution of tosyl-chloride (21.1 mg, 110.7 µmol) previously dissolved in 200 µL of DCM. The reaction 
was allowed to stir overnight at room temperature. Complete conversion of the starting material was 
reached after three successive additions of 0.5 eq triethylamine, 0.1 eq tetramethylhexane-1,6-
diamine and 0.5 eq tosyl-chloride (dissolved in DCM). The mixture was directly purified via silica gel 
chromatography (4 g silica column, 0-50% EtOAc/Hept over 20 min). Collected fractions were 
evaporated under reduced pressure to afford compound 7 as a colorless oil. (S)-methyl 2-(6-((2',6'-
dimethyl-4'-(3-((3-(tosyloxy)propyl)sulfonyl)propoxy)-[1,1'-biphenyl]3-yl)methoxy)-2,3-
dihydrobenzofuran-3-yl)acetate (42.7 mg, 60.0 µmol, 78 % yield). 1H NMR (500 MHz, CDCl3) δ: 1.99 
(s, 6H), 2.25 (m, 2H), 2.32 (m, 2H), 2.45 (s, 3H), 2.54 (dd, 1H, J = 16.2, 9.2 Hz), 2.75 (dd, 1H, J = 16.2, 
5.5 Hz), 3.09 (t, 2H, J = 7.5 Hz), 3.20 (t, 2H, J = 7.5 Hz), 3.72 (s, 3H), 3.80 (m, 1H), 4.10 (t, 2H, J = 5.9 
Hz), 4.19 (t, 2H, J = 5.7 Hz), 4.25 (dd, 1H, J = 9.2, 6.1 Hz), 4.74 (t, 1H, J = 9.0 Hz), 5.05 (s, 2H), 6.45 (d, 
1H, J = 2.1 Hz), 6.47 (dd, 1H, J = 8.1, 2.1 Hz), 6.64 (s, 2 H), 7.00 (d, 1H, J = 8.1 Hz), 7.07 (d, 1H, J = 7.5 
Hz), 7.15 (s, 1H), 7.36 (m, 3H, J = 8.2, 7.5 Hz), 7.41 (t, 1H, J = 7.5 Hz), 7.78 (d, 2H, J = 8.2 Hz); 13C NMR 
(125 MHz, CDCl3) δ: 14.1, 21.1, 21.7, 21.9, 22.3, 22.7, 31.9, 37.8, 39.5, 49.1, 50.4, 51.8, 65.3, 68.0, 
70.3, 77.6, 97.4, 107.3, 113.2, 121.5, 124.3, 125.6, 127.9, 128.6, 128.7, 129.1, 130.1, 132.5, 134.9, 
137.1, 137.7, 140.9, 145.3, 157.1, 159.9, 161.1, 172.3 ppm; HRMS (ESI-TOF) m/z: [M+H+Na]+: Calcd 
for C39H44NaO10S2: 759.2268; Found: 759.2089. 
(S)-2-(6-((4'-(3-((3-fluoropropyl)sulfonyl)propoxy)-2',6'-dimethyl-[1,1'-biphenyl]3-yl)methoxy)-2,3-
dihydrobenzofuran-3-yl)acetic acid (2) 
Alcohol 6 (30.2 mg, 49.2 µmol) was dissolved in 3 mL of DCM and cooled down at 0°C before the 
addition of deoxofluor (30 µL, 81.4 µmol). The reaction was allowed to warm up from 0°C to room 
temperature under agitation for 90 min. Volatiles were removed under reduced pressure and the 
crude was taken up into 750 µL of THF and 250 µL of methanol. Then 125 µL of 1N aqueous NaOH 
(125 µl, 125 µmol) were added to the mixture and the reaction was allowed to stir at room 
temperature for 2 hours. Finally, the reaction was neutralized with 125 µL of a 1M HCl aqueous 
solution and diluted with acetonitrile/water before being submitted to hplc purification to afford 
compound 2a as a white powder after lyophilization. (S)-2-(6-((4'-(3-((3-
fluoropropyl)sulfonyl)propoxy)-2',6'-dimethyl-[1,1'-bi-phenyl]3-yl)methoxy)-2,3-dihydrobenzofuran-
3-yl)acetic acid (8.5 mg, 14.9 µmol, 30 % yield). 1H NMR (600 MHz, d6-DMSO) δ: 1.91 (s, 6H), 2.05-
2.20 (m, 4H), 2.47 (dd, 1H, J = 16.5, 9.1 Hz), 2.66 (dd, 1H, J = 16.5, 5.5 Hz), 3.24-3.32 (m, 4H), 3.66 (m, 
1H), 4.09 (t, 2H, J = 6.2 Hz), 4.17 (dd, 1H, J = 9.2, 6.8 Hz), 4.50-4.62 (dt, 2H, 2J(F-H) = 47.0 Hz, J = 5.9 
Hz), 4.67 (t, 1H, J = 9.0 Hz), 5.09 (s, 2H), 6.44 (s, 1H), 6.46 (dd, 1H, J = 8.2 Hz), 6.70 (s, 2 H), 7.04 (d, 1H, 
J = 7.5 Hz), 7.08 (d, 1H, J = 8.2Hz), 7.13 (s, 1H), 7.36 (d, 1H, J = 7.5 Hz), 7.43 (t, 1H, J = 7.5 Hz); 13C NMR 
(150 MHz, d6-DMSO) δ: 20.4, 21.3, 22.4, 22.5, 36.8, 38.6, 47.7, 47.8, 48.5, 65.1, 69.1, 76.8, 81.2, 82.3, 
96.7, 106.7, 113.0, 121.7, 124.2, 125.6, 128.2, 128.3, 128.5, 133.6, 136.3, 137.1, 139.9, 156.6, 158.8, 
160.4, 172.8; 19F NMR (400 MHz, d6-DMSO) δ: -217.02 ppm (septet); HRMS (ESI-TOF) m/z: [M-H]: 
Calcd for C31H34FO7S: 569.2015; Found: 569.2071. 
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Condition screening for the displacement of tosylate 7 with KF 
In a microwave tube were dissolved tosylate (7) (1 eq, 7.5 µmol), KF (2 eq), K2CO3 (0.8 eq) and 
Kryptofix K2,2,2 (1.5 eq) in 200 µL of anhydrous acetonitrile. The tube was sealed under argon and the 
sample was stirred at room temperature for 10 min or was heated under microwaves irradiations at 
40°C, 100°C and 130°C for either 2, 5, 10 or 15 min. Indicated yields were determined from LC-MS 
profile by integration of the UV signal at 220 nm. No purifications were performed. No internal 
standard was used. 
 
(S)-2-(6-((4'-(3-((3-[18F]fluoropropyl)sulfonyl)propoxy)-2',6'-dimethyl-[1,1'-biphenyl]3-yl)methoxy)-2,3-
dihydrobenzofuran-3-yl)acetic acid (2a) 
N.c.a. [18F]fluoride was produced via the 18O(p,n)18F nuclear reaction at a Scanditronix MC35 
cyclotron using ≥97% enriched 18O-water in a 2.5 mL liquid target. N.c.a. [18F]fluoride (~2-5 GBq) was 
trapped on a preconditioned SepPak® light accell plus QMA-cartridge (Waters AG / ABX). The 
[18F]fluoride was eluted directly into a 5 mL sealed glass reaction vessel using a solution of 300 µL of 
an aqueous solution of potassium carbonate (1.65 mg, 12 µmol) and 850 µL of Kryptofix K2,2,2 (10 mg, 
26.5 µmol) in ACN. The reaction vessel was placed in a heating block and the solution was dried 
azeotropically under reduced pressure and a stream of argon for 10-15 min at 100°C. The argon was 
removed and the reaction vessel was further dried under full vacuum for at least 5 min at 100°C. 
Subsequently, the tosylate precursor (7) (5.0 mg, 6.8 µmol) previously dissolved in 1 mL of anhydrous 
acetonitrile was added to the dry 18F-cryptate-complex and heated at 100°C. Over a period of 15 min, 
aliquots of 10 µL were taken and analyzed by radioTLC. The reaction mixture was allowed to cool to 
room temperature, and 1 mL of a mixture of 250 µL of methanol and 250 µL of a 2.5M NaOH 
aqueous solution was added, and the reaction was kept at room temprerature for 5 min. For 
neutralization, the mixture was quenched with 500 µL of a 1.25M aqueous HCl solution, and filled 
with water (1.5 mL). The product was obtained in 16.7% ± 5.7% RCY with a specific activity of ≥0.6 
GBq/µmol. Total time of synthesis was 60–70 min. 
Rf-values were as follows: [18F]fluoride: 0.0, 18F-labelled protected intermediate: 0.9, product 2 and 
2a: 0.8. Analytical radioHPLC retention time of product 2 and 2a was 14.7 min. 
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Abstract  
 
 
 
Chemoselective functionalization of peptides and proteins to selectively introduce residues for 
detection, capturing or specific derivatization is of high interest to the synthetic community. Here we 
report a new method for the mild and effective mono-iodination of tyrosine residues within fully 
unprotected peptides. This method is highly chemoselective and compatible with a wide variety of 
functional groups. The introduced iodine can subsequently serve as a handle for further 
functionalization such as introduction of fluorescent dyes and thus be used for chemoselective labeling 
of isolated peptides. 
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Introduction 
While incorporation of conjugation sites into small peptides can be easily achieved at will by selection 
of appropriately functionalized amino acid building blocks for solid phase peptide synthesis, selective 
functionalization of isolated peptides and proteins not containing protecting groups still remains a 
challenging task. Among the 20 naturally occurring amino acids, the most relevant ones for 
bioconjugation purposes are cysteine and lysine as they can act as potent nucleophiles.1 However, the 
high abundance of lysine on protein surfaces makes specific acylation challenging and non-oxidized 
cysteines are less frequently displayed on protein surfaces. As they are most often involved in disulfide 
bridges in their natural environment, reduction of the target disulfide is a prerequisite before labeling, 
which may also alter the overall structure of the target protein. Therefore the development of 
additional modification techniques targeting alternative amino acids remains of high significance.  
Tyrosine offers a wide range of reactivities: the phenolate ring may be O-alkylated;2 it can undergo 
electrophilic addition using diazonium derivaties3 or can be involved in Mannich-type condensations4 
and reactions with ene-type electrophiles.5 Owing to the electron-rich aromatic ring, tyrosine residues 
can also be a target for halogenation. Notably, iodination is of particular importance due to its utility 
for further transformations. It has been used to label biomolecules for a wide variety of purposes, such 
as mass spectrometry,6 to help in the elucidation of foldamer structures7 or to improve the self-
assembly properties of peptides.8 Moreover, tyrosine iodination with 125I for the radiolabeling of 
compounds of medical and biological interest is the method of choice owing to its high specific 
radioactivity and convenience in counting γ-emissions.9 Iodinations are carried out either 
enzymatically, for example by the enzyme thyroid peroxidase,10 or by direct electrophilic aromatic 
substitution using an iodinating agent such as N-iodosuccinimide11 or Barluenga’s reagent.12 Other 
alternatives involve the combination of sodium iodide with strong oxidizing agents like Iodogen13,14 or 
Chloramin-T.13,15 However, existing methods display limitations as iodination frequently results in a 
mixture of unreacted starting material, mono- and di-iodinated peptides,9,11,13-30 which reduce yields 
and may also impose challenges in product purification. Formation of oxidized peptides9,16,19 and 
histidine labeling9,20,21 have also been described as limiting factors. For most applications a mono-
iodinated version of the compound of interest would be highly desirable in order to minimize the 
negative influence of the added substituents on the activity of the target biomolecule. Indeed, 
examples were reported where the di-iodinated peptide exhibited a 3 to 10-fold lower receptor 
binding activity whereas the binding of the mono-iodinated was maintained.17,18 Accordingly, further 
investigations towards a selective iodination method yielding selectively a mono-iodinated tyrosine 
are of high interest. 
Here we present a new and efficient iodinating agent allowing highly controlled mono-iodination 
reactions and demonstrate its utility in the preparation of a wide range of fully unprotected and 
complex biologically active peptides. 
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Results and Discussion 
We explored the combination of sodium iodide and Selectfluor in the search of a mild and selective 
iodinating reagent for tyrosine (Scheme 1, Supp Info 1). 
 
 
 
Scheme 1 Iodination of tyrosine with sodium iodide activated by Selectfluor 
 
 
We first examined the iodination reaction in different solvents on the protected tyrosine Ac-Tyr-NH-
Me as a model system to mimic the reactivity of a tyrosine incorporated in a peptide sequence. The 
reaction employing a slight excess (1.1 eq) of Selectfluor and NaI proceeded instantly at room 
temperature, affording a mixture of unreacted starting material (SM), mono-iodinated product (MI) 
and di-iodinated product (DI). Extending the reaction time to 120 min did not have an impact on the 
conversion rate (Supp Info 2). A strong influence of the solvent and pH was observed (Table 1). Aprotic 
polar solvents (entries 1, 2) or aqueous systems (entries 3 to 6) favored the formation of the di-
iodinated product. Dichloromethane supplemented with TFA (entries 7 to 11) proved to be the optimal 
conditions to achieve a controlled mono-iodination. Addition of TFA allowed proper dissolution of the 
starting material but, more importantly, positively modulated the iodination reactivity. Besides, most 
peptides are soluble on 1%-20% TFA/DCM, these conditions are commonly used for cleavage of resins 
with hyperacid labile linker systems like SASRIN, HAL or chlorotrityl. We assume that, after conversion 
of the iodide of NaI to an electrophilic iodonium species I+ by Selecfluor, the reaction proceeds via an 
electrophilic substitution mechanism as previously postulated by Syvret et al.22  
We further applied the iodination reaction to other amino acids containing aromatic residues, 
phenylalanine, tryptophane, and histidine, that are prone to undergo electrophilic aromatic 
substitutions. Under these conditions, no formation of iodinated product was observed (Supp info 3). 
We started to investigate the optimised iodination conditions on multifunctional, fully unprotected 
peptides. A total of eight biologically relevant peptides, either commercially available or prepared in 
our laboratory, were surveyed: Leucine-Enkephalinamide (agonist of μ and δ opioid receptors), 
Angiotensin III (agonist of AT1 and AT2 receptors), Cyclo(RGDyK) (high affinity αvβ3 integrin ligand), 
ACP fragment (65-74) (fragment of the acyl carrier protein), Goserelin (superagonist of LH- releasing 
hormone), Tocinoic acid (agonist of the oxytocin receptor), AcMeYVAD-CHO (reversible inhibitor of 
caspase-1), [Tyr0]-Bradykinin (ligand of the kinin B1 and B2 receptors) (Table 2, entries 1-8). 
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Entry Solvent TFA SM 1 (%)a MI 2a (%) DI 2b (%) 
1 DMSO - 49 7 44 
2 DMF - 45 24 31 
3 tBuOH/H2O (5/1) - 17 57 26 
4 MeOH/DCM - 23 54 23 
5 H2O/ACN (1/1) - 22 44 33 
6 H2O/ACN (1/1) 10% TFA 27 57 16 
7 DCM 1% TFA 46 48 6 
8 DCM 5% TFA 46 53 1 
9 DCM 10% TFA 47 53 - 
10 DCM 20% TFA 54 46 - 
11b DCM 20% TFA 6 86 8 
a SM=Starting material, MI=Mono-iodinated product, DI=Di-iodinated product. Relative 
ratio dertermined by LC/MS at 215 nm. b After extra addition of 2x0.25 eq of iodinating 
reagent.  
Table 1 Solvent screening for the mono-iodination of Ac-Tyr-NH-Me 1 
 
The peptides studied were structurally diverse and collectively included i) other aromatic amino acids, 
ii) a free acid at the C-terminus, iii) a disulfide bridge between two cysteines, iv) cyclic structures, v) 
non-natural amino acid, and vi) an aldehyde function. Since the typical protein absorbance at 280 nm 
can shift to a maximum around 315 nm due to the iodination of the tyrosine phenolate ring,23 we 
decided to carry out the analysis via LC-MS at 215 nm absorbance to quantify the relative amounts of 
starting material (SM), mono-iodinated product (MI) and di-iodinated product (DI). In all cases, the 
mono-iodinated product was the most predominant with a relative ratio of 88% to 97% as outlined in 
Table 2. The position of the tyrosine in the sequence did not seem to have an influence on the mono-
iodination efficacy. An example is shown on Scheme 2, the mild mono-iodination reaction proceeded 
cleanly in the presence of a tryptophane residue, an aza-peptide moeity, and a tert-butyl protected 
serine which remained untouched. Interestingly, this method delivered superior results compared to 
a previously reported approach using N-iodosuccinimide in the case of Cyclo(RGDyK).11  
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Scheme 2 Mono-iodination of Goserelin with Selecfluor and NaI 
 
Next, we applied our method on a peptide containing a methionine residue: [Tyr8]-Substance P (ligand 
of the neurokinin-1 receptor) (entry 9). The ability of sulfur to react with halonium in acidic conditions 
is known and widely exploited e.g. in glycosylation chemistry where thioglycosides can serve as 
glycoside donors143. As expected, when reacting the peptide with the first equivalent of iodination 
reagent, we observed oxidation at the methionine residue, but also formation of the desired mono-
iodinated product (around 25%). However, total consumption of both starting material and oxidized 
starting material was reached by careful addition of excess iodination reagent (2x0.35 eq) to afford an 
almost exclusive mixture of the mono-iodinated product and its oxidized methionine analog (Supp. 
info 4). 
 
We then searched for a strategy to effectively reduce the oxidized mono-iodinated product, while 
keeping the reduced version intact. Several reagents have been reported for the reduction of 
methionine sulfoxide residue in peptides: trimethylsilyl bromide with 1,2-ethanedithiol, N-methyl 
mercapto-acetamide, tetrabutylammonium bromide or ammonium iodide with dimethylsulfide. 
Treatment of the peptide reaction mixture with either Bu4NBr or NH4I–Me2S in TFA were successful in 
reducing the oxidized methionine but led to formation of byproducts, rendering these conditions 
ineffective. Finally, the use of potassium iodide and ascorbic acid in TFA24 offered a very clean 
conversion of the methionine sulfoxide to the desired reduced peptide (Scheme 3, Supp. Info 4). 
Nicolas et al.25 reports this reduction to proceeding via nucleophilic iodide attack on the protonated 
sulfoxide leading to the methionine sulfide and elemental iodine. The latter directly reacts with the 
ascorbic acid, with the consumption of the generated iodine driving further the reduction forward.24 
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Scheme 3 Mono-iodination strategy for a methionine-containing peptide [Tyr8]-Substance P 
 
 
To verify the relevance of the method, mono-iodinations of Cyclo(RGDyK), Leucin-Enkephalinamide, 
[Tyr0]-Bradykinin, Angiotensin III, ACP-fragment 65-74 and [Tyr8]-Substance P were performed on 
different scales varying from 1 mg up to 35 mg (1 to 65 µmol). After isolation by HPLC, yields of 
between 61% and 77% were obtained. Characterization by UPLC, HRMS and 1H-13C NMR confirmed the 
identity of the desired mono-iodinated products, including the desired insertion of the iodine atom at 
the ortho position of the –OH group, as expected. Additionally, no trace of iodination was observed on 
Phe, ormost importantly, on His - the second most reactive amino acid toward iodination26 - confirming 
the high chemoselectivity of the reagent for Tyr. Furthermore, careful UPLC and NMR analysis did not 
reveal any evidence of racemization.  
 
A recent peptide drug class for the treatment of type 2 diabetes mellitus is the group of glucagon-like 
peptide-1 (GLP-1) agonists which includes GLP-1 itself, but also modified analogues such as Victoza 
(Liraglutide) and others. We therefore sought to demonstrate the wide and general applicability of the 
strategy by examining the mono-iodination of GLP-1(7-37), a native hormone which binds to the GLP-
1 receptor and triggers insulin secretion glucose dependently. Single incorporation of an iodine atom 
on the tyrosine residue of the human GLP-1 (7-37) was achived with high selectivity (ratio of mono-
iodinated compound > 91%) and the desired mono-iodinated peptide was isolated with a 52% yield 
after HPLC purification, confirming the success of the approach on a challenging 31-mer peptides 
(Table 2, entry 10). 
 
Taking profit of the high reactivity of the newly formed aryl-iodo peptides, we applied a Suzuki-Miyaura 
cross-coupling as a final step in the preparation of bio-imaging probes, as examplified by [mono-Iodo]-
Leucin Enkephalinamide 8 (Scheme 4, A). Carboxylphenyl boronic acid pinacol ester functionnalized 
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with a dansyl fluorophore 9 was directly attached to the iodo-peptides using a water soluble complex 
of Pd(OAc)2 with the dihydroxypyrimidine ligand developed by Chalker et al.27 To circumvent prior 
chemical modification of expensive fluorophores, the cross coupling with a boronic acid pinacol ester 
functionnalized with an azide (such as 12) offers an alternative which enables subsequent copper-
catalyzed azide-alkyne cycloaddition (CuAAC) to connect the peptide to the dye - most of them being 
commercially available as alkyne derivatives (Scheme 4, B). In both cases, cross-couplings proceeded 
smoothly at 38°C in 12 hours and addition of glycerol was found to improve solubility of the coupling 
partners and to increase yields as previously reported.28  
 
 
 
 
Scheme 4 Conjugation of fluorophores to mono-iodinated peptides Leucin-Enkephalinamide and ACP fragment 
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Conclusion 
In summary, we have developed a new method enabling the efficient, specific and highly controled 
mono-iodination of tyrosine within fully unprotected peptides. Successful application of the approach 
was demonstrated on peptides with various sizes and complexity, including peptides containing other 
aromatic amino acids such as tryptophane and histidine, but also sulfur containing amino acids like 
methionine or cysteine. By exploiting the reactivity of the mono-iodo peptides we performed 
conjugation with fluorophore building blocks via Suzuki-Miyaura cross-coupling, as an example of bio-
imaging probe synthesis. We believe our findings will prove to be a useful additional tool in the arsenal 
of bioconjugation chemistry, notably for peptides obtained by isolation from natural sources in which 
incorporation of particular conjugation sites is not possible and lysine or free cysteine are not available 
for labeling. 
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Figure S1 – Iodination stock solution preparation 
Iodination stock solution 50 mM in acetonitrile was prepared freshly. Selectfluor (15 mg, 42.3 µmol) 
was dissolved in 840 µL of acetonitrile by vigorous vortexing (solution A) followed by NaI (6.8 mg, 
45.3 µmol). The addition of sodium iodide was easily visible by change in color: the transparent 
Selectfluor solution turned into a brown caramel mixture after 10 seconds (solution B). 
Upon addition of the iodination stock solution to Tyr-peptides dissolved in DCM + 20% TFA (solution 
C), the reaction mixture turned light pink (solution D). 
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Figure S2 – Iodination reaction occurs quickly at room temperature    
Ac-Tyr-NH-Me (2.0 mg, 8.5 µmol) was dissolved in 1 mL of DCM + 10% TFA. Then was added 
dropwise 1.1 eq of a 50 mM freshly prepared iodination stock solution. Reaction was allowed to stir 
at room temperature and monitored by LC-MS after 15 minutes and after 2 hours. No difference was 
observed. Analytical LC-MS chromatograms are shown below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 – Mild and selective mono-iodination of unprotected peptides as initial step for the synthesis of bioimaging probes 
 
135 
 
Figure S3 – Iodination is specific to Tyr residue 
Ac-Tyr-NH-Me (2.0 mg, 8.5 µmol), Ac-Phe-Tyr-NH-Me, Ac-Phe-His-NH-Me and Ac-Phe-Trp-NH-Me 
were respectively dissolved in 1 mL of DCM + 10% TFA. Then was added dropwise 1.1 eq of a 50 mM 
freshly prepared iodination stock solution. Reaction was allowed to stir at room temperature and 
monitored by LC-MS after 2 minutes and after 15 minutes. Under these conditions, iodination 
proceeded only on Tyr residues. Analytical LC-MS chromatograms are shown below: 
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Figure S4 – Mono-iodination of a Met-containing peptide: [Tyr8]-Substance P 
[Tyr8]-Substance P (0.81 mg, 0.59 µmol) was dissolved in 340 µL of DCM and 80 µL of TFA. Then were 
added dropwise 16 µL (1.4 eq.) of a 50 mM freshly prepared iodination stock solution. Reaction was 
allowed to stir at room temperature and monitored by LC-MS. A mixture containing the SM, the 
starting material with the oxidized methionine SM[Ox], and the MI. Addition of 4 µL (0.35 eq.) of a 50 
mM iodination stock solution generated the oxidized methionine mono-iodinated compound MI[Ox]. 
Two other successive additions of 4 µL (3x 0.35 eq.) of a 50 mM iodination stock solution afforded MI 
and MI[Ox] as the major product. Finally, addition of 100 µL of the reducing cocktail (freshly 
prepared: potassium iodide KI (10 mg) and ascorbic acid (10 mg) were sonicated in 500 µL of TFA for 
10 minutes) enabled reduction of MI[Ox] towards MI. Analytical LC-MS chromatograms are shown 
below: 
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General methods 
Unless otherwise noted, all reagents and solvents were purchased from commercial suppliers (Sigma 
Aldrich, ThermoFisher, Merck Millipore) and used without further purification. 
Reactions were monitored by LC-MS. For small molecules: data were acquired using the Agilent 1100 
MSD system with a Phenomenex Luna column (C-18, 100Å pore size, 3 μm particle size, 10x2.0 mm, 
flow: 1.1 mL/min). Gradient: 0 min 1% ACN (+0.05% TFA) / 99% H2O (+0.05% TFA); 0.3 min % ACN 
(+0.05% TFA); 1.3 min 95% ACN (+0.05% TFA); 1.75 min 1% ACN (+0.05% TFA); 1.80 min 1% ACN 
(+0.05% TFA). Mass detection range: 110-1000MW. Temperature: 30 °C. For peptides: data were 
acquired using the Agilent 1100 MSD system with a Phenomenex Aeris Widepore column (XB-C18, 
200Å pore size, 3.6 μm particle size, 100x2.1 mm, flow: 0.5 mL/min). Gradient: 0 min 5% ACN (+0.1% 
formic acid) / 95% H2O (+0.1% formic acid) to 10 min - 50% ACN (+0.1% formic acid); 11 min 90% ACN 
(+0.1% formic acid) to 12.5 min; 12.5 min to 13.5 min 5% ACN (+0.1% formic acid). Mass detection 
range: 500-1500MW. Temperature: 38°C. 
Purifications on reverse-phase preparative HPLC were performed on the HP-Agilent 1100 with either 
i) a column from Agilent (Zorbax Rx C18, 5 µm particle size, 250x9.4mm, flow: 4 mL/min). Gradient: 0 
min to 5 min 10% ACN (+0.1% TFA) / 90% H2O (+0.1% TFA); 5 min to 30 min 95% ACN (+0.1% TFA) / 
5% H2O (+0.1% TFA); 30 min to 32 min 95% ACN (+0.1% TFA) / 5% H2O (+0.1% TFA); 32 min to 35 min 
10% ACN (+0.1% TFA) / 90% H2O (+0.1% TFA) or ii) a column from Waters (Xbridge Prep C18 OBD, 5 
µm particle size, 250x19mm, flow: 16 mL/min). Gradient: 0 min to 5 min 10% ACN (+0.1% TFA) / 90% 
H2O (+0.1% TFA); 5 min to 30 min 95% ACN (+0.1% TFA) / 5% H2O (+0.1% TFA); 30 min to 32 min 95% 
ACN (+0.1% TFA) / 5% H2O (+0.1% TFA); 32 min to 35 min 10% ACN (+0.1% TFA) / 90% H2O (+0.1% 
TFA) or iii) a column from Waters (Acquity UPLC CSH C18, 130Å pore size, 1.7 µm particle size, 
2.1x150mm, flow: 0.5 mL/min). Gradient: 0 min to 3 min 20% ACN (+0.05% TFA) / 80% H2O (+0.05% 
TFA); 3 min to 23 min 75% ACN (+0.05% TFA) / 25% H2O (+0.05% TFA); 23 min to 23.5 min 95% ACN 
(+0.05% TFA) / 5% H2O (+0.05% TFA). 23.5 min to 25.5 min 95% ACN (+0.05% TFA) / 5% H2O (+0.05% 
TFA). Temperature: 50 °C. 
Purification on silica gel chromatography was performed on CombiFlash Rf-Isco Teledyne. 
Final peptides were analyzed by UPLC-MS Waters Acquity (C-18 CSH column - 130Å pore size, 1.7 μm 
particle size, 150x2.1 mm, flow: 0.5 mL/min – Gradient 1: 0 min 10% ACN (+0.1% formic acid) / 90% 
H2O (+0.1% formic acid) to 19.2 min - 90% ACN (+0.1% formic acid); 20 min 90% ACN (+0.1% formic 
acid). Gradient 2: 0 min 2% ACN (+0.1% formic acid) / 98% H2O (+0.1% formic acid) to 9.12 min - 40% 
ACN (+0.1% formic acid); 12 min 40% ACN (+0.1% formic acid). Mass detection range: 500-2000MW. 
Temperature: 40 °C. High resolution mass HRMS were recorded on the Agilent 6200 Series Accurate-
Mass Time-of-flight (TOF). 1H and 13C NMR spectra were recorded on a Bruker DRX-400 or 600 
systems in d6-DMSO or CDCl3. Chemical shifts are given in parts per million (ppm) with 
tetramethylsilane as an internal standard. Abbreviations are used as follows: s = singlet, d = doublet, 
t = triplet, q = quartet, p = pentet, m = multiplet or unresolved, dd = doublets of doublet, br = broad. 
Coupling constants (J values) are given in Hertz (Hz). Absorption and Emission spectra were acquired 
with a Thermo Varioskan using the SkanIt 2.4.3 software. 
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Abbreviations  
ACN = acetonitrile 
AUC = area under the curve 
Boc = tert-butyloxycarbonyl 
DCM = dichloromethane 
DI = di-iodinated product 
DIEA = N,N-diisopropylethylamine 
DMF = dimethylformamide 
DODT = 3,6-Dioxa-1,8-octane-dithiol 
ESI-TOF = electrospray ionization mass spectrometry – time of flight 
EtOAc = ethyl acetate 
HE-SPPS = high-efficiency solid phase peptide synthesis 
HPLC = high performance liquid chromatography 
HRMS = high resolution mass spectrometry 
LC-MS = liquid chromatography - mass spectrometry 
MI = mono-iodinated product 
NMR = nuclear magnetic resonance 
PEG = poly-ethylene glycol 
SM = starting material 
tBuOH = tert-butanol 
TFA = trifluoroacetic acid 
THPTA = tris(3-hydroxypropyltriazolylmethyl)amine 
TIS = triisopropylsilane 
UPLC-MS = ultra-performance liquid chromatography - mass spectrometry 
 
Peptides 
Tocinoic acid, Goserelin acetate and [Tyr8]-Substance P were purchased from Sigma Aldrich. 
Cyclo(RGGyK) was purchased from Selleckchem. AcMeYVAD-CHO, [Tyr0]-Bradykinin, and human GLP-
1 (7-37) were purchased from Bachem. 
 
HE-SPPS 
Leucin-Enkephalinamide, Angiotensin III and ACP fragment (65-74) were synthesized by High-
Efficiency Solid Phase Peptide Synthesis1 using a CEM Liberty Blue system on a 0.1 mmol scale with a 
Rink Amide AM resin low loading (0.29 mmol/g) 100-200 mesh from Novabiochem using 5-fold 
excess of reagents [0.2 M Fmoc amino acid solution (in DMF) with 0.5 M DIC (in DMF) and 1.0 M 
Oxyma (in DMF)] and 20% pipieridine in DMF for the Fmoc-deprotection cycles. Immediately after 
synthesis, the peptide resin was washed three times with 10 mL of DMF and then three times with 10 
mL of DCM. Cleavage was then performed in all cases with 10 mL of a freshly prepared King’s cocktail 
(TFA 82.5% / Phenol 5% / Thioanisol 5% / H2O 5% / DODT 2.5%) for 3 hours before being precipitated 
in 70 mL of ice cold diisopropyl ether. Precipitate was centrifuged (4 min, 4000 rpm, 4 °C) and 
washed with ice cold diisopropyl ether three times. Finally, the resin was filtered off and the peptide 
precipitate was dissolved in H2O + 25% ACN + 0.5% AcOH and lyophilized. Crude purity was > 95% for 
Leucin-Enkephalinamide. Angiotensin III and ACP fragment (65-74) were purified with reverse-phase 
preparative HPLC.  
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Solvent screening for Ac-Tyr-NH-Me mono-iodination  
Ac-Tyr-NH-Me (2.0 mg, 8.5 µmol) was dissolved in 1 mL of different solvents (indicated in Table 1). 
Then was added dropwise 1.1 eq of a 50 mM freshly prepared iodination stock solution. Reaction 
was allowed to stir at room temperature and monitored by LC-MS instantly after addition of 
iodination solution, and after 15 minutes. Relative amounts of SM, MI, and DI shown in Table 1 were 
quantified using AUC integration (absorbance at 220 nm). Analytical LC-MS chromatograms are 
shown below: 
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General Mono-iodination procedure 
Tyr-containing peptide was dissolved in DCM+ 20% TFA at a concentration of 1-2 mM. Then were 
added dropwise 1.4 eq of a 50 mM freshly prepared iodination stock solution. Reaction was allowed 
to stir at room temperature for 15 minutes and was monitored by LC-MS as followed: 10 µL of the 
reaction mixture were quenched with 20 µL of distilled water which were submitted to analysis. 
Depending on the conversion, extra 0.25 eq of iodination stock solution were added sequentially to 
reach the described ratio of starting material (SM), mono-iodinated product (MI) and di-iodinated 
product (DI) in Scheme 2. Relative amounts of SM, MI and DI were quantified using AUC integration 
(absorbance at 215 nm) corresponding to their respective masses. Analytical LC-MS chromatograms 
are shown below: 
Cyclo(RGD[mono-iodo]yK)
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Leucin-Enkephalinamide 
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Goserelin 
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[Tyr0]-Bradykinin 
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Angiotensin III 
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ACP fragment (65-74) 
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AcMeYVAD-CHO 
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Tocinoic acid 
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[Tyr8]-Substance P
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Human GLP-1 (7-37)
 
 
 
Mono-iodination of Cyclo(RGDyK) 
Cyclo(RGDyK) (1.02 mg, 1.18 µmol) was dissolved in 500 µL of DCM and 125 µL of TFA. Then were 
added dropwise 33 µL of a 50 mM iodination stock solution (1.65 µmol, 1.4 eq.) (stock solution 
freshly prepared: 29.1 mg of Selectfluor were dissolved in 1.6 mL of ACN before the addition of 12.5 
mg of NaI). The reaction mixture was allowed to stir at room temperature for 15 minutes. Two other 
additions of iodination solution (2 x 5 µL, 2 x 0.25 eq.) were needed to reach the following final ratio: 
SM: 5.5% - MI: 88.3% - DI: 6.2%. The reaction mixture was then evaporated under reduced pressure 
(TFA was co-evaporated three times with DCM) and redissolved in water/acetonitrile (1/1) before 
being submitted to HPLC (purification performed on Agilent Zorbax Rx C18, gradient: see general 
methods). The collected fraction was lyophilized to afford the desired product Cyclo(RGD[mono-
iodo]yK) (m= 0.88 mg, 0.90 µmol, 77 % yield). 
1H NMR (700 MHz, d6-DMSO, 308 K) δ: 1.10 (p, 2H), 1.36 (m, 2H), 1.45 (m, 4H), 1.57 (br, 1H), 1.72 (br, 
1H), 2.39 (dd, 1 H), 2.70 (m, 4H), 2.78 (dd, 1H), 3.08 (q, 2H), 3.24 (dd, 1H), 3.94 (m, 1H), 4.04 (dd, 1H), 
4.16 (q, 1H), 4.34 (q, 1H), 4.63 (q, 1H), 6.77 (d, 1H, J = 8.2 Hz), 6.87 (dd, 1H, J = 8.2, 2.0 Hz), 7.44 (d, 
1H, J = 2.0 Hz), 7.52 (t, 1H), 7.61 (d, 1H), 7.68 (br, 3H), 8.00 (d, 1H), 8.09 (d, 1H), 8.11 (d, 1H), 8.44 (q, 
1H), 10.10 (s, 1H), 12.20 (s, 1H).  
13C NMR (175 MHz, d6-DMSO, 308 K) δ: 22.4, 25.1, 26.4, 28.5, 30.6, 35.0, 35.9, 38.6, 40.3, 43.2, 48.8, 
51.8, 54.3, 54.5, 84.1, 114.6, 129.1, 130.2, 138.9, 155.0, 156.6, 169.4, 169.9, 170.5, 171.1, 171.5, 
171.8.   
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HRMS (ESI-TOF) Calcd for C27H40IN9O8: 745.2054; Found: 745.2078. 
UPLC-MS rt: 3.257 min (Gradient 2). 
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Mono-iodination of Leucin-Enkephalinamide (8) 
Leucin-Enkephalinamide (36.0 mg, 64.9 µmol) was dissolved in 26 mL of DCM and 6.5 mL of TFA. 
Then were added dropwise 1.8 mL of a 50 mM iodination stock solution (91 µmol, 1.4 eq.) (stock 
solution freshly prepared: 50.0 mg of Selectfluor were dissolved in 2.8 mL of ACN before the addition 
of 21.0 mg of NaI). The reaction mixture was allowed to stir at room temperature for 15 minutes. 
Two other additions of iodination solution (2 x 320 µL, 2 x 0.25 eq.) were needed to reach the 
following final ratio: SM: 1.0% - MI: 88.2% - DI: 10.8%. The reaction mixture was then evaporated 
under reduced pressure (TFA was co-evaporated three times with DCM) and redissolved in 
water/acetonitrile (1/1) before being submitted to HPLC (purification performed on Xbridge Prep 
C18, gradient: see general methods). The collected fraction was lyophilized to afford the desired 
product [mono-Iodo]-Leucin-Enkephalinamide (27.3 mg, 40.1 µmol, 62 % yield). 
1H NMR (500 MHz, d6-DMSO, 300 K) δ: 0.84 (d, 3H), 0.88 (d, 3H), 1.47 (m, 2H), 1.57 (m, 1H), 2.53 (s, 
1H), 2.80 (dd, 1H), 2.87 (dd, 1H), 3.02 (dd, 1H), 3.45 (q, 1H), 3.61 (dd, 1H), 3.70 (m, 3H), 4.18 (m, 1H), 
4.49 (m, 1H), 6.77 (d, 1H, J = 8.2 Hz), 6.97 (s, 1H), 7.03 (dd, 1H, J = 8.2, 2.0 Hz), 7.17 (m, 1H), 7.25 (d, 
4H, J = 4.4 Hz), 7.53 (d, 1H, J = 2.0 Hz), 7.96 (d, 1H, J = 8.2 Hz), 8.07 (d, 1H, J = 8.2 Hz), 8.11 (t, 1H, J = 
5.6 Hz), 8.18 (s, 1H), 8.30 (s, 1H), 10.10 (br, 1H). 
13C NMR (125 MHz, d6-DMSO, 300 K) δ: 21.56, 23.02, 24.19, 37.28, 38.53, 40.80, 41.90, 42.02, 50.99, 
54.09, 55.77, 84.36, 114.64, 126.26, 128.04, 129.17, 130.40, 130.62, 137.78, 139.22, 155.08, 163.38, 
168.75, 169.10, 170.69, 173.76, 173.88.  
HRMS (ESI-TOF) Calcd for C28H38IN6O6: 681.1892; Found: 681.1891. 
UPLC-MS rt: 3.878 min (Gradient 1). 
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Mono-iodination of [Tyr0]-Bradykinin 
[Tyr0]-Bradykinin (1.58 mg, 1.29 µmol) was dissolved in 740 µL of DCM and 180 µL of TFA. Then were 
added dropwise 36 µL of a 50 mM iodination stock solution (1.80 µmol, 1.4 eq.) (stock solution 
freshly prepared: 29.1 mg of Selectfluor were dissolved in 1.6 mL of ACN before the addition of 12.5 
mg of NaI). The reaction mixture was allowed to stir at room temperature for 15 minutes. Two other 
additions of iodination solution (2 x 6.5 µL, 2 x 0.25 eq.) were needed to reach the following final 
ratio: SM: 1.9% - MI: 92.7% - DI: 5.4%. The reaction mixture was then evaporated under reduced 
pressure (TFA was co-evaporated three times with DCM) and redissolved in water/acetonitrile (1/1) 
before being submitted to HPLC (purification performed on Agilent Zorbax Rx C18, gradient: see 
general methods). The collected fraction was lyophilized to afford the desired product [mono-Iodo-
Tyr0]-Bradykinin (1.46 mg, 0.93 µmol, 72 % yield). 
1H NMR (500 MHz, d6-DMSO, 300 K) δ: 1.43 (m, 1H), 1.51 (m, 5H), 1.61 (m, 2H), 1.70 (m, 2H), 1.79-
2.05 (br, 9H), 2.18 (m, 1H), 2.72 (m, 2H), 2.79 (dd, 1H), 2.89 (dd, 1H), 2.96 (dd, 1H), 3.11 (m, 5H), 3.51 
(m, 2H), 3.62 (m, 8H), 3.99 (m, 1H), 4.20 (m, 1H), 4.26 (dd, 1H), 4.30 (dd, 1H), 4.49 (m, 1H), 4.50-4.62 
(m, 4H), 5.36 (s, 1H), 6.78 (d, 1H, J = 8.2 Hz), 7.00 (dd, 1H, J = 8.2, 2.0 Hz), 7.15-7.30 (m, 10H), 7.51 (d, 
1H, J = 2.0 Hz), 7.56 (t, 1H), 7.61 (t, 1H), 7.70 (d, 1H), 7.94 (m, 2H), 8.08 (br, 2H), 8.13 (d, 1H), 8.31 (d, 
1H), 8.66 (d, 1H), 10.31 (s, 1H), 12.72 (s, 1H).  
13C NMR (125 MHz, d6-DMSO, 300 K) δ: 23.72, 24.43, 24.52, 25.09, 27.90, 28.12, 28.58, 28.81, 29.08, 
35.47, 37.26, 37.72, 40.27, 40.47, 41.67, 46.82, 46.90, 50.01, 51.49, 52.60, 53.12, 53.38, 53.45, 57.63, 
59.44, 59.60, 61.73, 84.78, 114.66, 126.26, 126.29, 126.90, 127.97, 128.02, 129.10, 129.13, 130.71, 
137.57, 137.68, 139.39, 155.85, 156.66, 156.74, 167.52, 168.48, 168.50, 169.63, 170.04, 170.85, 
170.95, 170.96, 171.77, 173.08.   
HRMS (ESI-TOF) Calcd for C59H81IN16O13: 1348.5214; Found: 1348.5255. 
UPLC-MS rt: 2.664 min (Gradient 1). 
Chapter 4 – Mild and selective mono-iodination of unprotected peptides as initial step for the synthesis of bioimaging probes 
 
157 
 
 
 
 
 
 
Mono-iodination of Angiotensin III 
Angiotensin III (20.0 mg, 15.7 µmol) was dissolved in 8.5 mL of DCM and 2.0 mL of TFA. Then were 
added dropwise 440 µL of a 50 mM iodination stock solution (22.0 µmol, 1.4 eq.) (stock solution 
freshly prepared: 14.8 mg of Selectfluor were dissolved in 830 µL of ACN before the addition of 6.9 
mg of NaI). The reaction mixture was allowed to stir at room temperature for 15 minutes. Three 
other additions of iodination solution (3 x 80 µL, 3 x 0.25 eq.) were needed to reach the following 
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final ratio: SM: 6.2% - MI: 91.3% - DI: 2.5%. The reaction mixture was then evaporated under reduced 
pressure (TFA was co-evaporated three times with DCM) and redissolved in water/acetonitrile (1/1) 
before being submitted to HPLC (purification performed on Xbridge Prep C18, gradient: see general 
methods). The collected fraction was lyophilized to afford the desired product [mono-Iodo]-
Angiotensin III (14.9 mg, 11.6 µmol, 74 % yield). 
1H NMR (500 MHz, d6-DMSO, 300 K) δ: 0.75 (d, 3H), 0.77 (t, 3H), 0.79 (d, 3H), 0.84 (d, 3H), 1.05 (p, 
1H), 1.36 (m, 1H), 1.46 (m, 2H), 1.64 (m, 4H), 1.77 (br, 2H), 1.99 (m, 2H), 2.59 (dd, 1H), 2.77 (dd, 1H), 
2.85 (dd, 1H), 2.93 (dd, 1H), 3.07 (m, 4H), 3.46 (br, 1H), 3.61 (m, 1H), 3.87 (br, 1H), 4.15 (t, 1H), 4.27 
(m, 2H), 4.38 (dd, 1H), 4.49 (m, 1H), 4.79 (br, 1H), 6.75 (d, J = 8.4 Hz, 1H), 7.08 (m, 2H), 7.17 (m, 1H), 
7.23 (m, 5H), 7.38 (br, 1H), 7.60 (m, 2H), 7.99 (s, 1H), 8.01 (s, 1H), 8.10 (br, 4H), 8.35 (d, 2H), 8.41 (d, 
2H), 8.93 (br, 1H), 10.17 (s, 1H), 14.19 (br, 1H). 
13C NMR (125 MHz, d6-DMSO, 300 K) δ: 10.85, 15.19, 17.57, 19.19, 24.10, 24.25, 24.28, 26.30, 28.62, 
29.13, 31.11, 35.77, 36.62, 37.01, 40.12, 46.99, 47.7, 51.72, 53.83, 53.93, 56.65, 57.12, 59.87, 84.27, 
114.41, 117.1, 126.2, 128.00, 129.17, 130.29, 130.36, 133.8, 137.88, 138.97, 155.02, 156.71, 168.22, 
170.48, 170.85, 170.97, 171.43, 172.55. 
HRMS (ESI-TOF) Calcd for C46H66IN13O8: 1055.4202; Found: 1055.4242. 
UPLC-MS rt: 4.481 min (Gradient 2). 
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Mono-iodination of ACP-fragment 65-74 (11) 
ACP fragment 65-74 (18.0 mg, 15.3 µmol) was dissolved in 6.0 mL of DCM and 1.5 mL of TFA. Then 
were added dropwise 428 µL of a 50 mM iodination stock solution (21.4 µmol, 1.4 eq.) (stock 
solution freshly prepared: 15.3 mg of Selectfluor were dissolved in 860 µL of ACN before the addition 
of 7.0 mg of NaI). The reaction mixture was allowed to stir at room temperature for 15 minutes. Two 
other additions of iodination solution (2 x 45 µL, 2 x 0.1 eq.) were needed to reach the following final 
ratio: SM: 2.3% - MI: 93.7% - DI: 4.0%. The reaction mixture was then evaporated under reduced 
pressure (TFA was co-evaporated three times with DCM) and redissolved in water/acetonitrile (1/1) 
before being submitted to HPLC (purification performed on Xbridge Prep C18, gradient: see general 
methods). The collected fractions were lyophilized to afford the desired product [mono-Iodo]-ACP 
fragment 65-74 (11.5 mg, 9.7 µmol, 63 % yield). 
1H NMR (500 MHz, d6-DMSO, 295 K) δ: 0.73 (d, 3H), 0.76 (t, 3H), 0.80 (m, 6H), 0.91 (d, 3H), 0.92 (d, 
3H), 1.00 (m, 1H), 1.06 (m, 1H), 1.17 (d, 3H), 1.18 (d, 3H), 1.35 (m, 1H), 1.43 (m, 1H), 1.66 (m, 2H), 
1.76 (m, 1H), 1.87 (m, 1H), 2.03 (m, 1H), 2.13 (m, 2H), 2.43 (m, 1H), 2.51 (m, 1H), 2.62 (m, 3H), 2.84 
(dd, 1H), 3.58 (m, 3H), 4.09 (t, 1H), 4.12 (t, 1H), 4.28 (m, 1H), 4.32 (m, 2H), 4.44 (m, 2H), 4.51 (m, 1H), 
6.74 (d, J = 8.2 Hz, 1H), 6.84 (s, 1H), 6.99 (br, 1H), 7.02 (dd, J = 8.2, 1.8 Hz, 1H), 7.14 (s, 1H), 7.19 (s, 
1H), 7.28 (s, 1H), 7.46 (s, 1H), 7.52 (d, J = 1.8 Hz, 1H), 7.67 (d, 1H), 7.77 (d, 1H), 8.04 (m, 5H), 8.10 (d, 
1H), 8.17 (m, 2H), 8.28 (d, 1H), 8.52 (d, 1H), 10.07 (s, 1H), 12.35 (s, 1H). 
13C NMR (125 MHz, d6-DMSO, 295 K) δ: 11.08, 11.11, 15.15, 15.27, 17.07, 17.79, 18.22, 18.33, 24.01, 
24.45, 28.02, 29.89, 31.29, 35.96, 36.27, 36.43, 36.57, 36.99, 42.41, 47.97, 48.02, 49.54, 49.92, 52.07, 
53.94, 56.6, 57.18, 57.25, 84.22, 114.49, 130.19, 130.34, 139.1, 155.01, 167.63, 170.29, 170.47, 
170.6, 170.83, 171.01, 171.07, 171.11, 171.65, 171.82, 171.86, 171.91, 173.73. 
HRMS (ESI-TOF) Calcd for C47H74IN13O15: 1187.4472; Found: 1187.4526. 
UPLC-MS rt: 3.774 min (Gradient 1).  
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Mono-iodination of [Tyr8]-Substance P (7) 
[Tyr8]-Substance P (3.0 mg, 2.2 µmol) was dissolved in 1.4 mL of DCM and 300 µL of TFA. Then were 
added dropwise 60 µL of a 50 mM iodination stock solution (3.0 µmol, 1.4 eq.) (stock solution freshly 
prepared: 15.0 mg of Selectfluor were dissolved in 840 µL of ACN before the addition of 7.2 mg of 
NaI). The reaction mixture was allowed to stir at room temperature for 15 minutes. Three other 
additions of iodination solution (3 x 15 µL, 3 x 0.35 eq.) were needed to reach the following final 
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ratio: SM: 5.9% - MI: 93.6% - DI: 0.5%. The reaction mixture was then quenched with 400 µL of 
reducing cocktail (freshly prepared: KI (10 mg) and ascorbic acid (10 mg) were sonicated in 500 µL of 
TFA for 10 minutes) and evaporated under reduced pressure (TFA was co-evaporated three times 
with DCM). The crude was dissolved in water/acetonitrile (1/1) before being submitted to HPLC 
(purification performed on Agilent Zorbax Rx C18, gradient: see general methods). The collected 
fractions were lyophilized to afford the desired product [mono-Iodo-Tyr8]-Substance P (2.9 mg, 1.6 
µmol, 72 % yield). 
1H NMR (700 MHz, d6-DMSO, 295 K) δ: 0.84 (d, 3H), 0.88 (d, 3H), 1.39 (m, 2H), 1.47 (m, 2H), 1.51 (m, 
1H), 1.54 (m, 2H), 1.61 (m, 3H), 1.67-1.77 (m, 6H), 1.78-1.88 (m, 6H), 1.91 (m, 3H), 2.03 (m, 4H), 2.11 
(m, 4H), 2.38 (m, 1H), 2.45 (m, 1H), 2.67 (dd, 1H), 2.75 (m, 3H), 2.92 (m, 2H), 3.13 (m, 2H), 3.60 (m, 
2H), 3.72 (m, 3H), 4.15 (m, 3H), 4.23 (m, 1H), 4.30 (m, 2H), 4.43 (m, 4H), 6.77 (d, 1H, J = 8.2 Hz), 6.87 
(s, 2H), 7.08 (m, 2H), 7.15 (m, 3H), 7.19 (m, 3H), 7.32 (s, 2H), 7.58 (d, 1H, J = 1.8 Hz), 7.69 (t, 1H), 7.77 
(br, 3H), 7.84 (d, 1H), 7.97 (t, 2H), 8.01 (t, 2H), 8.18 (br, 3H), 8.23 (t, 1H), 8.27 (d, 1H), 8.31 (d, 1H), 
10.10 (s, 1H). 
13C NMR (175 MHz, d6-DMSO, 295 K) δ: 14.65, 21.59, 21.84, 23.13, 23.62, 24.12, 24.67, 24.68, 26.56, 
27.11, 27.39, 27.90, 29.03, 29.22, 29.70, 30.12, 31.48, 31.57, 31.59, 36.18, 37.50, 38.58, 40.22, 40.70, 
41.99, 49.88, 47.04, 50.43, 50.48, 51.21, 51.76, 52.30, 52.80, 54.13, 54.29, 59.24, 59.83, 84.28, 
114.63, 126.20, 128.04, 129.11, 130.22, 130.33, 137.59, 139.21, 155.10, 156.79, 166.84, 168.64, 
170.38, 170.87, 170.92, 170.98, 171.30, 171.93, 172.04, 173.08, 174.19, 174.24. 
HRMS (ESI-TOF) Calcd for C63H97IN18O14S: 1488.6197; Found: 1488.6244. 
UPLC-MS rt: 2.555 min (Gradient 1). 
 
Chapter 4 – Mild and selective mono-iodination of unprotected peptides as initial step for the synthesis of bioimaging probes 
 
162 
 
 
 
 
Mono-iodination of GLP-1(7-37) 
GLP-1(7-37) (40.0 mg, 11.9 µmol) was dissolved in 5.6 mL of DCM and 1.4 mL of TFA. Then were 
added dropwise 330 µL of a 50 mM iodination stock solution (3.0 µmol, 1.4 eq.) (stock solution 
freshly prepared: 15.0 mg of Selectfluor were dissolved in 840 µL of ACN before the addition of 7.2 
mg of NaI). The reaction mixture was allowed to stir at room temperature for 15 minutes. Two other 
additions of iodination solution (2 x 55 µL, 3 x 0.25 eq.) were needed to reach the following final 
ratio: SM: 4.6% - MI: 91.3% - DI: 4.1%. The reaction mixture was then evaporated under reduced 
pressure (TFA was co-evaporated three times with DCM). The crude was dissolved in 
water/acetonitrile (1/1) before being submitted to HPLC (purification performed on Waters Acquity 
CSH C18, gradient: see general methods). The collected fractions were lyophilized to afford the 
desired product [mono-Iodo]-GLP-1(7-37) (21.5 mg, 6.2 µmol, 52 % yield). 
HRMS (ESI-TOF) Calcd for C151H227IN40O47 [M+3H]3+ 1741.2900; Found: 1741.2999. 
UPLC-MS rt: 6.217 min (Gradient 1). 
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Synthesis of Amino-PEG2-Dansyl 
Dansyl chloride (100 mg, 370 µmol) was dissolved in 1.0 mL of DCM before the addition dropwise of 
tert-butyl(2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (105 µL, 445 µmol) previously dissolved in 1 
mL of DCM. The mixture was allowed to stir at room temperature for 2 hours. Reaction was 
monitored by LC-MS. The mixture was then diluted with 4 mL of brine, washed with water three 
times before being dried over magnesium sulfate and filtered. Subsequently 450 µL of TFA were 
added to the mixture (~10% v/v DCM) to induce Boc deprotection. After 15 min, LC-MS showed 
completion of reaction. The mixture was evaporated under reduced pressure and redissolved in 
acetonitrile and water before lyophilization to afford the desired product as pale yellow oil (201 mg, 
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346 µmol, 93 % yield).  
1H NMR (400 MHz, d6-DMSO, 295 K) δ: 1.28 (s, 1H), 2.07 (s, 1H), 2.84 (s, 6H), 2.96 (m, 5H), 3.56 (m, 4 
H), 4.60 (s, 1H), 5.37 (br s, 3H), 5.75 (br s, 1H), 7.27 (d, J=7.46 Hz, 1H), 7.61 (m, 2H), 7.72 (br s, 3H), 
7.99 (t, J=5.81, 5.81 Hz, 1H), 8.11 (dd, J=7.34, 0.98 Hz, 1H), 8.30 (d, J=8.68 Hz, 1H), 8.47 (d, J=8.44 Hz, 
1H).  
13C NMR (150 MHz, d6-DMSO, 300 K) δ: 38.54, 42.16, 45.06 (2C), 66.58, 69.01, 69.30, 69.43, 115.13, 
119.23, 123.56, 127.75, 128.00, 128.99, 129.03, 129.27, 136.21, 151.17. 
HRMS (ESI-TOF) Calcd for C18H27N3O4S: 382.1795; Found: 382.1795. 
 
 
 
 
 
Synthesis of Boronic pinacol ester-PEG2-Dansyl (9) 
4-Carboxylphenylboronic acid pinacol ester (31 mg, 125 µmol), DIEA (45 µL, 258 µmol) and 
propylphosphonic anhydride T3P (75 µL, 125 µmol - 50% wt. solution in ethyl acetate) were dissolved 
in 1 mL of DCM and stirred at room temperature for 5 minutes before the dropwise addition of 
amino-PEG2-Dansyl (60 mg, 104 µmol) and DIEA (45 µL, 258 µmol) previously dissolved in 750 µL of 
DCM. The reaction mixture was allowed to stir at room temperature. After 30 min, LC-MS showed 
completion of reaction. The crude was evaporated under reduced pressure and purified via silica gel 
chromatography (0->100% EtOAc/Hept – product eluted around ~80% EtOAc/Hept) to afford the 
desired product as a yellow oil (39 mg, 64 µmol, 62 % yield). 
1H NMR (400 MHz, d6-DMSO, 295 K) δ: 1.17 (m, 1 H), 1.31 (s, 12 H), 1.91 (s, 1 H), 1.99 (s, 1 H), 2.50 
(u), 2.82 (s, 6 H), 2.94 (q, J=5.83, 5.83, 5.83 Hz, 2 H), 3.28 (m, 4 H), 3.45 (u), 4.03 (q, J=7.17, 7.17, 7.17 
Hz, 1 H), 7.24 (d, J=7.46 Hz, 1 H), 7.59 (m, 2 H), 7.74 (m(para), 2 H), 7.83 (m(para), 2 H), 8.11 (dd, 
J=7.34, 0.98 Hz, 1 H), 7.98 (t, J=5.81, 5.81 Hz, 1 H), 8.28 (d, J=8.68 Hz, 1 H), 8.44 (d, J=8.56 Hz, 1 H), 
8.52 (t, J=5.50, 5.50 Hz, 1 H).  
13C NMR (150 MHz, d6-DMSO, 300 K) δ: 24.65(4C), 39.51, 42.20, 45.03(2C), 68.72, 68.93, 69.29, 
69.38, 83.89(2C), 115.05, 119.21, 123.50, 126.47(2C), 127.71, 127.97, 129.01, 129.03, 129.24, 
134.21(2C), 136.32, 136.80, 151,27, 165.99. 
The carbon directly bonded to boron could not be detected due to quadrupolar relaxation. 
HRMS (ESI-TOF) Calcd for C31H43BN3O7S [M+Na]+ 634.2734; Found: 634.2737. 
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Synthesis of Boronic pinacol ester-PEG3-azide (12) 
4-carboxylphenylboronic acid pinacol ester (200 mg , 806 µmol), DIEA (422 µL, 2.42 mmol) and 
propylphosphonic anhydride T3P (720 µL, 1.21 mmol – 50% wt. solution in ethyl acetate) were 
dissolved in 500 µL of DCM and was allowed to premix at room temperature for 5 minutes before the 
dropwise addition of amino-PEG3-azide (211 mg, 968 µmol) previously dissolved in 500 µL of DCM .  
The reaction was stirred at room temperature for 10 minutes. Reaction was monitored by LC-MS. 
The crude was dissolved in 5 mL of DCM and 5 mL of 0.5M HCl aqueous solution, washed twice with 
water (2x5mL) before being dried with magnesium sulfate, filtered and evaporated under reduced 
pressure to afford the desired product as a white powder (308 mg, 687 µmol, 85 % yield). 
1H NMR (400 MHz, d6-DMSO, 295 K) δ: 0.94 (m, 1 H), 1.31 (s, 12 H), 1.48 (m, 1 H), 2.50 (u), 3.23 (br s, 
1 H), 3.44 (br s, 1 H), 3.53 (d, J=4.65 Hz, 9 H), 3.57 (m, 4 H), 7.79 (m(para), 4 H), 8.55 (t, J=5.50, 5.50 
Hz, 1 H). 
13C NMR (150 MHz, d6-DMSO, 300 K) δ: 24.65(4C), 39.51, 49.95, 68.78, 69.18, 69.57, 69.64, 69.73, 
69.76, 83.89(2C), 126.49(2C), 134.21(2C), 136.84, 166.00. 
The carbon directly bonded to boron could not be detected due to quadrupolar relaxation. 
HRMS (ESI-TOF) Calcd for C21H34BN4O6 [M+Na]+ 471.2389; Found: 471.2388. 
 
 
 
 
 
Synthesis of Dansyl-PEG2-Leucin Enkephalinamide (10) - Suzuki-Miyaura Cross-coupling 
Preparation of the Pd catalyst was performed as described by Chalker et al2. Briefly, 2-amino-4,6-
dihydroxypyrimidine disodium (7.6 mg, 44 µmol) was dissolved in 440 µL of water by stirring for 2 
minutes in a water bath preheated to 65°C. To the resulting solution was added Pd(OAc)2 (5.0 mg, 22 
µmol). The mixture was stirred vigorously at 65°C for 30 minutes to give a homogenous yellow-
orange solution. After cooling to room temperature, the stir bar was removed to give the catalyst 
stock solution 50 mM in Pd(II). 
In a 1.5 mL Eppendorf tube, [mono-Iodo]-Leucine Enkephalinamide (1.0 mg, 1.50 µmol) was 
dissolved in 75 µL of water and 75 µL of dioxane before the addition of glycerol (50 µL), K2HPO4 (1M 
aqueous stock solution, 45 µL, 45 µmol) and boronic pinacol ester-PEG2-Dansyl (9) (50 mM stock 
solution in dioxane, 45 µL, 2.25 µmol). Prior and after the addition of Pd(OAc)2.L2 (50 mM aqueous 
stock solution, 75 µL, 3.75 µmol) the mixture was bubbled with argon for 10 minutes. The resulting 
solution was capped and stirred at 38°C for 12 hours on an Eppendorf Thermomixer (1300 rpm). The 
reaction was monitored by LC-MS. The crude mixture was quenched with 1 mL of a 1M HCl aqueous 
solution before being submitted to HPLC (purification performed on Agilent Zorbax Rx C18, gradient: 
see general methods). The collected fractions were lyophilized to afford the desired product Dansyl-
PEG2-Leucine Enkephalinamide (0.55 mg, 0.53 µmol, 35 % yield). 
HRMS (ESI-TOF) Calcd for C53H67N9O11S: 1038.4754; Found: 1038.4753. 
UPLC-MS rt: 6.793 min (Gradient 1). 
Max Abs/Em - / 506 nm (absorption <400 nm cannot be measured with our device) 
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Synthesis of Azido-PEG3-ACP fragment (65-74) - Suzuki-Miyaura Cross-coupling 
In a 1.5 mL Eppendorf tube, [mono-Iodo]-ACP fragment (65-74) (2.43 mg, 2.05 µmol) was dissolved in 
100 µL of water and 100 µL of dioxane before the addition of glycerol (50 µL), K2HPO4 (1M aqueous 
stock solution, 50 µL, 50 µmol) and boronic pinacol ester-PEG3-azide (12) (50 mM stock solution in 
dioxane, 75 µL, 3.75 µmol). Prior and after the addition of Pd(OAc)2.L2 (50 mM aqueous stock 
solution, 80 µL, 4.0 µmol) the mixture was bubbled with argon for 10 minutes. The resulting solution 
was capped and stirred at 38 °C for 12 hours on an Eppendorf Thermomixer (1300 rpm). The reaction 
was monitored by LC-MS. The crude mixture was quenched with 1mL of a 1M HCl aqueous solution 
before being submitted to HPLC (purification performed on Agilent Zorbax Rx C18, gradient: see 
general methods). The collected fractions were lyophilized to afford the desired product Azido-PEG3- 
ACP fragment (65-74) (1.68 mg, 1.22 µmol, 59 % yield). 
HRMS (ESI-TOF) Calcd for C62H95N17O19: 1380.6917; Found: 1380.6899. 
UPLC-MS rt: 4.950 min (Gradient 1). 
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Synthesis of Alexa Fluor 488-PEG3-ACP fragment (65-74) (13) – CuAAC 
Azido-PEG3- ACP fragment (65-74) (1.68 mg, 1.22 µmol) was dissolved in 200 µL of water and 100 µL 
of tBuOH before the addition of Alkyne-Alexa Fluor 488 (1.0 mg, 1.29 µmol). Copper sulfate (50 mM 
stock solution in water, 3 µL, 0.15 µmol), Cu-ligand THPTA3 (200 mM stock solution in water, 3 µL, 
0.60 µmol) and ascorbic acid (100 mM stock solution in water, 7.5 µL, 0.75 µmol) were premixed 
together before being added to the reaction mixture. The resulting solution was stirred at 38°C in a 
Thermomixer (1300 rpm) for 12 hours. The reaction was monitored by LC-MS. The crude mixture was 
dissolved in water/ACN before being submitted to HPLC (purification performed on Agilent Zorbax Rx 
C18, gradient: see general methods). The collected fractions were lyophilized to afford the desired 
product as an orange powder Alexa Fluor488-PEG3-ACP fragment (65-74) (1.48 mg, 0.76 µmol, 62 % 
yield).   
HRMS (ESI-TOF) Calcd for C86H112N20O29S2 [M+2H]2+ 977.8760; Found: 977.8803. 
UPLC-MS rt: 5.009 min (Gradient 1). 
Max Abs/Em 494/524 nm.   
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NMR Spectra and proton assignment of mono-iodinated peptides 
[mono-iodo] Leucine Enkephalinamide 
 
 
1H NMR (500 MHz, d6-DMSO, 300 K) and 13C NMR (125 MHz, d6-DMSO, 300 K). 
 
 1H 13C 
Tyr-1               NH3+ broad - 
 3.46 55.77 
β 2.86/2.51 38.53 
 - 130.62 
1 7.53 139.22 
2 7.03 130.40 
1 - 84.36 
2 6.78 114.64 
ζ - 155.08 
ζ-OH ~ 10.1 (broad) - 
C’ - 173.76 
Gly-2                 NH 8.30 - 
 3.73 42.02 
C’ - 169.10 
Gly-3                 NH 8.12 - 
 3.73/3.61 41.90 
C’ - 168.75 
Phe-4                 NH 8.08 - 
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 4.50 54.09 
 3.04/2.80 37.28 
 - 137.78 
δ 7.25 129.17 
ε 7.25 128.04 
ζ 7.18 126.26 
C’ - 170.69 
Leu-5                 NH 7.95 - 
 4.20 50.99 
 1.47 40.80 
 1.57 24.19 
 0.88 23.02 
’ 0.83 21.56 
C’ - 173.88 
NH2 7.08/6.97 - 
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Cyclo(RGD[mono-iodo]yK) 
 
1H NMR (700 MHz, d6-DMSO, 308 K) and 13C NMR (175 MHz, d6-DMSO, 308 K). 
Chemical shifts are referenced to the solvent signals (1H: 2.50 ppm, 13C: 39.50 ppm). At 308K a better 
dispersion of the amide signals (Asp-3 and Lys-5) has been obtained. 
 1H 13C 
Arg-1   
NH 7.61 - 
 4.16 51.84 
β 1.71/1.48 28.48 
 1.37 25.11 
 3.09 40.26 
 7.52 - 
ζ - 156.61 
C’ - 171.10 
Gly-2   
NH 8.44 - 
 4.04/3.24 43.22 
C’ - 169.45 
Asp-3   
NH 8.09 - 
 4.64 48.81 
β 2.71/2.39 35.04 
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 (OH: ~12.2) 171.52 
C’ - 169.93 
D-Tyr-4   
NH 8.00 - 
 4.34 54.51 
β 2.78/2.69 35.89 
 - 129.81 
1 7.44 138.93 
2 6.97 130.21 
1 - 84.14 
2 6.77 114.61 
ζ - 155.02 
ζ-OH 10.10 - 
C’ - 170.54 
Lys-5   
NH 8.11 - 
 3.94 54.38 
β 1.58/1.43 30.62 
 1.10 22.42 
 1.46 26.41 
 2.71 38.62 
ζ 7.69 - 
C’ - 171.82 
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[mono-Iodo-Tyr0]-Bradykinin 
 
1H NMR (500 MHz, d6-DMSO, 300 K) and 13C NMR (125 MHz, d6-DMSO, 300 K). 
 1H 13C 
Tyr-1   
NH3+ 8.08 - 
 3.99 53.12 
β 2.89/2.79 35.44 
 - 126.90 
1 7.51 139.39 
2 7.00 130.71 
1 - 84.78 
2 6.78 114.66 
ζ - 155.84 
ζ-OH 10.31 - 
C’ - 167.52 
Arg-2   
NH 8.66 - 
 4.49 49.98 
β 1.69/1.50 28.54 
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 1.53 24.41 
 3.08 40.47 
 7.61 - 
ζ - 156.73 
C’ - (a) 
Pro-3   
 4.58 57.63 
β 2.18/1.84 27.87 
 1.87 24.49 
 3.60/3.48 46.90 
C’ - 169.63 
Pro-4   
 4.26 59.44 
β 2.00/1.81 29.05 
 1.93/1.89 24.41 
 3.66/3.58 46.81 
C’ - 171.77 
Gly-5   
NH 7.96 - 
 3.63 41.67 
C’ - 168.48 (or 168.50) (a) 
Phe-6   
NH 7.93 - 
 4.57 53.38 
β 2.96/2.73 37.68 
 - 137.57 
 7.19 129.13 
 7.24 128.02 
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ζ 7.18 126.29 
C’ - 170.96 (b) 
Ser-7   
NH 8.31 - 
 4.58  
β 3.63 61.73 
β-OH 5.36 - 
C’ - (a) 
Pro-8   
 4.30 59.60 
β 1.88/1.60 28.77 
 1.70/1.43 23.72 
 3.61/3.51 46.90 
C’ - 170.84 
Phe-9   
NH 7.70 - 
 4.54 53.45 
β 3.08/2.72 37.23 
 - 137.68 
 7.24 129.10 
 7.24 127.97 
ζ 7.18 126.26 
C’ - 170.95 (b) 
Arg-10   
NH 8.13 - 
 4.20 51.46 
β 1.79/1.64 28.09 
 1.51 25.06 
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 3.12 40.27 
 7.56 - 
ζ - 156.65 
C’ - 173.08 
(a) Could not be assigned 
(b) Might be interchanged 
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[mono-Iodo]-Angiotensin III 
 
1H NMR (500 MHz, d6-DMSO, 300 K) and 13C NMR (125 MHz, d6-DMSO, 300 K). 
 
 1H 13C 
Arg-1   
NH3+ 8.12 - 
 3.87 51.72 
β 1.64 28.62 
 1.46 24.28 
 3.09 40.12 
 7.60 - 
ζ - 156.71 
C’ - 168.22 
Val-2   
NH 8.35 - 
 4.27 57.12 
β 2.02 31.11 
 0.84 19.19 
γ' 0.79 17.57 
C’ - 170.48 
Tyr-3   
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NH 8.10 - 
 4.50 53.93 
β 2.77/2.59 35.77 
 - 130.29 
1 7.60 138.97 
2 7.09 130.36 
1 - 84.27 
2 6.75 114.41 
ζ - 155.02 
ζ-OH 10.17 - 
C’ - 170.97 
Ile-4   
NH 8.00 - 
 4.15 56.65 
β 1.66 36.62 
β-Me 0.75 15.19 
 1.36/1.05 24.10 
 0.77 10.85 
C’ - 170.85 
His-5   
NH 8.41 - 
 4.79 ~ 47.7 (broad) 
β 3.05/2.93 ~ 26.3 (broad) 
 - (a) 
 7.38 (broad) ~ 117.1 (broad) 
 ~ 8.9 (very broad) ~ 133.8 (broad) 
ε-NH2+ ~ 14.2 (broad) - 
C’ - (a) 
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Pro-3   
 4.26 59.87 
β 1.98/1.69 29.13 
 1.77 24.25 
 3.63/3.46 46.99 
C’ - 171.43 
Phe-9   
NH ~ 8.01 (very broad) - 
 4.38 53.83 
β 3.05/2.85 37.01 
 - 137.88 
 7.23 129.17 
 7.23 128.00 
ζ 7.17 126.20 
C’ - 172.55 
NH2 7.26/7.09 - 
(a) Could not be assigned due to extreme line broadening 
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[mono-Iodo]-ACP fragment 65-74 
 
1H NMR (500 MHz, d6-DMSO, 295 K) and 13C NMR (125 MHz, d6-DMSO, 295 K). 
 
 1H 13C 
Val-1             NH3+ 8.04 - 
 3.60 57.25 
 2.03 29.89 
 0.92 18.33 
’ 0.91 17.70 
C’ - 167.63 
Gln-2               NH 8.53 - 
α 4.33 52.07 
 1.87/1.76 28.02 
 2.13 31.29 
 - 173.73 
δ-NH2 7.29/6.84 - 
C’ - 170.29 
Ala-3                 NH 8.18 - 
 4.28 47.97 
 1.18 18.22 
C’ - 171.86 
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Ala-4                 NH 8.11 - 
 4.32 48.02 
 1.17 17.79 
C’ - 171.91 
Ile-5                 NH 7.69 - 
 4.13 56.60 
 1.65 36.99 
-Me 0.73 15.27 
 1.35/1.00 24.01 
 0.76 11.11 
C’ - 170.60 
Asp-6               NH 8.17 - 
α 4.51 49.54 
 2.62/2.43 36.27 
 - 171.65 
C’ - 170.47 
The amide protons of Ala3 and Asp6 overlap at 300K. 
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[mono-Iodo-Tyr8]-Substance P 
 
1H NMR (700 MHz, d6-DMSO, 295 K) and 13C NMR (175 MHz, d6-DMSO, 295 K). 
 1H 13C 
Arg-1               NH3+ 8.18 - 
 4.16 50.48 (a) 
 1.76/1.70 27.11 
 1.62 23.62 
δ 3.13 40.22 
ε 7.69 - 
ζ - 156.79 
C’ - 166.84 
Pro-2                       4.43 59.24 
β 2.11/1.75 29.22 
 1.91/1.83 24.66 
 3.70/3.46 47.04 
C’ - 170.98 
Lys-3                  NH 8.31 - 
 4.43 50.43 (a) 
 1.70/1.51 30.12 
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 1.39 21.84 
δ 1.54 26.56 
ε 2.75 38.58 
ζ 7.77 - 
C’ - 170.38 
Pro-4                       4.30 59.83 
β 2.09/1.82 29.03 
 1.92/1.85 24.66 
 3.60/3.57 46.88 
C’ - 172.04 
Gln-5                 NH 8.27 - 
 4.12 52.80 
 1.85/1.73 27.39 
 2.12 31.48 
δ - 174.24 
NH2 7.32/6.87 - 
C’ - 174.24 
Gln-6                 NH 7.85 - 
 4.15 52.30 
 1.81/1.71 27.90 
 2.04 31.57 
δ - 174.19 
NH2 7.33/6.87 - 
C’ - 170.87 
Phe-7                    NH 7.97 - 
 4.42 54.13 
 2.93/2.74 37.50 
 - 137.59 
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δ 7.15 129.11 
ε 7.19 128.04 
ζ 7.14 126.20 
C’ - 170.92 
Tyr8                       NH 8.03 - 
 4.42 54.29 
β 2.90/2.67 36.18 
 - 130.22 
1 7.58 139.21 
2 7.08 130.33 
1 - 84.28 
2 6.77 114.63 
ζ - 155.10 
ζ-OH 10.09 - 
C’ - 171.30 
Gly-9                    NH 8.23 - 
 3.73 41.99 
C’ - 168.64 
Leu-10                 NH 8.02 - 
 4.29 51.21 
 1.47 40.70 
 1.61 24.12 
 0.88 23.13 
’ 0.84 21.59 
C’ - 171.93 
Met-11                 NH 7.98 - 
 4.23 51.76 
 1.92/1.81 31.59 
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 2.45/2.38 29.70 
δ 2.02 14.65 
C’ - 173.08 
NH2 7.21/7.07 - 
(a) Might be interchanged 
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Diabetes mellitus is a worldwide disease which has reached pandemic levels, affecting 1 in 11 adults 
in 2015, a total of 415 million people.1 This is a major healthcare problem because the disease increases 
the risk of heart failure, stroke, and microvascular complications such as blindness, renal malfunction, 
and peripheral neuropathy. Consequently, diabetes imposes a severe economic burden on 
governments and individuals due to the demand for multi-modal treatment and the serious 
complications associated with the chronic nature of the disease. Today, putting aside bariatric surgery 
which is limited to a few extreme cases (extremely overweight T2D patients - with a body mass index 
greater than 35, and who are unresponsive to existing medical therapies) or the replacement of the 
lost β-cells by islet transplantation for T1D (which is also only temporary as autoimmunity persists), no 
cure for diabetes exists. 
Pancreatic β-cells are the only mammalian cells capable of producing and releasing insulin, which 
regulates blood glucose uptake in peripheral tissues. They are extraordinarily well-tuned sensors: 
insulin secretion must not only be sufficient in quantity to elicit effects in target tissues (restraining 
glucose output by the liver and promoting glucose uptake into muscle and fat), but secretion must also 
be appropriately timed: delayed release of normal amounts of hormone is associated with 
hyperglycemia. As well, to achieve tighter homeostasis, insulin release has to be well-controlled to 
anticipate glucose rises and prevent persistent glucose elevations, which is possible as healthy β-cells 
feature some form of glucose memory. Diabetes is characterized by frequent hyperglycemia, which is 
a result of insufficient insulin in the body. As depicted in Figure 1, this is caused by either the auto-
immune destruction of β-cells (for T1D) or a decrease in β-cell mass and function over time (for T2D). 
While much research has been conducted since the discovery of Langerhans islets, the pathogenesis 
of diabetes is still poorly understood, and further studies are required to provide a more accurate 
picture of the disease. Notably, even though factors such as increasing urbanization, aging populations, 
obesity, and falling levels of physical activity are known to contribute to rising levels of diabetes, the 
etiology of the decline in β cell mass and function remains to be elucidated. 
How many functional β-cells are needed to maintain euglycemia and remain healthy? Trying to answer 
this question highlights the complexity of the interplay between β-cell mass and their sensing and 
secretory capacities. A surprising finding is that even after 50 years, residual amounts of functional β-
cells were detected in a majority of type 1 diabetic patients,2 which indicates that autoimmune-
mediated β-cell destruction is for unknown reasons incomplete. Calculations based on the daily rate 
of insulin release in a nondiabetic individual suggest that as few as 40% of β-cells would be sufficient 
for adequate glucose control.3 This figure is supported by the observation that patients who 
underwent a 50% partial pancreatectomy only had a small change in glucose tolerance.4 Therefore, it 
seems that the remaining β-cells are capable of compensating for the increased insulin secretory 
burden by intensifying their production, but, to what extent and for how long before showing signs of 
failure of metabolic control is still unclear. Because no longitudinal and quantitative studies of β-cell 
mass in man exist, it is uncertain whether individuals with T2D start with a defect in their β-cell mass 
or if this develops as a consequence of sustained hyperglycemia. A non-invasive method for 
determining β-cell mass based on imaging could help answer these questions. Such a method would 
undoubtedly enable further understanding and elucidation of the pathogenesis of diabetes. 
Additionally, β-cell imaging would be useful for additional applications such as monitoring the success 
of islet transplantation and the viability of the graft. 
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Figure 1 Loss of β-cell mass and function are the hallmarks of the development of both T1D and T2D.  
Defects in β-cell mass, resulting from an auto-immune reaction is a feature of T1D, but is also observed in late 
stages T2D. The of defects in function can be many i) A loss of sensing receptor expression,5 or inactivation of 
key transcription factors,6 producing “stunned” β-cells that temporarily stop responding to glucose7 ii) High and 
prolonged exposure to free fatty acids leads to an alteration in the colocalization of Ca2+ channels and secretory 
granules. Consequently, although the calcium channels continue to open, the resulting increase in [Ca2+]i occurs 
at the ‘‘wrong’’ location and fails to evoke secretion.8 Aberrant granule docking9 or a lack of ZnT8 zinc transporter 
expression10 were also reported as sources of exocytosis impairment iii) In response to gradual cell exhaustion 
depletion of insulin content arises, or as a defense mechanism in response to a high-fat diet β-cells can undergo 
dedifferentiation11 or autophagy12. The above-described cases are schematic, most of the T2D patients suffer 
from both a defect in mass and defects in function of a various nature. 
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This thesis describes the design, the synthesis and the characterization of fluorescent probes and 
radioactive tracers targeting the free fatty acid receptor (FFAR1-GPR40). This receptor is highly and 
predominantly expressed at the surface of the β-cells, but was never examined as a potential target 
for β-cell imaging. Lipids have complex effects on β-cell function: in the short term, free fatty acids 
potentiate glucose-induced insulin secretion, and in the long term, they are suspected to induce 
lipotoxicity. Hence, the FFAR1-GPR40 - as one receptor of the “fat sensor” family – could play a crucial 
role in the biology of β-cells. When it was deorphanized in 2003, the corresponding mRNA levels were 
evaluated to characterize the tissue distribution of the receptor. Although regarded as good surrogates 
in general, there are cases where the mRNA levels do not correlate with the level of the receptor 
protein it encodes. Accordingly, the development of FFAR1-GPR40 targeting molecules with high 
specificity is of great interest to enable direct and reliable FFAR1-GPR40 detection.  
 
Development of a fluorescent FFAR1-GPR40 targeting probe  
The novel probe was prepared by attaching a fluorescent molecule to the scaffold of TAK-875, a 
synthetic ligand which binds the FFAR1 with high affinity and selectivity. When optimizing the linker 
and the fluorophore moiety, we selected a short length amine-containing linker conjugated to Alexa 
Fluor 488. It was observed that fluorescent dyes with negative charge, such as the di-sulfonated Alexa 
Fluor 488, showed better specificity compared to dyes with neutral or positive charges. The new probe 
was shown to specifically label FFAR1-GPR40, and the target was successfully visualized at low 
nanomolar concentration on transfected HEK293 cells overexpressing the receptor using live cell 
microscopy. When the probe was used on cells expressing endogenous levels of the receptor such as 
MIN6 or INS1E, signal amplification based on antibodies was needed to boost the fluorescent signal 
and enable target detection, as receptor abundance was low. However, a possible alternative to the 
amplification protocol is the utilization of fluorescence-activated cell sorting (FACS) for the detection 
of cells expressing FFAR1-GPR40. With the help of this much more sensitive method, we were able to 
demonstrate that the probe shows detectable binding to FFAR1-GPR40 not only in overexpressing 
HEK293 cells, but also in MIN6 cells. Finally, it was confirmed that the developed probe still behaves 
as a FFAR1-GPR40 agonist, activating the receptor and stimulating insulin secretion in a glucose-
dependent manner. As the reliability of the antibody based method for FFAR1-GPR40 detection has 
recently been challenged, the novel fluorescent probe, with the scaffold of a small molecule, provides 
a new tool for studying the receptor. Interestingly, shortly after submission of our initial manuscript, 
two other fluorescent probes were reported by two independent research groups underscoring the 
high interest for FFAR1-GPR40.13, 14 All such probes were designed using a similar approach, but the 
two groups used them for different purposes than ours (Figure 2). While we focused on β-cell imaging, 
the group of Christiansen et al. developed their probe (TUG-905 analog labeled with NBD) to establish 
a bioluminescence resonance energy transfer (BRET)-based binding assay to measure the affinity of 
selected FFAR1 agonist.13 Similarly, the group of Ren et al. utilized their fluorescent probe (TAK-875 
analog labeled with FITC) to assess the binding affinity of free fatty acids to FFAR1-GPR40, but using 
an assay based on flow cytometry.14  
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Figure 2 Structures of FFAR1-targeting fluorescent probes and their different applications. 
 
 
Utilization of the above-described fluorescent probe for in vivo imaging in humans is unsuitable due to 
the light limited depth of penetration through skin and other biological tissue. However, by replacing 
the UV-visible fluorophore with a fluorophore absorbing and emitting in the near-infrared (NIRF) 
region, we were able to use non-invasive IVIS imaging to visualize FFAR1-GPR40 on BALB/c nude mice 
with subcutaneous FFAR1-GPR40 xenografts. Probe uptake 18 hours post-injection was greater in 
FFAR1-GPR40 xenografts compared to non-transfected xenografts lacking FFAR1-GPR40 expression 
(mouse 2 and mouse 5), or to control mice injected with PBS (mouse 10), as shown in Figure 2. To our 
disappointment, blocking experiments failed to reduce probe uptake in FFAR1-GPR40 xenografts 
(mouse 7), which possibly could be explained by a higher metabolization rate, or by quicker excretion, 
of the non-labeled blocking compound. However, due to the small number of animals this study 
remains very preliminary. More experiments are needed to conclude on the ability of the NIRF-probe 
to selectively target and image the receptor in vivo. These data result from a collaboration with Selen 
Ekim supervised by Prof. Martin Gotthardt from the Nuclear Medicine Department of the Radboud 
UMC, Nijmegen, The Netherlands. 
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Figure 3 IVIS imaging of BALB/c nude mice with subcutaneous FFAR1-GPR40 xenografts, 18h post injection of the 
NIRF-probe. For each animal: on the left flanks (blue arrows – negative control) non-transfected xenografts, on 
the rights flanks (green arrows) FFAR1-GPR40 xenografts. Upper panel: the NIRF-probe accumulated preferably 
on the FFAR1-GPR40 xenografts. Lower panel (controls): blocking experiment failed to reduce the uptake of the 
probe on FFAR1-GPR40 xenografts (left) – injection of PBS vehicle shows no detectable fluorescent signal (right). 
 
Development of a radioactive FFAR1-GPR40 targeting tracer 
As already mentioned, methods based on optical imaging are not suitable for β-cell imaging in vivo in 
humans, therefore we sought to develop a FFAR1-GPR40 radioligand as potential tracer for PET-
imaging. We first performed the tritiation of TAK-875 to get a model compound for in vitro binding 
evaluation studies on transfected HEK293 cells overexpressing the receptor of interest. Based on the 
encouraging results obtained with the tritiated compound, which showed a preference for binding to 
cells expressing FFAR1-GPR40, we developed a fluorinated analog of TAK-875. This latter derivative 
showed similar agonistic activity to the parent compound TAK-875 in a FLIPR-Ca2+ functional assay. 
After preliminary experiments to find suitable labeling reaction conditions that used potassium 
fluoride as a non-radioactive fluoride source, we implemented the radiolabeling which was achieved 
in reasonable radiochemical yield using azeotropically dried no-carrier-added [18F], which was 
activated by a potassium carbonate-Kryptofix 2.2.2 system. Low expression of the receptor on the 
surface of primary cells and the high lipophilicity of the tracer might both limit its utility. Accordingly, 
further characterization of the [18F]-tracer is needed and is currently ongoing in in vitro and in vivo 
studies, whose outcome will be reported in due course.  
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Targeting FFAR1-GPR40 for β-cell imaging & other purposes 
 
Targeting FFAR1-GPR40 represents a new option as a detectable and functional putative β-cell marker. 
Being able to follow another β-cell specific receptor type besides GLP-1R, which is well established, 
will complement available information and may provide new insights in disease pathogenesis. 
Importantly, with concerns about potential downregulation of some receptors (such as GLP-1R) in the 
course of the disease, it might be useful for the islet biology community to define a set of several β-
cell specific biomarkers. This set of markers, useful to generate a characteristic fingerprint could, for 
instance, include a combination of genes (Nkx6.1 - protein Nk6.1 homebox), transcription factors (Pdx1 
- pancreatic duodenal homebox 1), ion transporters (ZnT8 - zinc transporter 8), ion channels (Kir6.2 - a 
major subunit of the ATP-sensitive K+ channel), membrane proteins (TMEM 27- transmembrane 
protein 27), and G protein-coupled receptors (GLP-1R, FFAR1-GPR40), among others. The positive 
detection of a combination of these markers could confirm β-cell identity, even if one marker is 
missing. Relying on such a fingerprint would allow more consistent studies on β-cell and could result 
in a more comprehensive understanding of β-cell biology. In the case of a cell presenting an insulin 
secreting dysfunction (one example described in Figure 1), e.g. due to ZnT8 expression failure, we can 
easily assume that a ZnT8 targeting antibody will fail to detect this cell as a β-cell – even if this cell is 
loaded with insulin.10 Similarly, a cell not detected by an Exendin-scan targeting the GLP-1R, may simply 
be an exhausted β-cell that has downregulated the receptor for some reason, but which is still capable 
of relevant glucose-stimulated insulin secretion. 
Aside from β-cell biology, it is suggested that FFAR1-GPR40 may be implicated in the control of breast 
cancer cell growth by fatty acids, and that FFAR1-GPR40 could provide a link between fat and cancer.15 
Indeed, existence of functional FFAR1-GPR40 was detected in MCF-7, a human breast cancer cell line.16 
The availability of a FFAR1-GPR40 fluorescent probe and a radioactive probe could be useful in 
detecting the receptor and elucidating its role in the development of breast cancer. 
Collectively, all these promising results should encourage researchers to further develop and 
characterize FFAR1-GPR40 targeting probes and tracers in order to: i) confirm with high confidence 
that FFAR1-GPR40 is a β-cell specific marker, ii) to determine their suitability for non-invasive β-cell 
imaging, iii) to verify their potential for other applications such as breast cancer imaging. 
 
 
Functional β-cell imaging, a crucial complement to β-cell mass imaging  
 
The three most clinically advanced tracers for β-cell imaging to date, namely [111In]-Exendin, [18F]-FP-
DTBZ and [11C]-5-HTP,17 are restricted to detecting β-cells based on the presence or not of their 
molecular targets (respectively GLP-1R, VMAT2 and DDC). As shown on Figure 1, there are many 
possible functional defects in insulin-producing cells, any combination of these may be responsible for 
diabetes. Therefore, in order to complement the tools available for evaluating β-cell mass, new 
imaging modalities examining β-cell function are desperately needed to better understand progression 
of the disease. Examples of approaches aimed at imaging β-cell function include the use of Zn2+ 
chelators, Mn2+-enhanced MRI (MEMRI) or superoxide ion detection by chemiluminescence.  
Exploiting the fact that Zn2+ is co-released with insulin during secretion, the group of Li et al. developed 
a new Zn2+ chelator called ZIMIR, which displays robust fluorescence enhancement on Zn2+ chelation. 
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With this novel probe, they were able to image the exocytotic activity of dispersed single primary cells, 
as well as of intact islets.18  
Manganese ions Mn2+ can significantly enhance the contrast of MRI by entering stimulated β-cells 
through calcium channels. Mn2+-enhanced MRI was successfully used to detect the decline in β-cell 
mass in a rodent model of T1D, as pancreatic MEMRI signals dropped with progress of the disease.19  
Superoxide anion O2- is produced during normal cellular respiration and plays key roles in cellular 
physiology. As a consequent of utilizing mitochondrial-derived reactive oxygen species as signaling 
molecules during the process of insulin secretion, and of having an unusually low expression of some 
scavenger enzymes, β-cells possess very high superoxide anion concentrations. Interestingly, in 
response to variation in glucose concentrations, dynamic changes in cellular O2- concentration were 
observed: hyperglycemia was correlated with diminution of the chemiluminescent signal. The small 
molecule coelenterazine, by generating a chemiluminescence fluorescent signal in a superoxide anion 
levels-dependent fashion, acts as an in vitro and in vivo reporter of intracellular O2- concentration. 
Using O2- detection with coelenterazine, the group of Bronsart et al. recently showed that 
chemiluminescence correlates with a loss of functional β-cell in NOD diabetic mouse model, which is 
one of the predominant models for T1D. Although the chemiluminescence-based approaches are 
limited to small animal imaging (as all optical imaging methods – see above), they might prove to be 
very useful for dynamic and longitudinal studies.20  
 
 
Future perspectives for β-cell imaging and how it could support novel therapeutic 
options  
 
It is critical that islets maintain adequate β-cell mass and function in response to various fluctuations 
in demand. For this purpose, β-cells adapt to fit the appropriate requirements. To do so, they can 
increase the overall β-cell mass via a number of processes: proliferation (replication of β-cells), 
neogenesis (differentiation from non- β-cells), hyperplasia (increased β-cell number) and hypertrophy 
(increased β-cell size). In contrast, if needed, β-cell regulation can occur via death (through apoptosis, 
necrosis, autophagy, and ferroptosis), hypoplasia (decreased β-cell number) and hypotrophy 
(decreased β-cell size).21 Novel therapies will not be restricted to those that achieve euglycemia, but 
will include those that change the course of the disease by reversing the processes of β-cell failure. We 
can assume that new antidiabetic drugs will possess β-cell protective action, exert proliferation, or will 
even be able to restore impaired function. As an example, researchers from the Genomics Institute of 
the Novartis Research Foundation reported in 2015 an orally available small molecule inducing human 
adult β-cell proliferation. Islets treated with the new drug retained functionality in vitro and after 
transplantation into diabetic mice.22 Such small-molecule inducer of β-cell proliferation was exploited 
in a delivery strategy which leveraged the tissue specificity of the β-cell imaging agent DTBZ.23 Within 
the booming field of regenerative medicine, new promises for diabetes treatment have emerged. A 
group from Harvard described a scalable differentiation protocol that can generate hundreds of 
glucose-responsive β-cells from human pluripotent stem-cells.24 They show hallmarks of mature β-cells 
such as variation of intracellular Ca2+ in response to glucose, the packaging of insulin into secretory 
granules, and demonstrating insulin release after sequential glucose challenges in vitro. 
Transplantation of these cells ameliorates hyperglycemia in diabetic mice. To verify and validate the 
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above-mentioned claims (actual preservative action or β-cell proliferation after compound treatment, 
actual expression of β-cell marker for differentiated cells etc.) β-cell imaging will have a central role. 
Finally, it was recently reported that β-cells may be divided in two subcategories: those that express 
the Fltp gene, and those that do not. This gene encodes the protein Flattop, a Wnt/planar cell polarity 
effector and reporter gene involved in the acquisition of tissue polarity and 3D architecture. The 
proliferation-competent (Fltp-) cells were distinguished from the mature ones (Fltp+) by distinct 
molecular, physiological, functional and ultrastructural features.25 Interestingly, the proliferation-
competent cells (Fltp-), accounting for around 20% of the total β-cell number, showed the ability to 
differentiate into mature ones (Fltp+). This pool of (Fltp-) cells could represent an interesting 
therapeutic target, if they can be induced into mature and functional β-cells in diabetic patients. In this 
case β-cell imaging could again prove to be valuable if it is able to distinguish between these two kinds 
of cell subpopulations. This would enable the monitoring of proliferation-competent (Fltp-) cells as 
they convert into mature functional β-cells (Fltp+). 
 
Discovering new labeling methods as fuel for novel bioimaging probes and 
tracers 
Incorporation of conjugation sites into small peptides can be easily achieved by selection of 
appropriately functionalized amino acid building blocks for solid phase peptide synthesis, however 
selective functionalization of isolated peptides and proteins not containing protecting groups still 
remains a challenging task. Among the naturally occurring amino acids, the most commonly used for 
bioconjugation are cysteine and lysine as they are potent nucleophiles. However, the high abundance 
of lysine on protein surfaces makes specific acylation challenging and non-oxidized cysteines are less 
frequently displayed on protein surfaces. Therefore we focused on the development of an additional 
modification technique targeting tyrosine as an alternative to the widely used amino acids lysine and 
cysteine. We devised a new method for the mild and effective mono-iodination of tyrosine residues in 
fully unprotected peptides. This method is highly chemoselective and compatible with a wide variety 
of functional groups. The introduced iodine can subsequently serve as a handle for further 
functionalization, such as introduction of fluorescent dyes, and thus be used for the labeling of isolated 
peptides. By extending chemical options to modify peptides and proteins, the possibilities to design 
and synthetize novel bioimaging probes are multiplied, and chances to find the best tools to decipher 
complex biological process are maximized. 
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Conclusion 
The development of ideal imaging tools will be the result of achievements from the fields of both 
biology and chemistry. While the finding of an ideal target specifically expressed by β-cells will arise 
from innovative molecular biologists, the design and synthesis of probes and tracers, and the discovery 
of new fluorescent dyes or optimized (radio)labeling methods, will be the task of talented organic 
chemists. Combining forces and exchanging knowledge at the interface of chemistry and biology will 
be of paramount importance, and even a prerequisite, to eventually reach the ambitious goal of 
selective and non-invasive β-cell imaging. This could play a key role in combating one of today’s most 
widespread yet poorly understood diseases, diabetes. 
“Connaître, ce n’est point démontrer, ni expliquer. C’est accéder à la vision.” 
Antoine de Saint Exupéry 
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The aim of the studies reported in this thesis was twofold: first, we sought to design, synthesize and 
characterize novel fluorescent probes and radioactive tracers for noninvasive β-cell imaging. Second, 
we desired to develop a new methodology for the bioorthogonal labeling of peptides for the synthesis 
of imaging probes. 
Chapter 1 is a general introduction which presents diabetes and the associated complications, its 
prevalence, the main sub-categories of the disease, and its daunting economic impact. The 
determinants of diabetes, especially type 2 diabetes, consist of a matrix of genetic and environmental 
factors that interact with one another, and even though an unhealthy lifestyle (such as sedentarity, a 
high sugar and fat diet) and obesity are widely suspected to promote the disease, the exact causes are 
still unclear. Notably, what exactly happens to the mass and function of the pancreatic β-cells - -the 
only cells of the body capable of secreting insulin - during the onset and the progression of the disease 
is still poorly understood. Therefore, new tools are urgently needed to study and get better insights 
into the physiopathology of diabetes, and β-cell imaging could be highly valuable for this purpose. 
Several probes and tracers for β-cell imaging have been described; the most promising are exendin-4 
analogs targeting the cell surface GLP-1 receptor, and dihydrotetrabenazine derivatives which bind the 
type 2 vesicular monoamine transporter. However, some shortcomings and challenges still hamper 
their use for in vivo β-cell mass determination in humans. Consequently, the search for alternative 
targets and probes with ideal properties for accurate imaging of β-cell mass should continue. We 
introduce in Chapter 1 the free fatty acid receptor 1 (FFAR1-GPR40), which is highly and predominantly 
expressed at the surface of the β-cells, as a new potential target for β-cell imaging.  
Accordingly, in Chapter 2 is described the design, the synthesis and the characterization of the first 
fluorescent probes targeting the FFAR1-GPR40. The novel probe was prepared by attaching a 
fluorescent molecule to the scaffold of TAK-875, a synthetic ligand which binds the FFAR1 with high 
affinity and selectivity. It was determined that the key moiety involved in receptor interaction was the 
dihydrobenzofuran carboxylic acid and that modifying the 4′-position of the terminal biphenyl ring 
would not affect binding affinity. Various linkers of different length were examined: a short amine-
containing linker was selected because it was well tolerated and it enabled convenient conjugation 
with the dyes, most of them being commercially available as amine-reactive N-hydroxysuccinimide 
esters. It was also observed that fluorophores with neutral or positive charges showed high membrane 
labeling, giving higher nonspecific signal in comparison to negatively charged fluorophores such as 
Alexa Fluor 488. Consequently, further biological characterizations were carried out with the Alexa 
Fluor 488 conjugate. The new probe was shown to specifically label FFAR1-GPR40, the target was 
successfully visualized at low nanomolar concentration on transfected HEK293 cells overexpressing the 
receptor using live cell microscopy. When the probe was used on cells expressing endogenous levels 
of the receptor such as MIN6 or INS1E, signal amplification based on antibodies was needed to detect 
the target. Finally, it was verified that the developed probe still behaves as a FFAR1-GPR40 agonist, 
activating the receptor and stimulating insulin secretion in a glucose-dependent manner. As the 
reliability of the method for FFAR1-GPR40 detection based on antibodies was recently challenged, the 
novel fluorescent probe, with the scaffold of a small molecule, provides a new tool for studying the 
receptor. Although utilization of fluorescent probes is limited to in vitro imaging, it represents a new 
option to detect an important functional putative β-cell marker. 
Optical imaging using fluorescent probes has a very high resolution, but the restriction of the approach 
lies in the depth of penetration in tissue, which is limited to a few millimeters for dyes in the visible 
range, and to 2-3 cm for near-infrared fluorophores. This precludes the imaging of internal organs, 
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such as the pancreas, from outside the body in humans. On the other hand, imaging methods such as 
positron emission tomography (PET) or single-photon emission computed tomography (SPECT) are 
extremely sensitive and are not limited by penetration depth. Therefore, we envisioned using a FFAR1-
GPR40 ligand as a potential tracer for in vivo examinations, this work is reported in Chapter 3. The first 
tritiation of TAK-875, a synthetic ligand which binds the FFAR1-GPR40 with high affinity and selectivity, 
is reported. The [3H]-TAK-875 was used as a model compound for in vitro binding evaluation studies 
on transfected HEK293 cells overexpressing FFAR1-GPR40. The tritiated analog showed a binding signal 
sevenfold higher for cells expressing the receptors compared to cells lacking expression of the target. 
Based on these positive results, the design of a [18F]-tracer started with the modification of TAK-875 
and the introduction of a suitable labeling position. As already mentioned above, modifications at the 
4′-position of the terminal biphenyl ring are well tolerated in terms of agonistic activity and binding 
affinity, we thus used the phenol side chain to introduce a tosylate leaving group as precursor for [18F]-
introduction. The fluoride labeled derivative showed similar agonistic activity to the parent compound 
TAK-875 in a FLIPR-Ca2+ functional assay. After preliminary experiments to find suitable labeling 
reaction conditions using KF as a non-radioactive fluoride source, we implemented the radiolabeling 
with [18F] which was achieved in reasonable radiochemical yield and was transferred to an automated, 
cassette-based radiosynthesis module. Further characterization of the [18F]-tracer is ongoing in in vitro 
and in vivo studies, whose outcome will be reported in due course. 
 
Progress in the development of new imaging probes is made possible by research endeavors in biology, 
for instance through identification of new cellular targets for imaging, but progress is also thanks to a 
strong contribution from research in chemistry. Notably, chemists have discovered fluorophores with 
enhanced photo-chemical properties used in the field of optical imaging. In the field of nuclear 
medicine, they have also helped in the elaboration of new chelators with superior complexation 
features, and have developed more efficient and high-yielding radiolabeling protocols. The design and 
synthesis of both [111In]-Exendin, [18F]-FP-DTBZ and [11C]-5-HTP benefited from these innovations, 
which were accomplished by chemists. Therefore, Chapter 4 focuses on the development of a new 
methodology for the labeling of fully unprotected peptides. While most conjugation strategies rely on 
the reactivity of lysine or cysteine, these approaches can be limited by the high abundance of lysine 
on protein surfaces, or by the fact that cysteins are very often involved in non-reactive disulfide 
bridges. Consequently we aimed at exploiting tyrosine, as an alternative labeling option, to 
functionalize peptides and proteins. A new method for the mild and effective mono-iodination of 
tyrosine is reported. The combination of sodium iodide and Selectfluor in dichloromethane 
supplemented with trifluoroacetic acid allows the introduction of a single iodine atom in ortho position 
of the phenol ring. This method is highly chemoselective and compatible with a wide variety of 
functional groups, as verified on numerous biologically active peptides such as derivatives of Leu-
Enkephalimanide, Angiotensin, Bradykinin, Oxytocin, and GLP-1(7-37) among others. Using the 
reactivity of the mono-iodo peptides, conjugation with fluorophore building blocks was performed via 
Suzuki-Miyaura cross-coupling, which serves as an example of bio-imaging probe synthesis. These 
findings will prove to be a useful additional tool in the arsenal of bioconjugation chemistry, notably for 
peptides obtained by isolation from natural sources (an important example of such a peptide is 
Exendin-4, which was originally isolated from the salivary glands of the Gila Monster) rather than 
through chemical synthesis, or where lysine and free cysteine are not available for labeling. 
Finally, in Chapter 5 all the results described in this thesis are summarized and discussed, together 
with the latest discoveries in β-cell biology and the potential future perspectives in β-cell imaging.  
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Het doel van de studies beschreven in dit proefschrift was tweeledig: ten eerste wilden we nieuwe 
fluorescente probes en radioactieve tracers ontwerpen, synthetiseren en karakteriseren om op niet 
invasieve wijze β-cellen in beeld te brengen. Ten tweede wilden we graag een nieuwe methodologie 
ontwikkelen voor het bioorthogonaal labelen van peptiden voor de synthese van imaging probes. 
 
Hoofdstuk 1 is een algemene introductie over diabetes en de bijbehorende complicaties, de 
prevalentie, de voornaamste subcategorieën van de ziekte, en de ontmoedigende economische 
impact. De factoren die bepalen of iemand diabetes krijgt, en dan vooral type 2 diabetes, bestaan uit 
een matrix genetische factoren en omgevingsfactoren die interactie hebben met elkaar. En ondanks 
dat een ongezonde levensstijl (weinig bewegen, een dieet met veel suiker en vet) en zwaarlijvigheid 
ervan verdacht worden de ziekte te stimuleren, zijn de exacte oorzaken nog steeds onduidelijk. 
Bijvoorbeeld wat er precies gebeurt met de massa en functie van β-cellen in de alvleesklier – de enige 
cellen in het lichaam die insuline kunnen produceren -  tijdens het ontstaan en de ontwikkeling van de 
ziekte, is nog niet bekend. Daarom zijn er met spoed nieuwe tools nodig om de fysiopathologie van 
diabetes beter te kunnen bestuderen en begrijpen, en β-cel imaging kan voor dit doel van grote waarde 
zijn. Verschillende probes en tracers voor β-cel imaging zijn beschreven; de meest veelbelovende zijn 
exendin-4 analoga die binden aan de GLP-1 receptor op het celoppervlak, en dihydrotetrabenazine 
derivaten die binden aan de type 2 vesiculaire monoamine transporter. Toch zijn er een aantal 
tekortkomingen en uitdagingen aan deze tracers die hun gebruik voor in vivo β-cel massa in mensen 
hinderen. Daarom zal de zoektocht naar alternatieve targets en probes met ideale eigenschappen voor 
accurate beeldvorming van β-cel massa nog doorgaan. We introduceren in Hoofdstuk 1 de free fatty 
acid receptor 1 (FFAR1-GPR40), die in hoge mate tot expressie komt op het oppervlak van β-cellen, als 
nieuwe potentiële target voor β-cel imaging. 
 
In Hoofdstuk 2 wordt het ontwerpen, synthetiseren  en karakteriseren van de eerste fluorescente 
probes beschreven die de FFAR1-GPR40 targeten. De nieuwe probe is gemaakt door een fluorescent 
molecuul aan een scaffold van TAK-875 te binden, een synthetische ligand die met hoge affiniteit en 
selectiviteit bindt aan FFAR1. We hebben bepaald dat de dihydrobenzofuran carboxyl zuur de 
belangrijkste groep is voor de interactie met de receptor en dat het modificeren van de 4’ positie van 
de terminale biphenyl ring geen effect heeft op de affiniteit van de binding. Linkers van verschillende 
lengte zijn onderzocht: een korte amine bevattende linker werd geselecteerd, omdat deze goed 
getolereerd werd en de linker zorgde voor goede conjugatie met de dyes, waarvan de meeste 
commercieel beschikbaar waren als amine reactieve N-hydroxysuccinimide esters. We hebben ook 
gezien dat fluorophoren met neutrale of positieve ladingen hogere membraan binding lieten zien, 
waardoor een hoger aspecifiek signaal werd gezien in vergelijking met negatief geladen flourophoren, 
zoals Alexa Fluor 488. Daarom zijn verdere biologische karakteriseringen uitgevoerd met het Alexa 
Fluor 488 conjugaat. De nieuwe probe bond specifiek aan FFAR1-GPR40 en het werd succesvol in beeld 
gebracht in een laag nanomolaire concentratie met microscopie op getransfecteerde HEK293 cellen 
die de receptor tot overexpressie brengen. Toen we de probe gingen testen op cellen met een 
endogeen niveau van receptor expressie zoals MIN6 of INS1E, was er een amplificatie van het signaal 
nodig met antilichamen om het target te detecteren. Uiteindelijk hebben we geverifieerd dat de 
ontwikkelde probe zich nog steeds gedraagt als een FFAR1-GPR40 agonist, en dus nog steeds de 
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receptor activeert en de insuline secretie stimuleert op een glucose afhankelijke manier. Omdat de 
betrouwbaarheid van de methode om FFAR1-GPR40 te detecteren met behulp van antilichamen 
recent in twijfel is getrokken, vormt de nieuwe fluorescente probe, met de scaffold van een klein 
molecuul, een nieuwe tool om de receptor te bestuderen. Ondanks dat het gebruik van fluorescente 
probes gelimiteerd is tot in vitro imaging, biedt dit een nieuwe optie om een belangrijke functionele 
β-cel marker te detecteren. 
 
Optical imaging met fluorescente probes heeft een hele hoge resolutie, maar een sterke beperking van 
deze benadering is de penetratiediepte in weefsel, die beperkt is tot een paar millimeter voor dyes in 
zichtbare bereik, en 2-3 cm voor near-infrared fluorophoren. Dit sluit beeldvorming van interne 
organen in het menselijk lichaam uit, zoals de alvleesklier. Echter, beeldvormende technieken zoals 
positron emission tomography (PET) en single-photon emission computed tomography (SPECT) zijn 
extreem gevoelig en zijn niet gelimiteerd door penetratiediepte. Daarom wilden we een FFAR1-GPR40 
ligand ontwerpen voor in vivo gebruik. Dit werk is beschreven in Hoofdstuk 3. De eerste tritiatie van 
TAK-875, een synthetisch ligand dat bindt aan FFAR1-GPR40 met hoge affiniteit en selectiviteit, is 
beschreven. [3H]-TAK-875 is gebruikt als een modelverbinding voor in vitro bindings experimenten met 
getransfecteerde HEK293 cellen die FFAR1-GPR40 tot overexpressie brengen. Het getritieerde analoog 
toonde een zeven keer hogere binding op getransfecteerde cellen in vergelijking met cellen die de 
receptor niet to expressie brengen. Gebaseerd op deze positieve resultaten zijn we gestart met het 
ontwerpen van een [18F]-tracer door modificatie van TAK-875 en de introductie van een geschikte 
positie voor labeling. Zoals hierboven al werd beschreven, werden modificaties aan de 4’ positie van 
de terminale biphenyl ring goed getolereerd met betrekking tot agonistische activiteit en 
bindingsaffiniteit. Daarom gebruikten we de phenol side chain om een tosylate leaving group te 
introduceren als een precursor voor de introductie van [18F]. Het derivaat gelabeld met fluoride toonde 
vergelijkbare agonistische activiteit als het oorspronkelijke TAK-875 in een FLIPR-Ca2+ functioneel 
essay. Na preliminaire experimenten om geschikte labeling condities te vinden waarbij we KF 
gebruikten als een niet radioactieve bron, implementeerden we de radioactieve labeling met [18F] met 
een goede radiochemische opbrengst in een geautomatiseerde radiosynthese module met cassettes. 
Er wordt nog gewerkt aan verdere karakterisering van de [18F]-tracer in verschillende in vitro en in vivo 
studies, waarvan de uitkomst nog gerapporteerd zal worden. 
 
Vooruitgang in de ontwikkeling van nieuwe imaging probes wordt mogelijk gemaakt door 
onderzoeksinspanningen in de biologie, bijvoorbeeld door de identificatie van nieuwe cellulaire targets 
voor beeldvorming, maar vooruitgang is ook te danken aan een sterke contributie uit het veld van de 
chemie. Zo hebben chemici fluorophoren ontdekt met versterkte fotochemische eigenschappen die 
gebruikt worden in het veld van de optical imaging. In het veld van de nucleaire geneeskunde hebben 
ze ook geholpen in de ontwikkeling van nieuwe chelatoren met superieure complexerende 
kenmerken. Ook hebben ze protocollen ontwikkeld voor radiolabeling die efficiënter zijn en een 
hogere opbrengst opleveren. Het ontwerp en de synthese van zowel [111In]-Exendin, [18F]-FP-DTBZ en 
[11C]-5-http hebben geprofiteerd van deze innovaties, die zijn bereikt door chemici. Daarom focust 
Hoofdstuk 4 op de ontwikkeling van een nieuwe methodologie voor de labeling van volledig 
onbeschermde peptiden. De meeste conjugatiestrategieën gebaseerd zijn op de reactiviteit van lysine 
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of cysteine. Echter, deze benadering kan gelimiteerd zijn door hoge aanwezigheid van lysine op eiwit 
oppervlakken, of door het feit dat cysteines erg vaak betrokken zijn bij de vorming van niet reactieve 
disulfidebruggen. Derhalve zijn wij gaan kijken naar de mogelijkheden van tyrosine als een alternatieve 
optie voor labeling om peptiden en eiwitten te funtionaliseren. Een nieuwe methode voor de milde en 
effectieve mono-iodinatie van tyrosine is beschreven. De combinatie van natriumiodide en Selectfluor 
in dichloromethaan gesupplementeerd met trifluorazijnzuur biedt de mogelijkheid van een introductie 
van een enkel iodine atoom in ortho positie op de fenol ring. Deze methode is sterk chemoselectief en 
compatibel met een grote variëteit aan functionele groepen, zoals geverifieerd bij vele biologisch 
actieve peptiden, zoals onder andere derivaten van Leu-Enkephalimanide, Angiotensin, Bradykinin, 
Oxytocin, and GLP-1(7-37). Door gebruik te maken van de reactiviteit van de mono-iodo peptiden, 
voerden we conjugaties uit met fluorophore building blocks via Suzuki-Miyaura cross-coupling, dat 
dient als een voorbeeld van de synthese van een bio-imaging probe. Deze resultaten zullen bewijzen 
dat dit een nuttige additionele tool is in het arsenaal van bioconjugatie chemie, vooral voor peptiden 
die worden verkregen door isolatie uit natuurlijke bronnen (een belangrijk voorbeeld hiervan is het 
peptide Exendin-4, dat geïsoleerd wordt uit de speekselklieren van het Gilamonster) in plaats van door 
chemische synthese, of wanneer lysine en vrij cysteine niet beschikbaar zijn voor labeling. 
 
Uiteindelijk worden in Hoofdstuk 5 alle resultaten beschreven in dit proefschrift samengevat en 
bediscussieerd, aangevuld met de laatste ontdekkingen in β-cel biologie en de potentiële 
toekomstperspectieven in β-cel imaging. 
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